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 Introduction 2
2.1 Fundamentals-The kidney 
2.1.1 Structural and functional components 
The physiologic inner milieu of the vertebrate’s organism has to be permanently 
adapted to its outer environment. The kidneys thereby play a major role. These 
two vital organs play a central role in the maintenance of extracellular electrolyte 
and volume homeostasis [13, 37]. Basically they serve as a chemical and 
mechanical blood filtration system, which removes extra-water and waste products 
from the body and finally secrets them as urine via the ureters and the bladder. 
The kidneys can be separated into different functional components, the nephrons 
and the collecting duct to be named as the core ones.  
2.1.2 Nephron and renal corpuscle  
Each human kidney has about 2000 nephrons. They are the structural and 
operational units of the kidney, comprising an initial blood filtrating component, the 
renal corpuscle and a recovery, reabsorbing component, the tubulus [10].The 
nephrons travers the complete cross-section of a kidney. A schematic picture of a 
single nephron is shown below (Fig. 2.1) 
 
Fig. 2.1: Structure of the nephron, the blood filtering station. Each nephron is composed of a renal 
corpuscle and a tubule. The glomerulus, a part of the renal corpuscle, filters wastes and 
excess fluids, while the tubules modify the primary urine. Source: [10] 
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The renal corpuscles are located within the kidneys cortex. Basically they consist 
of two major functional subunits: the Bowman`s capsule and the glomerulus, which 
together are responsible for ultrafiltration of the blood and synthesis of the primary 
urine. The blood enters the kidneys and is transported towards the renal 
corpuscle. Here the afferent vessels build a three-dimensional cauliflower-like knot 
structure, the glomerulus (Fig. 2.2). By passing the glomerulus the blood gets 
filtrated and leaves the kidney via the efferent arteriole towards the heart. During 
the blood filtration process, the primary urine is produced, secreted into the urinary 
space of the Bowman`s capsule and forwarded to the tubular structures where it 
gets further processed.    
 
 
 
Fig. 2.2: Schematic image of the structure and the different cell types of the glomeruli (modified from Ross & 
Romrell 1989[101]). (Adapted with permission of Prof. Kriz: Sructural organization of the 
mammalian kidney in [2]) 
2.1.3 Glomerulus 
As mentioned, the glomerulus is formed by a capillary tuft. The renal afferent 
arteriole (Fig. 2.2) delivers the blood at the vascular pole to the glomerulus, where 
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it forms a ball of vessel-loops [2]. Within these loops, specialized contractile 
fibroblasts, the mesangial cells, support this skeletal structure and drive the blood 
filtration [72]. 
The renal corpuscle filters water as well as low- molecular metabolites out of the 
blood plasma. Therefore the blood filtrate has to percolate the filtration- or blood-
urine-barrier, consisting of three major compartments [37, 42, 101]:  
 The fenestrated, capillary endothelium, which holds small gaps of 60- 
80 nm in diameter and allows passage of small molecules but inhibits the 
passage of blood cells or macromolecules up to a size of about 68 kDa.   
 The attached basal lamina, a kind of glycocalyx which is responsible for 
the reservation of large proteins and  
 a last filtration barrier, the foot processes of the podocytes. They build a 
tight network of filtration slits, which finally inhibit the passage of smaller 
proteins.  
The cleaned up blood leaves the kidney via the efferent arteriole towards the heart 
to re-enter blood circulation.  
The Bowman capsule surrounds the glomerulus. It consists of a visceral inner 
layer, formed by glomerular epithelial cells called podocytes and a parietal outer 
layer composed of a single layer of flattened cells, the parietal epithelium (Fig. 
2.2). These two boundaries build a small lumen, the urinary space. After the 
ultrafiltration of the blood the primary urine leaves the Bowman`s capsule and is 
processed within the tubular system. Nearly 99 % of the primary urine is 
reabsorbed here. 
2.1.4 Mesangium and mesangial cells (MCs) 
The cauliflower-like structure (Fig. 2.2) of the capillary tuft in the glomerulus is 
mainly achieved by the mesangium. It is formed by mesangial cells and their 
surrounding extracellular matrix. This interstitial connective tissue emanates from 
the vascular pole into the capillary tuft and builds a skeletal structure to fix the 
capillaries to the pole. 
The mesangial cells are divided into two functional groups of cells:  
 extraglomerular mesangial cells (eMCs) are situated at the top of the 
vascular pole, near the distal convolute tubulus. Here they are, together 
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with the juxtaglomerular cells (Fig. 2.2) mainly responsible for the reading 
and adjusting of the body`s blood hormone and electrolyte level [122].  
 The intraglomerular mesangial cells (iMCs) lie in between the capillaries 
and work as contact surface for the capillary endothelium. The contractile 
microfilaments [60, 68, 77] of the mesangial cells are linked within the basal 
membrane. This enables a combined contraction and folding of basal 
membrane and the endothelium, resulting in a modification of the vascular 
diameter and a change of vascular afterload and resistance, respectively 
[68]. Additionally iMCs are the major producers of extracellular matrix [23, 
63], which builds the connective tissue components of the mesangium.  
2.2 Mesangioproliferative glomerulonephritis  
With a diagnostic frequency of 10 % of all renal biopsies the mesangioproliferative 
glomerulonephritis (MesPGN) represents the most prevalent form of inflammatory 
glomerular diseases [12, 124, 128]. It is classified as a primary glomerulonephritis 
(GN) [29] meaning that it is an autoimmune disease of so far unknown source. 
Hyperproliferation of mesangial cells as well as accumulation of extracellular 
matrix and deposition of immune complexes within the mesangium belong to the 
main characteristics of MesPGN. Mesangioproliferative glomerulonephritides are, 
especially with their representative forms IgA-Nephropathy and Lupus 
Nephropathy one of the major causes of terminal renal failure worldwide and 
therefore produce, beside enormous personal burden by side effects during 
therapy, huge costs for the health care system.   
Therapeutic issues are more or less of curative character and mainly try to achieve 
preservation of the renal function and try to avoid diseases progression [28]. 
Treatment correlates with the type and state of MesPGN and putative underlying 
diseases. Normally patients are medicated with anti-inflammatory or immune 
suppressing drugs like Cortisol and Cyclophosphamid or Azathioprin. In terms of 
developing an end stage renal disease (ESRD) with renal failure, dialysis is mostly 
inevitable.    
2.2.1 Animal model of mesangioproliferative glomerulonephritis 
The anti-thy-1 nephritis in rats [6, 7] describes the so far best characterized animal 
model in terms of understanding the cellular processes occurring during human 
mesangioproliferative glomerulonephritis. This experimental animal model is 
induced by a single injection of the monoclonal antibody (mAB) ER4 (mouse), 
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specifically recognizing the Thy-1.1 antigen exclusively expressed on mesangial 
cells of rat`s kidneys. The disease is characterized by rapid activation of the 
complement cascade triggered via the antibody`s Fc-part. It is detectable by 
glomerular deposition of C3 and C9 factors [5], an activation of the coagulation 
cascade with presence of fibrinogen deposition in the affected glomeruli, 
macrophage infiltration and lysis of mesangial cells.  
The mechanism proceeding within the glomerular structure of the rat`s kidney in 
this model for proliferative glomerulonephritis is described in Fig. 2.3. Directly after 
bolus-injection of the monoclonal anti-Thy 1.1 IgG antibody, complement factors 
are initiated, leading to recruitment of macrophages and other inflammatory cells. 
 
 
Fig. 2.3: Progression of anti-thy-1 nephritis in rats. After intravenous injection, the murine ER4 
antibody marks the intraglomerular mesangial cells via their Thy-1 antigen (a). The 
complement cascade gets activated and leads to lysis of mesangial cells (b). Release of 
growth factors is followed by hyperproliferation of residual mesangial cells and 
accumulation of extracellular matrix(c). Source: [69] 
As described above, acute mesangiolysis within the mesangium and early 
endothelial injury of the capillary loops are detected in the first hours after antibody 
administration. Within the first two days after disease induction regeneration of the 
capillaries [59, 89] and repopulation of the mesangium by activated mesangial 
cells originating from the hilus region [57] lead to hypercellularity and accumulation 
of extracellular matrix (ECM) and stepwise loss of kidney function around day 7 
[41]. Two different variants of the rat model can be induced: 
1. On the one hand, simple injection of the anti-Thy 1.1 antibody leads to 
reversible MesPGN with a reconstitution of the mesangium and healing of 
the glomerulus within 3 to 4 weeks after injury [6].  
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2. A more severe and progredient variant of MesPGN can be proceeded by 
disease induction via a combination of uni-nephrectomy plus subsequent 
administration of the anti-Thy 1.1 antibody. Here the strong injury prevents 
glomerular healing, reflected by severe proteinuria and the development of 
chronic renal impairment [18].  
The progress of the proliferative glomerulonephritis depicted within this model 
shows, in comparison to other experimental models of MesPGN [31], strong 
resemblance to the corresponding human disease, especially the correlation of 
complement recruitment and proteinuria of patients with mesangioproliferative 
glomerulonephritis [42].  
On the basis of this experimental model several new clinical therapeutic 
approaches, e.g. the PDGF-antagonism to inhibit mesangial cell hyperproliferation, 
were developed during the last years [11, 90, 132]. Nevertheless, the Thy-1 
antigen is not presented on murine mesangial cell surface, implicating that the 
anti-thy-1 nephritis is not accessible as a murine model here. In consequence a 
huge variety of knockout and transgenic mouse models is obstructed for research 
and therefore impeding the progress in this field. 
  
2.3 Phage Display- a tool for generating highly specific 
antibodies 
During the last two decades the generation of recombinant monoclonal antibodies 
for therapeutic and diagnostic approaches has emerged a key technology in 
clinical and scientific research.  Usage of recombinant in-vitro selection of specific 
binding components apart from active immune systems already created several 
antibodies or antibody fragments used for clinically applications [24, 25, 35, 43, 98, 
99, 125, 134, 138]. 
2.3.1 Phage display selection of antibody libraries- clonal 
selection  
Phage Display technology was found to be one of the most important and fast 
approaches to screen gene libraries for highly specific binding molecules against a 
variety of different antigens. It is a fast and very efficient in-vitro procedure. The 
method itself is based on the presentation of small proteins or peptides of interest 
on top of filamentous bacteriophages as vehicles. Therefore the genes of these 
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proteins are fused to the 5’ end of one of the bacteriophage’s coat protein genes, 
leading to the presentation of the fusion proteins on its surface. Selection of 
binders is achieved by exposing and incubating a presented gene library with the 
antigen of interest, followed by washing out of unspecific, irrelevant phages and 
elution of the antigen binding, specific ones. The phages are selected according to 
their binding properties towards a presented antigen [25, 51, 94]. During the whole 
selection process the potential antigen binding phage-presented proteins 
(phenotypes) remain physically linked to their genetic profile (genotypes) by fusing 
their coding genes to the genes of certain coat proteins of the bacteriohages. 
Phage Display therewith imitates the principle of B-lymphocyte antigen recognition 
and is also described as clonal selection of binding molecules [53, 79].  
2.3.2 Recombinant antibody derivatives as displayed proteins 
The choice of a certain coat protein as fusion partner, as well as of the binding 
molecule as selection partner depends on the later application of selected 
candidates. As a central tool in pharmaceutical product development and 
immunological research, mainly antibody-like proteins against relevant targets are 
of major interest in phage display technology [75].  
Full length antibodies consist of two types of protein chains, represented in double. 
Two light chains and two heavy chains [91]. Linked via covalent disulphide bridges 
they have a Y shaped conformation (Fig. 2.4), which can be separated in two 
functional regions. On the one hand there are the two Fab regions, each 
consisting of the face to face located variable regions of the light (VL) and 
corresponding heavy chain (VH) plus two short highly conservative, so called 
constant regions from the heavy (CH1) and light chain (CL). These two “arms” of 
the antibody serve as highly selective antigen-detecting and -binding sites. In 
detail, the complementarity determining regions (CDRs) within the variable 
regions (marked in red in Fig. 2.4) of the VH and VL drive the antigen binding and 
are, due to their enormous variability, responsible for the antibody`s variability and 
the high amount of different antibodies in vertebrates.  
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Fig. 2.4: Schematic representation of an immunoglobulin (IgG) and descending antibody fragment 
(scFv). Dark blue regions (CH1, CH2 and CH3) are part of the antibodies heavy and 
constant regions. They represent special functional units; the CH3 is responsible for 
binding antibody derived activation of macrophages (ADCC), whereas the CH2 recruits 
complement system components (CDC). Linked with a polypeptide linker, the single 
variable domains of an antibody (VH and VL) can be used as binding components in 
phage display. Such constructs are called single chain fragment variable (scFv).       
On the other hand a second part of the antibody, named the Fc-part, is exclusively 
composed of constant regions of the heavy chains and serves as effector 
component. It is linked to the Fab fragment via a short hinge region, responsible 
for the knick within the heavy chain. The constant regions of the Fc parts are 
highly conserved all over the antibody families but can vary in amount of 2-3 
compartments in between the different antibody family members. Basically the Fc-
part works as activator of the immune system and has two major functions: 
 CH2: activation of the complement cascade after immune response (CDC) 
 CH3: recruitment of antibodies during immune reaction (ADCC) 
Summed up, full length antibodies, as large proteins with a size of at least 
150 kDa, are not suitable for “display” technologies. That is why Fab-fragments 
(fragment antigen binding) and single-chain variable fragments (scFv) as smaller 
derivatives are preferably used in phage display. They include the complete 
antigen binding domain and binding properties of a full length antibody, but are of 
strongly reduced size, improving their antigen penetration during the selection 
process as well as their subsequent application. 
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2.3.3 Phage display systems 
Beside the decision towards a suitable displayed protein type and display vehicle, 
the genetics of the phage display system itself is an essential component. Three 
types of phage display system are possible, each of them with its own limitations 
and advantages.  
Within the phage system, the library DNA is fused to the only copy of the coat 
protein gene within the viral genome. Peptides or proteins displayed in phage 
systems are therefore presented by each copy of the corresponding fusion coat 
protein [20, 141].  
The hybrid system can be used in case of steric hindrances among the displayed 
antibody fragments in phage systems.  Thereby a native copy of the chosen coat 
protein of interest is amended with an artificial copy of the same coat protein. The 
two genes are part of the phage genome but are under the control of two separate 
promoters, which are designed to express higher amounts of wild-type coat 
protein. This leads to both, integration of fusion-coat protein as well as high levels 
of native coat protein.  
The phagemid system represents a compromise between the two other systems. 
Here, the antibody fragment library is cloned into an exogenous plasmid carrying 
antibiotic resistances, replication origins specific for phage and bacterial 
replication, a phage packing signal and the phage gene for the coat protein from 
which the library will be displayed. Each single library gene is cloned into one 
phagemid (upstream of the phage gene) to be finally presented at the N-terminal 
end of the coat protein. These phagemid libraries are transformated into bacteria 
and can from then on be treated like normal circular plasmids. In contrast to 
phage- or hybrid display systems, the phagemid system is initially detached from 
any kind of bacteriophage. Only after the expression of for example a scFv- or 
Fab-coat protein in the phagemid transformated bacteria, helper phages are 
required to introduce the residual phage genes into the bacteria. Their 
transcription and production within the host finally leads to the assembly of 
complete recombinant bacteriophages presenting the coat-fusion protein on the 
top of their coat proteins (see 2.3.4). The advantage of this type of phage display 
system is clearly the fact that the basic information of the library DNA is available 
and preserved in bacteria, which are, compared to phages, easier to handle. 
Additionally the central feature of clonal selection is maintained in the phagemid 
system: phages produced with the phagemid system can, beside their own viral 
DNA, also encapsulate the additional phagemid DNA within their protein shell and 
therefore link the presented phenotype of an antibody fragment to its coding 
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genotype [4]. Compared to the phage system this simplified phagemid system is 
less complex in terms of cloning approaches and library usage and allows to 
prepare highly divers libraries.       
2.3.4 M13 bacteriophages as vehicles  
The structure of lysogen bacteriophages describes the essentials of the decision 
towards a potential type of coat protein as fusion partner. Bacteriophages are 
lysogen viruses, exclusively infecting bacteria. Their genetic material is 
encapsulated within a protein shell built of about 2700 copies of the major coat 
protein pVIII (Fig. 2.5). At the one end 5 copies of each minor coat protein pIX and 
pVII cap the shell [56], whereas on the other end 5 copies of the minor coat 
proteins pVI and pIII form the infection complex. The fusion-coat protein is 
subsequently used during the phage-assembly process in the same manner the 
non-fusion surface proteins would have been: the phage-protein-domain is 
integrated into the new bacteriophage and the coupled scFv-domain is presented 
on the bacteriophages surface.  
 
 
Fig. 2.5: Simplified schematic representation of a filamentous M13 bacteriophage representing an 
antibody structure, a scFv in this case, used for phage display selections. The major coat 
protein pVIII envelopes the bacteriophages as well as the phagemid ssDNA. With about 
five copies of each of the minor coat proteins pIX and pVII one end of the bacteriophage 
is formed. Detailed information about their functions are not yet described. The other end 
of a M13 bacteriophage is formed by the minor coat proteins pVI and pIII. The structure 
and function of the pIII protein are described in detail within the text. 
So far all of the five coat proteins have been used as potential fusion partners for 
antibody fragments. Originally and most commonly, phage display was described 
using fusion proteins based on the pIII minor coat protein [116, 133], but during the 
last years also fusions to other minor (pIX) [44] and major coat proteins (pVIII) 
were established [113]. The concrete decision finally depends on the foreign, 
displayed protein and its properties. The functionality of the displayed antibody 
fragment as well as of the coat protein is of central importance. During this thesis 
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the pIII-fusion approach was predefined due to the characteristics of the used 
Tomlinson gene libraries.  
Bacteriophages are, like other viruses, not able to reproduce themselves without a 
host [66, 102]. They are lysogen viruses, exclusively using bacteria as replication 
host. The life cycle of bacteriophages follows three major steps [120]: 
 Infection occurs between bacteriophages and fertility-pilus (F-Pilus) 
positive bacteria. The bacteriophages are binding to the tip of the host` s 
F-Pilus via their D1 domain of the minor coat protein pIII [27, 119]. 
Subsequently the F-Pilus is retracted to the bacterium and the 
bacteriophages are getting in contact with Tol-receptors within the bacterial 
outer membrane. Subsequently, the injection of the virus ssDNA into the 
bacterial cytoplasm takes place without destruction of the host`s membrane 
integrity [81].    
 Once within the host, the virus DNA is converted into replicative dsDNA 
serving as template for reproduction and translation/expression of the 
phage genes.    
 The phage- assembly is a trans-membrane process. Therefore all phage 
coat proteins are directed to the bacterial periplasmic membrane, are 
transported through it via special protein channels and are finally 
assembled on the outside of the host bacterium, again without affecting its 
membrane integrity [82, 105].  
Basically two different types of bacteriophages are available which shall shortly be 
explained on the example of pIII protein surface exposure. On the one hand 
bacteriophages exist which bear a complete phage genome and are able to 
produce any relevant phage particle protein on their own. After infection of gene 
library bearing E.coli bacteria, an extraordinary, modified pIII coat-protein 
expressed from the phagemid library can be integrated but is not necessarily 
meant to be.  An example for such a type of bacterio- or also called helperphage is 
the M13 helperphage (see A.11). Here normally only a limited amount of library-
coat proteins is integrated during the phage assembly process, mainly due to 
steric hindrances. To trigger the percentage of presented library related proteins 
another type of bacteriophage can be used. It is called hyperphage due to its 
excess of presented proteins. It has been described by Rondot et al. in 2001 [102]. 
This phage lacks an endogenous pIII gene and therefore is not able to produce its 
own pIII coat protein. After infection of E.coli bacteria these phages can only 
integrate the externally supplied pIII coat proteins expressed by the library host 
bacteria.   
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2.3.5 The Tomlinson libraries I and J 
One example of a filamentous phagemid display system the Tomlinson libraries I 
and J can be described. The phagemid libraries are provided and conserved in 
E.coli bacteria cryo-batches and need to be re-cultivated and subsequently 
infected with lysogen bacteriophages to be expressed. Both libraries are semi-
synthetic, naïve gene libraries, established on the basis of the non-immunized B- 
cell v-gene repertoire from healthy humans. The pIT2 phagemid used within these 
libraries is constructed as described in Fig. 2.6. A single-chain variable fragment 
(scFv) is fused to the N-terminus of the minor coat protein pIII. His- and myc tags 
between the scFv and the pIII-protein enable the detection of assembled 
recombinant bacteriophages at any step of the phage display procedure. Each 
phagemid exclusively codes for one v-gene combination fused to the pIII gene.     
 
 
 
Fig. 2.6: Design of a representative phagemid used in the Tomlinson Phage Display libraries [45]. 
This type of recombinant dsDNA was used as gene-vector for phage display selection 
during this thesis. Detailed properties of the pIT2 phagemid are described under A.8.1. 
To enhance the diversity of the naïve variable regions within the heavy (VH) and 
the light chains (VL) of these libraries the CDRs of the side chains were 
randomized and maturated by target-oriented mutagenesis following the DVT 
(library I) and NNK (library J) principle. According to the IUPAC code for nucleic 
acid this means that the amino acid triplets can consist of the following base-
triplets for coding amino acids: 
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Tab. 2.1: Possible nucleotides within the randomized base triplets of the CDRs   
 1st nucleotide  2nd nucleotide 3rd nucleotide 
DVT Adenine,  
Thymine or  
Guanine 
Adenine,  
Cytosine or  
Guanine 
Thymine 
NNK any base:  
Adenine,  
Cytosine,  
Guanine or  
Thymine 
any base:  
Adenine,  
Cytosine,  
Guanine or  
Thymine 
Thymine or  
Guanine  
 
Due to this diversification step the Tomlinson libraries I and J reach sizes of about 
1.47 x 108 and 1.37 x 108 different scFv-genes per library, respectively. Depending 
on their source and their processing, gene libraries used in phage display 
technology can consist of up to 1*109 - 1*1012 different fusion genes.  
2.3.6 Panning procedure with Tomlinson libraries 
In general Phage Display is a panning procedure, normally performed over 3-5 
rounds of selection [45, 138]. Its principle is described in Fig. 2.7. For the selection 
of potential scFv-binders against a special target antigen each Tomlinson library 
has to be amplified in its host bacteria, in case of the Tomlinson libraries E. coli 
TG1 (Tab. 7.9) are default. The infection process is initiated with the addition of a 
multiple amount of helper phages compared to amplified bacterial cells. Essential 
for successful infection is the development of the F-pilus by the host bacteria 
which is reached within the exponential growth phase. A “multiplicity of infection” 
(MOI) of at least 20 times more infectious phages than hosts to be infected 
enhances the effective infection rate and thereby improves the variety of amplified 
scFv-phages. After entering the host bacteria as already described under 2.3.4, 
the phage ssDNA is translated into dsDNA. This enables expression of the wild-
type helper phage genes, together with the scFv-pIII fusion protein coded on the 
host`s recombinant phagemid. All phage relevant proteins are translocated into the 
periplasmic space of the E. coli TG1 bacteria, where they are assembled to new 
recombinant bacteriophages presenting antibody-fragments on the top of one of 
their coat proteins.  
The whole of the recombinant scFv-presenting bacteriophage library is exposed to 
an immobilized or soluble antigen to allow binding (see Fig. 2.7) of the antibody-
fragment domains to the antigen. Removal of unbound or non- antigen specific 
phages in several washing-steps is followed by the elution of residual, 
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specifically bound phages. Since the recombinant fusion-phages bear all native 
phage properties, they can be used to re-infect F-pilus positive TG1s.  
 
 
Fig. 2.7: Schematic description of Phage display panning using pIII-fusion proteins as done in the 
Tomlinson libraries I and J  
With this step the recombinant library phagemid DNA (genotype) coding for the 
presented fusion protein (phenotype), together with the residual native phage 
genes, is transduced into so far phage-genetically unaffected new host bacteria. A 
host amplification step completes one panning round. The eluted, reduced but 
antigen-specified phage library is backed up in the re-infected hosts. After each 
panning round, single phage candidates can be analysed for their binding 
properties to the antigen.  
From panning round to panning round the amount of different antibody fragments 
from the selected libraries will be reduced, but the specificity of the residual 
antigen-binding scFv-phage will increase. The choice of selection strategies has a 
massive influence on the result of a phage display selection. For example the 
increase of washing stringency reduces the amount of unspecific bound phage 
particles and selects especially strong binders. The same happens for the variety 
of the antigen concentration. Decreasing antigen amounts normally lead to more 
specific scFv-phages created during the selection procedure. The success of a 
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phage display selection of antibody-fragments specific for a certain kind of antigen, 
not only depends on the quality of the antigen but strongly depends on the whole 
selection procedure.  
2.4 SNAP-tag technology 
For all fields of biological research and development, the visualization and 
detection of proteins, not only in living cells, has ever been of major interest to get 
deeper insight into physiological processes and molecular mechanisms. 
Appropriate functionalization and labelling of protein structures thereby plays a 
central role, especially in terms of utilization. For many years, luciferase-fusion 
proteins, or ß-galactosidase enzymes have been applied in different areas, like 
protein localization, protein detection in in-vitro assays or protein interaction 
studies. With the discovery of the green fluorescent protein (GFP) [112] and it` s 
subsequent establishment [15] as a labelling moiety for proteins the use of 
fluorescent proteins (FP) became a standard procedure in molecular imaging. 
During the last twenty years the functionalization was even forwarded to be used 
in therapeutic set ups by attaching effector domains like toxophores to targeting 
proteins. But though permanently ongoing improvements of available fusion 
partners and enhanced developability characteristics the technique has its 
limitations. Until now, the tailored genetic fusion of target proteins together with 
fluorescent proteins is still in-variable, case-specific and therefore time-consuming.  
In 2002 a new technology pioneered by Kai Johnsson targeted this issue, by 
introducing the SNAP-tag. The principle of this enzymatic tag is to serve as an 
anchor polypeptide genetically fused to and expressed with a protein of interest. 
The SNAP-tag is a 20 kDa small engineered form of the human DNA repair 
enzyme O6-alkylguanine-DNA-alkytransferase (AGT) which endogenous function 
is to remove and repair defects at guanosine-sites of the DNA.  
The AGT interacts with alkyl residues and removes them via a nucleophilic 
substitution towards its active enzyme site [96]. This feature has been used for the 
labelling process of proteins. Initially the DNA sequence of the small SNAP 
polypeptide is introduced into the DNA sequence of a target protein to be labelled. 
The labelling partner of interest is chemically coupled to benzylguanine (BG)-NH2, 
the substrate of the SNAP tag. A schematic overview about the enzymatic reaction 
is described in Fig. 2.8. This so derived parasubstituted O6-benzylguanine (BG) 
derivate interacts with the Cysteine145 of the SNAP-tag by transferring its benzyl 
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group and therefore forming a stable thioester bond between the SNAP-tagged 
protein and the labelling moiety.  
 
 
Fig. 2.8: Coupling of SNAP-tagged proteins to BG-modified substrates (fluorochrome as a 
representative). A shows the reaction of the Cystein145 residue within the enzymatic site 
of the SNAP-tag with its BG- substrate linked labelling partner. During this nucleophilic 
SN2 reaction free guanine is released. B describes a bit more detailed the transfer of the 
alkyl group from the functionalizing moiety towards the thiol group of the cysteine within 
the SNAP-tag, leading to a stable thioester coupled protein. Picture was kindly provided 
by Katharina Kolberg from the Fraunhofer Institute IME in Aachen. 
The irreversible post translational labelling reaction has several advantages 
compared to fully genetically labelling and all over expression of proteins, from 
which the most prominent ones are named here: 
1. The labelling process is implemented after the successful expression of the 
protein, which enhances correct protein folding and therefore corresponding 
function.  
2. Due to the covalent binding via the cysteine-residue, the attaching of an 
effector moiety is as stable as direct genetic fusion and expression of two 
binding partners and is protected against potential proteolytic cleavage 
within the expression host.  
3. The SNAP-tag anchor allows the attachment of a huge variety of different 
effector domains like fluorescent dies or toxophores to a single batch of 
expressed proteins.  
SNAP-tagged proteins can be expressed in eukaryotic yeast and mammalian cells 
as well as in prokaryotic E.coli systems [64, 67]. Additionally it was shown that C- 
as well as N-terminal SNAP-fusions were functional, although the functionality 
strongly depends on the fusion partners and has to be proven case by case. All 
these characteristics and the hence resulting flexibility made the SNAP-tag 
technology to an easy, fast and enhanced protein functionalization approach.  
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2.5 Aim of the study 
With a worldwide incidence of about 3- 5% (state 2013) [14] renal impairment is 
still one the most prominent health problems in developed countries. 
Mesangiproliferative Glomerulonephritis thereby represents one of the most 
frequent reasons for endstage renal failure and, in contrast to other kidney related 
diseases, frequently concerns young patients. Triggers for this kind of 
inflammatory diseases are various and its pathogenesis is still not completely 
understood. Nevertheless the immune system is described as main actor.  
To get deeper insight in detailed disease mechanisms suitable animal models are 
mandatory. The best described and commonly used model for 
mesangioproliferative Glomerulonephritis is the anti-Thy 1.1 nephritis in rats. Here 
a single intravenous injection of an antibody directed against rat mesangial cells 
leads to accumulation of antibodies within the glomerular supporting tissue, 
directly resulting in complement derived immunoreactions on the spot. Lysis of 
antibody-marked mesangial cells is followed by rupture of the glomerular 
capillaries, as well as migration and hyper-proliferation of residual cells within the 
mesangial region. Depending on the experimental objectives, the model can be 
performed as an acute approach which enables spontaneous recovery or in a 
chronicle setup finally ending up in progressive renal failure.  Despite enormous 
robustness and high reproducibility, the anti-Thy 1.1 nephritis has it`s restrictions, 
especially in terms of species limitations. The specific Thy 1.1 target is nearly 
exclusively expressed on rat mesangial cells of adult animals, which means that 
for example a huge variety of murine, renal models is strictly inaccessible. Up to 
now there is no relevant murine model for mesangioproliferative 
glomerulonephritis described.  
The development of an antibody-like tool for highly specific detection of mouse 
mesangial cells (mMCs), bearing the potential to induce mesangiolysis as well as 
a mesangioproliferative glomerulonephritis in mice was the main objective of this 
study.  Thereby Phage Display technology should serve as a starting point for the 
generation of the first antibody fragments directed against the surface of murine 
MCs as targets. The establishment of two different selection strategies should 
finally reveal on the one hand strong and selective binders and on the other hand 
moderate but highly mMC specific binders. To functionalize the antibody-like 
proteins an effector domain should be fused to the selected binding domains. 
Following disease characteristics an antibody Fc-part as effector domain should 
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initiate complement driven immune reaction on the binding site and therefore 
mimic the mechanistic approach of the anti-Thy 1.1 rat model.  
Within the framework of this study`s objectives, the following issues were of major 
interest: 
1. The establishment of a stable primarily mMC cell culture as basis for 
robust and consistent antigen preparation during the Phage Display 
selection. 
2. The selection of first, highly murine mesangial cell specific antibody 
fragments.  
3. The functionalization of the proven mMC binders with a murine Fc-part 
ending up with an antibody like protein structure. 
 
All together these generated fusion proteins should be used to induce an anti-
Thy 1.1 like mesangioproliferative mouse Glomerulonephritis model. The new 
perspectives gained from such a model should offer new insights in the disease 
progression and reciprocal effects of mesangioproliferative Glomerulonephritis and 
could finally facilitate new therapeutic approaches within the field of renal 
impairment and failure.  
 
Fig. 2.9: Schematic overview of the working program performed during the objectives of this thesis  
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 Methods 3
If not mentioned otherwise, all works described and performed for this thesis, were 
carried out at standard room temperature (20 °C). 
3.1 Cell biological/Cytological Methods 
3.1.1 Procaryotic cell growth 
Culturing of all stems of E.coli bacteria normally was performed overnight under 
permanent shaking conditions of about 225 rpm. Growth temperature, medium 
composition, as well as addition of appropriate antibiotics were adapted to the 
intended purpose as described below. 
Tab. 3.1: Bacterial cell culture growth media 
Bacterial strain  Medium  Application Temperature Antibiotics 
E.coli TG1 2x TY Library amplification 37 °C 100 µg/ml ampicillin 
2x TY Phage production 30 °C 100 µg/ml ampicillin 
50 µg/ml kanamycin 
E.coli XL1 blue LB DNA  amplification 37 °C 100 µg/ml ampicillin 
 LB DNA  amplification 37 °C 100 µg/ml zeocin 
 
Glycerol stocks of bacterial cultures were produced by adding sterile filtered 60% 
glycerol to bacterial ON cultures in sterile eppendorf tubes up to a final 
concentration of 15 % (v/v). Stocks were permanently stored at -80 °C. 
3.1.2 Transformation of chemi- competent bacterial cells by 
heatshock 
An aliquot of 25 µl chemi-competent E.coli cells were thawed on ice for about 
10min and mixed with 0.4 µl ß- mercaptoethanol prior to DNA addition (for 
reducing disulfide bonds in periplasmic DNAses, resulting in a higher 
transformation efficiency). Subsequently, 0.1- 0.5 µg DNA in 10 mM Tris-HCl, pH 
8.5 are added to the cells and incubated for further 30 min on ice. A heat shock 
was performed for 45 sec in 42°C warm water bath, followed by a 2 min resting 
time on ice resulting in DNA uptake of the bacterial cells. The cells are diluted in 
250 µl pre-heated (37°C) SOC medium and regenerated under shaking conditions 
(200 rpm) at 37°C for about 60 min. 60 µl  transformated bacterial cells are plated 
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out onto LB agar plates supplemented with appropriate antibiotics and incubated 
at 37°C overnight. 
3.1.3 Eucaryotic cell growth  
Cell culture works were performed on a HeraSafe HS18 clean bench (Heraeus 
Instruments & Co. KG, Hanau). 
All cell lines were cultured in appropriate growth medium as described in Tab. 3.2.   
Tab. 3.2: Eucaryotic cell culture growth media 
Cell line  Growth medium Antibiotics heat inactivated FCS 
mMC RPMI 1640 D-Valin 
(Biochrom, Berlin) 
50µg/ml penicillin 
50µg/ml streptomycin 
20 % (w/v)  
NiH3T3 
 
RPMI 1640,L-glutamine 
(Gibco, Karlsruhe) 
50µg/ml penicillin 
50µg/ml streptomycin 
10 % (w/v)  
MCT DMEM, 4500 mg/ml glucose, 
pyruvate, Glutamax, 
L-glutamine 
(Gibco, Karlsruhe) 
50µg/ml penicillin 
50µg/ml streptomycin 
10 % (w/v)  
VSMC DM- VSMC,  
incl. supplement mix  
(PromoCell GmbH, Heidelberg) 
50µg/ml penicillin 
50µg/ml streptomycin 
10 % (w/v)  
Podocytes 
(“Mundel cells”) 
RPMI 1640,L-glutamine 
(Gibco, Karlsruhe) 
50µg/ml penicillin 
50µg/ml streptomycin 
10 % (w/v)  
HEK293T 
 
RPMI 1640 
(Gibco, Karlsruhe) 
50µg/ml penicillin 
50µg/ml streptomycin 
(100µg/ml zeocin) 
10 % (w/v)  
L540cy RPMI 1640 
(Gibco, Karlsruhe) 
50µg/ml penicillin 
50µg/ml streptomycin 
10 % (w/v)  
 
Detaching and passaging of adherent growing eukaryotic cells was performed with 
1 ml Accutase/T75 culture flask at 37°C. Accutase instead of Trypsin/EDTA is 
useful due to the ability to prevent shadding and degradation of cell surface 
structures and hence generation of a maximum native antigen composition. 
The cell maintenance of all cell types was carried out in a humidified atmosphere 
of 5% CO2 at 37°C. 
3.1.4 Transfection of eukaryotic cells 
The transfection of eukaryotic cells was performed using FuGENE® HD (Roche, 
Penzberg) following the manufacturer’s instructions. The transfection kit is based 
3 Methods 27 
on the principle of lipofection. Thereby the negatively charged transfectant DNA is 
transported into the eukaryotic cells via cationic liposomes.   
In short, 1 µg of transfectant DNA is pre-mixed with serum-free RPMI 1640 
medium (final volume of 100 µl) and incubated with 3 µl FuGENE® HD for 15 min 
at room temperature. Afterwards the mixture was carefully added to HEK293T 
cells seeded into 12 well plates.  After incubation for 48 h in serum-free RPMI 
1640 medium cells were subsequently transferred into cell culture flasks (T25 cm2) 
and further grown under selective conditions using RPMI 1640 (see Tab. 3.2). 
As transfection control, all applied plasmids contain an eGFP (enhanced green 
fluorescent protein) reporter gene, which enables direct verification of successful 
transfection by visualizing in fluorescence microscopy at an excitation wavelength 
of 488 nm.  
The cell culture supernatants were collected and used for extraction and 
purification of recombinant expressed proteins as well as direct functionality 
analysis.  
 
3.1.5 Isolation of murine mesangial cells 
The isolation of murine glomeruli as basis for the isolation of target cells was 
performed using a technique described by Takemoto et al (2002) [121].  
First of all C57BL/6 mice were weighed to determine the amount of intra-peritoneal 
anaesthesia needed. Afterwards the animals were pre-sedated with isofloran for a 
few seconds, followed by an intra-peritoneal anaesthesia with 15 µl/g bodyweight 
Avertin (by now withdrawn from the market, due to evidenced lack of response to 
toe or tail pinch). After opening of the peritoneum and freeing of the urinary tract, 
both kidneys were perfused at once via retrograde injection of 2 ml dissolved, 
spherical superparamagnetic beads (Dynabeads® M-450) into the vena cava 
inferior. The beads are entering the kidney via the vena renalis and stack within 
the capillary structure of the glomerular tuft due to their diameter of about 4.5 µm. 
Successful perfusion is visual by the brightening of the kidneys. A light colour of 
the liver and the kidneys showed an effective perfusion due to a flush out of the 
blood from these organs. Subsequently, both kidneys are removed from the body 
and detached from any residual connective tissue, fat and the renal capsule.  
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The kidneys are transferred into a sterile culture dish filled with 10 ml tissue digest 
medium (Tab. 7.5) and are incubated for about 45 min at 37°C and 5% CO2. This 
enzymatic driven digest is supported by additional mechanical disruption of the 
organ structure with sterile scalpels and pipettes. Finally straining the cell-
suspension through a 100 µm cell-strainer separated residual connective tissue 
debris from a cell suspension containing parts of tubular structures as well as 
murine glomeruli.   
Separation of intact glomeruli was performed with a Dynal MPC™-S magnetic 
separator (Dynal, Oslo, Norway). The cell suspension was therefore transferred 
into 1.5 ml eppendorf tubes, the magnet was placed behind, causing accumulation 
of beads at the backside of these tubes. Repeated washing steps with RPMI1640 
D-Valin culture medium (Tab. 3.2) are performed till a purity of at least 80-90 % 
glomeruli within the cell suspension is reached, which is confirmed by microscopic 
control.   
The purified glomeruli suspension is incubated in RPMI1640 medium containing 
D-valin as separating agent for one week without moving. Within this time the 
mesangial cells are, due to their ability to convert D-valin into L-valin [121], able to 
grow out of the glomerular structure. Selective pressure implemented via the 
culture medium, as well as regular visual controls of the cultured cells, are 
performed over the whole cultivation procedure. Over a time of about 2- 4 weeks, 
all residual tubular or glomerular cells are rejected and a pure, primary, murine 
mesangial cell culture is present.  
Primary mesangial cells were cultivated in RPMI1640 D-valin medium containing 
20% FCS and 1% P/S. The cells were further on used for whole cell ELISA 
experiments as well as for membrane preparations. Primary mesangial cells were 
always used at a maximum number of 8 to 10 passages to ensure a stable and 
native expression pattern of the cell surface specific structures.  
 
3.1.6 Preparation of eukaryotic membrane fractions  
In case of generating antibodies against so far undefined antigens in complex 
biological systems, small membrane fragments of eukaryotic cells were more 
suitable as antigens then whole cells are. Whole cells experience the 
disadvantage that disruption during the panning procedures released cytosolic 
proteins and nuclear structures, which served as potential miss-antigens for the 
putative cell-specific antibodies.  
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The protocol for antigen preparation used in this thesis was described by Tur et al 
[127] and is based on a combination of sonification and ultracentrifugation ending 
up in isolated, small membrane fraction particles that retained, regarding the 
membrane surface pattern, their native conformation and functionality and 
therefore served as appropriate selection antigen.    
For this, an undefiled eukaryotic cell suspension with a quantity/an amount of 
1* 107 cells of interest is washed with 10 ml 1x PBS, harvested with 1 ml 
Accutase/tissue flask (see 3.1.3) and pelleted by centrifugation at 200 g for 6 min. 
Washing is repeated twice by re-suspending the cell pellet in 10 ml 1xPBS and 
centrifugation under the same conditions. Finally the cells are taken up in 8 ml ice-
cold homogenization buffer (Tab. 7.2) and put on ice. Applying ultrasonic sound 
with an intensity of 30% for 1 min on ice broke up the cell integrity. This step is 
repeated 4 times until the cell particle solution becomes clear. Centrifugation of 
this suspension at 1000 g and 4°C for 12 min pelleted unneeded large cell 
membrane fragments, whereas the supernatant containing small membrane 
fragments of interest is transferred into an ultracentrifugation tube and is 
centrifuged at 100.000 g and 4°C for 20 min. Within the second step, the pellet of 
the small outer cell membrane fractions is re-suspended in 10 ml re-suspension 
buffer (50 mM Tris-HCl, pH 7.5) and again centrifuged under the above named 
conditions. The pellet of the membrane fragments is re-suspended in 1 ml PBS 
ending up with a stock concentration of 1*107 cells/ ml. 200 µl aliquots are stored 
at -80 °C for further usage as selection and screening antigen in ELISA 
experiments. 
 
3.2 Molecular genetic methods 
General recombinant DNA techniques including DNA precipitation, restriction 
enzyme digest, DNA ligation and DNA agarose gel electrophoresis were 
performed according to the standard protocols described by Sambrook et al. 
(1996) or following the manufacturer’s manuals. 
3.2.1 Isolation of plasmid and phagemid DNA from E.coli 
Preparation of plasmid DNA from recombinant E.coli clones was performed using 
Plasmid DNA isolation kits from Macherey & Nagel (Düren), following the 
manufacturer’s manual. Depending on the amount of demanded DNA, a 
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NucleoSpin® Plasmid kit (5 ml ON culture) or a NucleoBond® PC100 kit (25 ml 
ON culture) were chosen. 
Purity and concentration of isolated DNA were determined by analytical agarose 
gel electrophoresis and photometric analysis.  
 
3.2.2 Determination of nucleic acid concentration 
Quality and quantity of DNA was confirmed by spectrophotometric  analysis.  
DNA concentrations were determined by measuring the optical density of a DNA 
solution at a wave length of 260 nm (OD260nm).  A value of 1 corresponds 
to ~ 50μg/ml for double stranded (ds) DNA.  
Purity of the nucleic acid was ascertained by the OD260nm/OD280nm ratio of the 
measured optical density, which has its optimum at a value of 1.8 for pure DNA. 
    
3.2.3 Restriction of DNA 
All DNA restriction endonucleases used, as well as their appropriate buffers, were 
obtained from Fermentas (St. Leon-Rot, Germany) and New England Biolabs 
(Ipswich, USA). 
Restriction of DNA was performed following enhanced protocols related to the 
manufacturers' ones. In case of using two different endonucleases (double digest) 
the restriction was carried out following the manufacturers' instruction in the most 
suitable buffer system. 
3.2.4 Dephosphorilation of restricted vectors 
The dephosphorylation of restricted plasmid DNA (see 3.2.3) was performed using 
the Alkaline Phosphatase (Calf Intestinal; CIP) following the manufacturers 
protocols. CIP catalysed, amongst others, the removing of 5’- phosphate of DNA 
and therefore prevented the re-ligation of the plasmid after restriction. 
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3.2.5 Ligation of restricted DNA 
The fusion of two DNA fragments treated with restriction endonucleases (3.2.3) 
was carried out using T4-DNA ligase (Tab. 7.6: Enzyme and reaction kits from 
Invitrogen (Darmstadt) following the manufacturers' instructions in a total volume 
of 40 µl. The molar insert/vector ratio was set to 5:1. The ligation samples were 
incubated in a PCR cycler (Tab. 7.1) for 3 hours at 23°C. Ligation samples were 
transformated into supercompetent XL1-blue cells (see 3.1.2) and stroke onto 
selective LB-agar plates containing vector-specific antibiotics. Insert control was 
performed using colony PCR and subsequent DNA sequencing analysis of insert-
positive clones.   
3.2.6 Analytical agarose gel electrophoresis  
Any kind of recombinant DNA, undigested (see 3.2.1) or restriction enzyme 
digested plasmid DNA (see 3.2.3) and PCR fragments (see 3.2.9) were separated 
by horizontal gel electrophoresis in 0.8- 1% (w/v) agarose gels prepared in 1x TAE 
buffer containing 0.1 µg/µl ethidium bromide for DNA visualization.  
Defined amounts of appropriate DNA molecular mass rulers, e.g. the MassRuler™ 
DNA Ladder Mix (Fermentas, St. Leon-Rot, Germany) were used for accurate 
determination of DNA size, quality/purity and concentration.  
After electrophoretic separation the DNA was visualized in a UV-transluminator 
system from Biostep (Jahnsdorf) at 302 nm wave length. The processing and 
documentation of results was performed using Argus X1 software (see A.2). 
3.2.7 Preparative agarose gel electrophoresis 
If isolation of specific DNA products after analytical agarose gelelectrophoresis 
was necessary a so called preparative gel electrophoresis was carried out. The 
displayed DNA fragments of interest were cut out of the agarose gel using a 
scalpel. Purification was performed with the QIAquick gel extraction kit (Qiagen, 
Hilden, Germany) following the manufacturer’s instructions.  Concentrations were 
determined as described above (3.2.2). 
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3.2.8 Sequencing of recombinant DNA 
Sequencing of recombinant plasmid, genes or DNA amplification products was 
performed by Eurofins MWG GmbH (Ebersberg). The commercial provider uses a 
method called Cycle sequencing, based on the protocol of the chain terminator 
sequencing method by Sanger et al. [108]. 
Subsequent chromatogram analysis was performed using the Chromas software 
package, sequence analysis were performed using VectorNTI and Geneious 
software (see A.2).  
 
3.2.9 Polymerase Chain Reaction (PCR) 
Enzymatic driven amplification and modification of special DNA fragments was 
performed using Polymerase Chain Reaction (PCR) as a standard in-vitro-method 
[106]. 
If not mentioned otherwise all PCR reactions were performed under the thermal 
reaction conditions shown in table Tab. 3.3 below. Standard PCR reactions 
normally included 25 cycles of steps 2- 4.  
The optimal annealing temperatures of the primer were determined in combination 
with manufactures specifications based on the formula  
   Tp = 4(G +C) + 2(A + T) 
and on experimental try outs with temperature gradients. The elongation time 
varied between 1 and 4 min, depending on the elongation speed of the applied 
polymerase and the DNA template size.    
3.2.9.1 Standard hot-start PCR amplification for DNA fragments 
The PCR reactions were carried out in 0.2 ml PCR-tube strips (Nalgene®, 
Rochester, USA) using a GeneAmp PCR thermocycler from Applied Biosystems 
(Carlsbad, California, USA). The standard reaction volume was 30 µl samples and 
was composed as follows:  
Tab. 3.3: Composure of standard PCR sample preparation 
Component Volume  Final concentration 
5 x GoTaq Polymerase buffer  4 µl 1 x 
MgCl2  (included within buffer) 2 mM 
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dNTP mixture 1 µl 10 mM/µl 
Forward oligonucleotide primer 1 µl 10 pmol/µl 
Reverse oligonucleotide primer 1 µl 10 pmol/µl 
Template DNA 0,5- 1,5 µl 10-400 ng 
GoTaq Polymerase (5 U/µl) 0.5 µl 2.5 U 
Sterile, de-ionized water H2O ad 30 µl 
 
If not mentioned otherwise all PCR reactions were performed under reaction 
conditions shown in Tab. 3.4: below.     
Tab. 3.4: PCR reaction conditions 
Step  Time [s] Temperature  [°C]  Step 
1 120 94 inital denaturation 
2 30 94 denaturation 
3 45 Tp annealing 
4 60-240 72 elongation 
5 420 72 final elongation 
 
All PCR products were analyzed on a 1 % (w/v) agarose gel with appropriate DNA 
ladders to confirm a successful amplification and integrity of the amplified product. 
 
3.2.9.2 Colony PCR 
In some cases PCR reactions were not performed with purified DNA samples, but 
with a small amount of a bacterial colony from a selection agar- plate. The 
standard sample composition remained as already described above (3.2.9.1), with 
the change of 1 tip of a bacterial colony instead of 10- 400 ng purified DNA as 
template.  The reaction conditions were extended by an additional denaturation 
step in the beginning. This was necessary to break up the bacterial cell structure 
and release the plasmid DNA into the reaction sample. To ensure best 
performance environment for the DNA polymerase this denaturation step was 
performed for 10 min at 94 °C before the addition of the enzyme. Directly after this 
pre-denaturation step, the polymerase was added to the sample mixture and the 
standard hot-start PCR was started.   
All further steps, namely gel electrophoretic analysis and sequencing were carried 
out as already described (3.2.6 and 3.2.8).  
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3.2.10 Site-directed PCR mutagenesis of scFv- phagemids 
The principle of site- directed mutagenesis of double stranded plasmid DNA is 
based on standard PCR amplification, described in 3.2.9. This mutagenesis 
method allowed the introduction of point mutations and the insertion or deletion of 
small base-sequences at nearly any point of a plasmid/gene.  
Therefore mutagenic primers, incorporating the desired mutation in form of a 
mismatch to the maternal DNA sequence were used as starting point for the 
elongation of the new DNA and were directly integrated into the new plasmid. In 
comparison to standard polymerase chain reaction, the whole site-directed 
mutagenesis only comprehended of twelve cycles, including denaturation, 
annealing and elongation (steps 2-4). The tables below show the detailed sample 
composition as well as the reaction protocol.  
Tab. 3.5: Composure of site-directed mutagenesis sample preparation 
Component Volume  Final concentration 
10 x Pfu Polymerase buffer  3 µl 1 x 
MgCl2  (included within buffer) 2 mM 
dNTP mixture 1 µl 10 mM/µl 
Mut_forward primer 1 µl 10 pmol/µl 
Mut_reverse primer 1 µl 10 pmol/µl 
Template plasmid DNA 0,5- 1,5 µl 10-400 ng 
Pfu Polymerase (5 U/µl) 0.5 µl 2.5 U 
Sterile, de-ionized water H2O ad 30 µl 
Tab. 3.6: Site-directed mutagenesis reaction conditions 
Step  Time [s] Temperature  [°C] Step 
1 30 95 inital denaturation 
2 30 95 denaturation 
3 60 55 annealing 
4 60/kb of plasmid length 68 elongation 
 
Site-directed mutagenesis was essentially performed with a proof-reading DNA 
polymerase to ensure high fidelity extension during the elongation process without 
replacing the mutant primer and mutation sites, respectively. Directly after thermal 
cycling, the product was treated with DpnI. This restriction enzyme specifically 
recognizes methylated DNA and has its target site/sequence at 5’-Gm6ATC-3’. 
Since recombinant plasmid DNA, such as PCR amplified one, is not methylated, 
only the parental, bacterial sourced plasmid was digested. The nicked circular 
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DNA containing the mutation was subsequently transformed into XL1-blue 
supercompetent cells, where the open form is immediately repaired.  
Potential bacterial clones were analysed in terms of correct mutation and plasmid 
integrity by agarose gel electrophoresis and sequencing analysis, see 3.2.8. 
3.3 Methods for phage analysis 
As source for all phage display experiments the Tomlinson single-chain libraries I 
and J provided from MRC Cambridge UK were used.  
First-step propagation and stock production of the libraries was performed by pre-
cultivation of an aliquot of a single chain library in 200 ml 2xTY-AG medium at 
37°C, shaking at 225 rpm for about 2 hours until an OD600 of 0.5 was reached.  
For small or large scale production of single chain presenting phages 200 µl to 
50 ml of this culture can be infected with helper- phage (moi ≥ 20).  The infection 
procedure is described below. The helper-bacteriophages used during this thesis 
were commercially acquired (see A.11). 
For stock production, the E. coli TG1F+ cultures were grown for further 2 hours 
without helper-phage infection, centrifuged for 10 minutes at 10 800 g and 4°C and 
were re-suspended in 10 ml 2xTY-AG containing 15% glycerol. Aliquots of 500 µl 
were stored at -80°C for further usage.           
3.3.1 ScFv- phage production 
After the E. coli TG1F+ culture reached the exponential growth phase at an OD600 
of 0.5, 5 ml of the bacteria were infected with 25 µl M13KO7 helperphage (moi ≥ 
20) and incubated for 30 min at 37°C without shaking plus additional 30 min at the 
same temperature, shaking (225 rpm). After the infection-process, the bacterial 
cultures were centrifuged at 3000 g for 10 min to separate the excess helper-
phages from the infected E. coli TG1F+. The helperphage containing supernatant 
was discarded, whereas the bacterial pellet was subsequently re-suspended in 25 
ml fresh 2xTY-AK medium containing 0.25 mM IPTG to induce scFv-phage 
production. Expression of phage particles in E. coli TG1 was induced by 
incubation of the infected, re-suspended bacterial culture at 30°C, shaking (225 
rpm), for at least 17-20 hours. The bacterial overnight cultures were centrifuged for 
30 min at 4500 g and 4°C. The supernatant containing the assembled 
scFv-phages was forwarded for phage precipitation. 
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3.3.2 Phage precipitation 
Precipitation, or “rescue” of soluble scFv-phages produced in bacteria and 
secreted into the growth medium supernatant is performed by adding 
polyethylenglycol (PEG) to the phage supernatant. This type of polymer modified 
the phage`s hydrate-shell by withdrawing water and therewith changing the 
phage`s weight. Therefore 1/5 volume ice-cold 20 % PEG/NaCl (Tab. 7.2) solution 
were added to the bacterial supernatant and incubated for 60 min on ice with 
occasional shaking. Subsequent centrifugation of the mixture for 30 min at 
12.000 g and 4°C pelleted the precipitated phages. After careful but complete 
removing of the PEG/NaCl supernatant the phage-pellet was re-suspended in an 
appropriate volume (see Tab. 3.7) PBS, transferred into a 2 ml eppendorf tube and 
centrifuged again at maximum g force (13000 g) to eliminate residual bacterial 
debris. The cleared supernatant, containing soluble scFv-phages is separated 
from the pellet and stored at 4°C for further usage.  
Tab. 3.7: Re-suspension volumes for phage rescue 
Phage Display selection round  Re-suspension volume 
1st  400 µl 
2nd  200 µl 
3rd  100-200 µl 
4th  100 µl 
Large scale phage production  400 µl 
3.3.3 Phage titration 
The determination of infective phage titre after phage precipitation and before and 
after each phage display selection round was carried out via an indirect titration 
assay, counting the number of colony forming units (cfu) of infected bacteria. 
Therefore non-modified, fresh E. coli TG1F+ bacteria were grown to mid-log phase 
in 2x TY medium. 900 µl of this culture were inoculated each with 100 µl of one 
serial dilution step (10-6 – 10-10) of the appropriate phage preparation or stock. The 
infection was completely performed at 37°C for 30 min without shaking followed by 
additional 30 min shaking at 225 rpm. After transduction 100 µl/dilution step of the 
bacterial culture were plated out on 2x TY-AG agar plates and incubated over 
night at 37°C.  After counting the number of grown infected bacterial colonies, the 
average phage titre was calculated according to the following equation: 
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  phage titer [phage/ml] = number of counted bacterial colonies/ (df x V [ml]) 
       df = dilution factor 
       V = volume for stroke out  
 
3.3.4 Selection of surface-binding single-chain bacteriophages 
Efficient enrichment of antibody fragments against cell surface structures depends 
on several facts. The decision for the type of selection antigen plays a major role. 
On the one hand a maximum of the antigens native confirmation and environment 
increases specificity of the selected antibody fragment. On the other hand 
stringent experimental conditions, for example with detergents like Tween within 
the washing buffers or strong shearing forces during binding and washing 
procedures can disrupt the antigens structures and expose unwanted miss-
antigens. A well-considered choice decides upon success or failure of phage 
display selection. During this thesis immobilised membrane fragments (3.1.6) of 
target murine mesangial cells and competing, related cells were used for selection 
of surface specific scFv-phages on 96 well plates. Validating binding assays of the 
selected scFv-binder pool on viable cells were performed to ensure specific 
binding on cell surface antigens.    
3.3.4.1 Negative selection or depletion of antibody fragments  
For pre-sorting of single-chain presenting phages the precipitated phage library 
was incubated with membrane fractions of strongly related, but non-target cell 
membrane fractions. Therefore membrane fractions of murine fibroblasts and 
murine tubular cells were immobilized on a 96 well MaxiSorp™-plate for at least 
16 hours at 4 °C. The antigens for the negative selection were washed three times 
with PBS and blocked with 200 µl 5 % MPBS per well for 2 hours shaking at room 
temperature. The selection antibody fragments likewise were blocked 1:1 with 5% 
MPBS under the same conditions to mask potential unspecific binding epitopes on 
the antigen as well as on the scFv-phages. After incubation of 200 µl pre-blocked 
antibody fragments on the blocked negative antigen for 1 hour, shaking on a 
microtiter plate shaker at room temperature, the unspecific scFv-phages were 
transferred “well to well” to the blocked target antigens to be further used for 
positive selection.   
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3.3.4.2 Positive selection  
The target membrane fractions were as well immobilised and blocked on 96 well 
MaxiSorp™-plates as already described above. Depending on the state of the 
selection round and its purpose (see 2.3.6) the positive antigen was used in suited 
dilutions. The 200 µl of the pre-sorted, depleted scFv-phages per well were 
incubated with the membrane fractions for 1 hour shaking at 350 rpm at room 
temperature. All unbound scFv-phages were removed and discarded by careful 
pipetting. A stepwise washing procedure (described in 2.3.6) with PBST was used 
to remove residual unspecific single-chain phages from the selection antigens. 
Elution of the specifically bound phage pool from the antigen was performed by 
addition of 200 µl 0.2 M Glycin-HCl buffer (pH 2.2) to each antigen-coated well. 
After incubation for 10 min at room temperature under shaking conditions, 200 µl 
eluted scFv-phages were pH -neutralised in 125 µl of 1 M Tris-HCl (pH7.5).  
3.3.4.3 Rescue of selected scFv-phages 
Directly after elution and neutralisation of the selected phage pool, the output titer 
of the selection round was determined as already described in 3.3.3. 
Subsequently, the selected phage pool was used for reinfection of 14 ml fresh 
E. coli TG1F+ bacteria grown up to mid-log phase. Additionally 200 µl of such 
E. coli TG1F+ bacteria were added to each selection well to be as well reinfected 
with strong-bound scFv-phages left in the microtiter selection wells. The reinfection 
was allowed by incubation of phages with bacteria for 30 minutes at room 
temperature without shaking plus 30 min under shaking conditions.  All reinfection 
mixtures were collected in a falcon tube and spun down for 5 min at 4500 g. The 
supernatant was completely discarded, the bacterial pellet was resuspended in 
600 µl 2xTY medium and stroke out on LB-AG agar plates. After overnight 
incubation of the plates at 37°C, 1.5 ml 2xTY-AG medium per agar plate were 
used to scrape off the bacteria.  
The rescued, phage-infected, bacterial suspension can be either used directly for 
new phage production and another selection round or can be stored in aliquots 
at - 80°C by addition of sterile glycerol to a final concentration of 15%.        
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3.4 Protein-biochemical methods 
3.4.1 SDS-Polyacrylamid electrophoresis (SDS-PAGE) 
Separation of protein samples according to their electric charge and their 
molecular size was performed using discontinuous, reducing sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) according to Laemmli et 
al.. Protein samples were diluted 1/5 in 5 x protein sample buffer (Tab. 7.2) and 
denatured at 99°C for 5 min. The samples were applied to 10% SDS gels and 
separated at 120 V for about one and a half hour. For unspecific visualization of 
separated proteins the SDS gel was stained in coomassie stain (Tab. 7.2) for 
45 min. Excessive staining solution was removed and the gel was incubated with 
coomassie destain (Tab. 7.2) at room temperature until an appropriate background 
bleaching was reached. The AIDA software (see A.2), together with a BSA 
reference standard curve was used for the densitometric evaluation of protein 
amount. The sizes of the proteins were estimated using a broad range molecular 
weight standard.  
3.4.2 Western Blot analysis 
In case of specific detection of proteins owing to their specific properties or tags 
Western Blot analysis was performed. Therefore proteins were separated by SDS-
PAGE as described above (3.4.1) and transferred onto a nitrocellulose membrane 
by electroblotting. Blocking of unspecific binding sites was carried out by 
incubating the membrane with 2% MPBS for 2 hours at room temperature. After 
washing threefold with 0.05% PBST for 5 min, the protein detection was performed 
by addition of a protein specific primary antibody (dissolved in 2% MPBS), at least 
for 1 hour at room temperature. Removing of unbound primary antibody, followed 
by repeated washing steps as already described was essential for detection of 
bound antibody by an enzyme-conjugated (horse radish peroxidise, HRP), 
secondary antibody (dissolved in 2% MPBS). After incubation of this detection 
antibody, the membrane was washed five times with 0.05 % PBST to clear from 
any residual free antibodies. The colorimetric development of the protein blotted 
onto the nitrocellulose membrane was carried out with diaminobenzidine (DAB) as 
substrate for HRP. After sufficient staining the conversion of the substrate was 
stopped by the addition of de-ionized water. As described above (3.4.1), a broad 
range molecular weight standard was used for the estimation of protein size.  
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3.4.3 Protein Purification  
The processing of recombinant proteins comprises different purification steps 
depending on their subsequent applications. Eucaryotic protein production in cell 
culture systems as well as prokaryotic production in bacteria leads to a 
heterogeneous mixture of host proteins and host DNA including the recombinant 
protein of interest.  
3.4.3.1 Immobilized metal ion affinity chromatography (IMAC) 
Affinity chromatography is a method to isolate poly-His-tagged, recombinant 
proteins. It is based on the specific, reversible interactions between the poly-His-
tag of the target protein and positively charged, chelating gel matrices. These 
matrices can be part of particular purification columns or act as solid phase of 
batch-purification resins. Nitrilotriacetic acid (NTA) or alternatively Talon™ 
represent the most common chelating agents. In detail, consecutively arranged 
histidines, especially their functional imidazole groups as electron donator, interact 
with bivalent, positive ions (e.g. Ni2+ or Co2+) immobilized on gel matrices.  This 
covalent binding of the His-tagged proteins can be reversed by addition of 
competitive molecules (e.g. free imidazole within elution buffer), displacing the 
functional recombinant imidazole groups and thereby eluting the protein of interest 
from the matrix.  
HEK293T cells were used to express recombinant scFv-Fc proteins and secrete 
them into the cell culture supernatant. The supernatant was cleared from cell 
debris by centrifugation at 4500 g and 4°C for 5 minutes. Three volume units 
(9 ml) supernatant were mixed with one volume unit (3 ml) 4x equilibration/wash 
buffer (Tab. 7.3). After addition of 100 µl Ni-NTA resin, pre-equilibrated with 1x 
equilibration buffer, the mixture was incubated for 1 hour 30 min at room 
temperature under continuous shaking (300 rpm) to allow covalent binding of the 
His-tagged proteins to the Ni2+-ions of the resin. Afterwards the matrix was washed 
two times by centrifugating for 5 min at 4500 g and 4°C. The first washing step 
was performed with 1x equilibration/wash buffer including 10 mM imidazole, the 
second step with 40 mM in order to reduce the amount of unspecifically bound 
proteins at the matrix. Finally the matrix-bound His-tagged single-chains were 
eluted by incubation with 100 µl 1x equilibration/wash buffer for 10 min at room 
temperature and centrifugation as already described. The isolated proteins were 
either stored at 4°C or were directly analysed in SDS-PAGE and Western Blot 
analysis.  
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3.4.3.2 Size exclusion chromatography (SEC) 
As additional step after IMAC in case of unwanted proteins left from the 
expression and purification process or in case of degradation products of the scFv-
proteins a size exclusion chromatography (also called: gel filtration) was 
performed. The principal of this chromatographic method is to separate proteins 
according to their molecular size by filtering them through a porous polymer 
matrix. The matrix consists of dextran beads with pores of different sizes, packed 
within a horizontal column. While the aqueous protein solution is applied to the 
column under low pressure, passing proteins can enter the different pore spaces 
according to their size and are therefore decelerated in their passing time. The gel 
filtration was performed using Superdex 75 prep grade XK16/70 column 
(Amersham Biosciences, GE Healthcare, Munich) and PBS as elution buffer 
following the manufacturer’s manual. Due to the single-chain-Fc protein size of 
75 kDa the flow rate was adjusted to 0.75 ml/min. Elution fractions were collected 
in 500 µl/ fraction and were analyzed by SDS-PAGE and Western-Blot.       
3.4.4 Enzyme-linked immunosorbent assay (ELISA) 
3.4.4.1 Polyclonal phage-ELISA 
Enrichment of antigen-positive phages during the library`s selection rounds was 
analysed in polyclonal phage ELISA experiments. Therefore the precipitated, 
mixed phages, emerged after the single selection rounds, were used as primary 
antibody for the detection assay. As antigen the membrane fractions of interest 
were prepared in the same dilutions in PBS as used for the selection procedures 
and were coated to MaxiSorp™ microtiter plates at 4°C overnight. The next day 
the antigens were washed three times with PBS and blocked with 2% MPBS for 
2 hours at room temperature, shaking at 350 rpm. The blocking agent was 
removed, the wells were washed again and 100 µl per well of the heterogeneous 
phage pool were pipetted into one coated, blocked microtiter plate. The scFv-
phages were also blocked with 2% MPBS during the incubation time of 1 hour at 
room temperature and shaking at 350 rpm to decrease unspecific binding of the 
phages. Unbound single-chain phages were carefully removed from the coated 
antigen wells and discarded, the antigens were washed three times with PBS. 
Binding of scFv-phages to the coated antigen was detected with the anti-M13-HRP 
antibody (see A.7) diluted 1:5000 in 2% MPBS. Visualisation of the binding was 
carried out with 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS). 
100 µl of the prepared substrate were added to each coated well. The readout of 
the polyclonal phage ELISA was monitored spectrophotometrically at three time 
points, 15 min, 45 min and 60 min.  
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3.4.4.2 Monoclonal phage ELISA 
In case of an enrichment of antigen-specific scFv-phages after a certain number of 
selection rounds, single monoclonal antibody fragments were analysed for their 
binding abilities to murine mesangial and related competitive cells. Monoclonal 
scFv-phages were generated by picking single bacterial colonies from the titration 
plates after the selection round of interest and inoculated them, each into one 
single well of a microtiter cell culture plate, prepared with 150 µl 2xTY-AG medium 
per well. This resulting master plate was cultivated overnight at 37°C under 
shaking conditions. Cross contaminations from well to well were avoided by 
sealing the microtiter plates with sterile, breathable films. The next day, a copy of 
the plate was generated by inoculating a small drop of each overgrown well into 
the corresponding well of a fresh microtiter plate, also prepared with 2xTY-AG 
medium. The master plate was stored as backup for further experiments at -80°C 
by addition of 50 µl 60% glycerol (final concentration 15%) to each well. The new 
infection plate was incubated, shaking at 250 rpm at 37°C for 2 hours, until the 
bacteria are grown to mid log phase. Each well containing a monoclonal bacterial 
culture was infected with 109 helperphages. The infection plate was cultivated 
30 min at 37°C without shaking, to allow infection of the bacteria by the M13KO7 
helperphage and additionally 30 min at the same temperature, shaking at 250 rpm. 
As already described in 3.3.1, the microtiter plate was centrifuged at 3000 g for 10 
min. The supernatant, containing helperphages, was removed and the bacterial 
cell pellet was re-suspended in 150 µl 2xTY-AK medium supplemented with 0.25 
mM IPTG to induce the production of monoclonal scFv-phages within the single 
wells. After overnight incubation at 30°C, shaking, the infection plate was 
centrifuged at 1800 g for 10 min. The supernatant containing monoclonal scFv-
phages was used as primary antibodies in ELISA experiment as already described 
in 3.4.4. 
 
3.4.4.3 Whole cell phage ELISA 
Additionally to binding analysis of selected scFv-antibodies on membrane fractions 
of primary murine mesangial cells and competitive cell lines, monoclonal 
scFv-presenting phages were also tested on viable, whole cells as antigen. 
Therefore cells were seeded into single wells of a 96 well plates and were grown 
at 37°C and 5% CO2 till confluence of about 70-80% cells/well was reached. After 
allowing the cells to attach onto the ELISA plate for at least 24 hours, the cell 
culture medium of each well was removed and the cells were carefully washed 
with PBS. Cells were air-dried by removing the PBS and leaving them for 5 min at 
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room temperature. Fixation was performed applying 100 µl 100% ice cold ethanol 
(-20°C) to each well, leaving them for about 10 min at RT and finally air drying the 
cells for 5 min at room temperature. The immobilized cell antigens were blocked 
with 2% MPBST for at least 2 h at room temperature and shaking at 350 rpm. The 
96-well plate was washed three times with PBST and incubated with a mixture of 
50 µl monoclonal scFv-phages and 100 µl blocking buffer. As already described, 
unbound phages were removed by washing the wells three times quickly with 
PBST. Phage antibodies were detected with monoclonal anti-M13-HRP antibody 
and visualized by enzymatic conversion of ABTS as substrate. Evaluation of 
absorbance was carried out spectrophotometrically using a microplate reader 
(TECAN, Männedorf, Switzerland) and i-control™ microplate reader software 
(TECAN, Männedorf, Switzerland). 
3.4.4.4 Monoclonal soluble protein ELISA 
In-vitro binding analysis of recombinant, soluble single chain proteins, produced in 
eukaryotic HEK293T cells was carried out in ELISA experiments on immobilized 
membrane fractions of murine mesangial cells and concurrent cell types. As 
already described in 3.4.4, membrane fractions diluted in PBS, were coated on 
MaxiSorp™ microtiter plates overnight at 4°C. After three short washing steps with 
PBS the membrane fractions were blocked with 2% milk powder in PBS for 2 
hours at room temperature. Exhausted supernatant of HEK293T cells transfected 
with scFv-Fc coding DNA was diluted in blocking buffer (1:1 in 2% MPBS) and 
200 µl were incubated with the antigen coated to the microtiter plate wells. 
Interactions of soluble scFv-antibodies with exposed antigens were detected via 
the protein`s C-terminal His-tag and a HRP-coupled α-poly-His antibody (Sigma 
Aldrich, St. Louis, USA). Absorbance of converted ABTS was detected at 405 nm 
with 490 nm reference wave length as already mentioned above.  
3.4.5 Immunohistochemistry  
The specificity of selected scFv-binders to their antigens within the native tissue 
environment was evaluated on cryo-tissue sections of murine kidneys. Therefore 
healthy kidneys and all other murine control organs of interest were embedded in 
Tissue-Tek® (Sakura Finetek Germany, Staufen) and deep frozen in liquid 
nitrogen for at least 10 minutes. The tissues were stored at -80°C. Tissue sections 
of 4-6 µm were prepared using a Cryostat. For immunohistochemical analysis, 
target tissue slices were washed twice for 5 min with PBS at room temperature 
and were then incubated with either scFv-phages, cell culture supernatants of 
scFv-Fc transfected HEK293T cells or purified scFv-Fc antibodies (each diluted 
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1:1 in 2% BSA to block unspecific epitopes) for at least 16 hours at 4°C in a wet 
chamber. Leaving out the primary antibodies and instead applying 2% BSA/PBS to 
the sections was used as negative controls. After incubation unbound primary 
scFv-binders were eliminated by washing twice with PBS for 5 min at room 
temperature. The distribution of scFv- fusion proteins over the target tissue 
sections was visualized using two different techniques.  
3.4.5.1 Light microscopic immunohistochemistry with scFv-phages  
In case of immunohistochemistry using scFv-phages as primary antibody towards 
tissue sections, the HRP-coupled anti-M13 antibody (GE healthcare, 
Buckinghamshire, UK) diluted 1:300 in 2% BSA, served as chromogenic reporter 
antibody. After incubation for 1hour at room temperature in a wet chamber, the 
reporter antibody was removed by quickly washing twice with PBS. The tissue 
sections were incubated with a 3,3'-Diaminobenzidine (DAB) solution as substrate 
for the horse reddish peroxidase (HRP) for 10 min at 37°C. The enzymatic 
conversion of the substrate was stopped with de-ionized H2O for 5 min. For a 
better orientation within the tissues, the sections were counterstained with 
methylene green for 2 minutes. Afterwards tissues were dehydrated by dipping 
through an increasing alcohol row (2 x 95% EtOH; 3 x100% EtOH) and were 
finally fixed by exposing 3 x 5 minutes to a xylene bath. To preserve the tissue 
sections the object slides were immediately covered with Roti®Histokitt inclusion 
medium (Carl Roth, Karlsruhe, Germany) and coverslips. The covered tissue 
sections were dried at room temperature for at least 2 hours and were further 
stored at room temperature. The analysis was performed using a light microscope.  
3.4.5.2 Fluorescence microscopic immunohistochemistry with soluble 
scFv-Fc fusion proteins 
Immunofluorescence was used as method for analysing the binding specificity of 
selected scFv-antibodies towards their target cells in direct comparison to a single 
related cell target. If not mentioned otherwise, all immunofluorescence 
experiments were performed as double-stainings. In contrast to immune staining 
based on chromogenic secondary, reporter antibodies all steps carried out with 
fluorogenic reporter antibodies must have been carried out in lightproof wet 
chambers and jars to prevent bleaching of the fluorophor.  As already described 
above (3.4.5.1), the kidney tissue sections were incubated with soluble scFv-Fc 
fusion proteins diluted 1:1 in 2% BSA over night (ON) at 4°C in a wet chamber to 
ensure that the tissue is not dehydrated and therefore damaged. The next day, the 
unbound scFv-antibodies were washed away from the kidney sections with PBS 
(2 x 5 min) and were incubated with the additional primary co-staining antibody of 
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interest, also diluted in 2% BSA (1:300). After 1 hour at room temperature in a wet 
chamber the co-staining antibody was as well removed by washing twice for 5 min 
with PBS. The bound primary antibodies, scFv-Fc fusion proteins and the 
antibodies against the related cell types, were detected with their corresponding 
secondary antibodies labelled each with one fluorophor of differing colour. A 
mixture of both secondary antibodies, diluted 1:1:500 in 2% BSA was incubated 
with the pre-stained kidney sections and afterwards washed twice with PBS for 
5 min at room temperature. To prevent quenching of the fluorescent dyes coupled 
to the secondary antibodies or interference of the mounting medium with the tissue 
targets, Immu-Mount (Thermo Scientific, Waltham, MA, USA) was used for 
covering procedure. A drop of this aqueous, non-fluorescing mounting medium 
was applied to a cover slip, which was used to seal the tissue section. As already 
described (3.4.5.1) the tissue slides were dried for about 2 hours at room 
temperature in the darkness. The slides were analysed by fluorescence 
microscopy directly after the drying process and were stored at 4°C for about 2 
weeks.  
3.4.5.3 PAS reaction 
Detection of glycoproteins and -lipids, polysaccharides like glycogen, basement 
membrane and collagen in paraffin embedded tissue sections was performed 
using Periodic acid and Schiff`s reagent (PAS reaction). Paraffin embedded tissue 
sections of 1 µm thickness were de-paraffined/de-waxed by 3x incubation in 
Xylene for 5 min, followed by a rehydration step in de-ionized water for 5 min. The 
sugar residues within the tissue structure were oxidized by incubation in 2% 
periodic acid for 30 min at room temperature. The addition of Schiff`s reagent for 
60 min resulted in the formation of chemical bonds between the free aldehyde 
groups of the sugars and the Schiff`s reagent, showing a magenta colour. 
Counterstaining with Gill`s Hematoxylin #3 (Polysciences Europe GmbH, 
Eppelheim, Germany) for 4 min and blueing in Tris buffer (pH8) resulted in blue 
staining of the nuclei. Finally the tissue sections were dehydrated and cleared in 
Histo-Clear (Biozym Scientific GmbH, Hessisch Oldendorf, Germany) and 
embedded in Histomount mounting solution (Invitrogen, Darmstadt, Germany). 
The tissue sections were stored at room temperature. Analyses were performed 
using light microscopy.     
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3.5 In vivo application of single-chain-Fc fusion 
proteins  
Purified mMC specific single-chains fused to murine IgG2a-Fc part were analysed 
regarding their capability in C57BL/6 mice.  
Male C57BL/6 mice, 8 weeks of age, were injected with 50µg/animal of sterile 
scFv-Fc protein dissolved in 200 µl PBS into the tail vein at day 0. Control mice 
were injected iv with 200 µl sterile PBS. Due to the experimental design, the 
animals were sacrificed at day 7 and all relevant organs were prepared and stored 
appropriately as described below (Tab. 3.8). During the observation period each 
mouse was weighed at day 0, 3 and 7. At least for the last 24 h the animals were 
housed in metabolic cages and urine and faeces were collected separately for 
further analysis.  
All animal experiments were carried out in the laboratories of the Institute for 
Laboratory Animal Science (ILAS) at the University Hospital Aachen.  
Tab. 3.8: Organ storage for further experiments 
 
Cryostat Sectioning 
(Tissue-Tek®) 
Paraffin Sectioning 
(4% PFA)  
RNA analysis 
(RNAlater®) 
Kidneys + + + 
Liver + + + 
Lung + + + 
Brain + + + 
Heart + + + 
Spleen + + + 
Muscle + + + 
Lymph nodes + + + 
Blood Analysis of laboratory parameters (by ILAS) 
Urine Analysis of laboratory parameters (by ILAS) 
 
The animals were housed in standard cages under “barrier green” housing 
conditions. The mice had access to tap water and standard feed and were daily 
monitored by eye for the complete time period of the experiment.  
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4 Results 
4.1 Preparation of selection antigen 
The aim of this study was to generate antibody fragments that are able to 
selectively detect mesangial cells in mice kidneys and are subsequently able to 
induce a complement driven inflammation similar to the anti Thy 1.1 nephritis in 
rats. 
4.1.1 Isolation of mouse glomeruli 
The generation of cell surface associated antibodies required intact cells with a 
native and functional expression pattern. Primary murine mesangial cells (mMCs) 
were chosen to serve as target antigen for antibody selection during this thesis. 
Tab. 4.1: Perfusion of mouse kidney with magnetic particles.  
 Operation field in an appropriate laboratory room 
provided by the animal facilities of the University 
Hospital Aachen. The perfusion of all animals was 
performed under reflected-light microscope control.  
C57BL/6 mice were deep anaesthetised via intra 
peritoneal Avertin injection (by now withdrawn from the 
market). The coat was carefully opened from the lower 
side of the abdomen. 
Bared peritoneum of a sedated C57BL/6 mouse.  The 
coat was folded away from the operation area to avoid 
contamination from the mouse`s coat.  
Retrograde injection of 2 ml Dynabeads450 into the 
vena cava inverior (labbeled in blue) . The magnetic 
beads were entering the kidney and were stuck within 
the renal capillaries located in the glomerular tuft.  
Both kidneys were removed and used for further 
isolation of murine mesangial cells. 
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MMCs were isolated from kidneys of C57BL/6 mice as described under 3.1.5 by 
kidney perfusion with magnetic Dynabeads® M-450. Loss of tiptoe reflex control 
after Avertin® injection indicated deep anaesthesia and allowed animal fixing on 
the operating field. The preparations for the surgery and the execution of the 
kidney perfusion were visualised and summed up in table (Tab. 4.1). 
The complete surgery was performed under microscopic control with a reflected-
light microscope.  
After successful perfusion of the kidneys by retrograde (vena cava inferior) 
injection of magnetic beads, the kidneys were removed from the mice and 
prepared for glomeruli extraction.  The kidneys were minced with scalpels and 
digested with collagenase I (1 mg/ml, see Tab. 7.4), followed by size filtration of 
large non-target kidney tissue. The Dynal MPC™-S was used as an instrument to 
separate the perfused glomeruli from residual tubular tissue which was, together 
with glomerular structures, as well capable to pass the 100 µm filter pores before. 
 
 
Fig. 4.1: Light microscopic picture of an isolated mouse glomerulus in RPMI1640 D-Valin cell 
culture medium. Mouse kidneys were perfused with magnetic Dynabeads® M-450 (black 
arrows). The beads are mainly visible at the apical end of the glomerulus, underlining, 
that they do not pass through the complete capillary system all over the renal corpuscule, 
but are already stuck at the entrance of the capillary system. Isolated and purified 
glomeruli were cultivated under selective pressure to stimulate outgrowth of mesangial 
cells. Source: picture generated in cooperation with the Clinic for Renal and Hypertension 
Diseases at the University Hospital Aachen, in detail the group of Prof. Dr. rer. nat. 
Tammo Ostendorf, University Hospital Aachen.      
To ensure a maximum purity of the glomeruli solution it was cleared from 
unspecific residual kidney tissue by washing with RPMI 1640 D-Valin medium till 
at least 80-90 % of the cell solution consisted of glomeruli (Fig. 4.1). Typically, on 
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average 4-6 washing steps were necessary to reach this level. Purity of the 
solution was checked by visual control using a reflected-light microscopy.  
 
Fig. 4.2: Primary murine mesangial cell culture selected by D-valin as substitute in growth medium. 
Cultivation period: 10 weeks after isolation. Magnification: 100X 
Isolated glomeruli from C57L/6 mice were cultured in RPMI 1640 D-Valin medium 
for at least one week without moving. The usage of medium with D-Valin instead 
of L-valine enabled murine mesangial cells to proliferate out of the glomerular 
explants (Fig. 4.2). This was based on their special quality to convert the 
substituted D-valine in the growth medium into it` s usable L-enantiomer [48]. The 
selective medium was used during the entire culturing process. The mesangial 
cells were not cultivated for longer than a maximum of eight or nine passaging 
steps (3.1.3), because of enormous changes concerning reduced growth rate and 
growth pattern (data not shown). Finally we were able to generate a stable cell 
culture procedure for primary murine mesangial cells, including the extraction from 
mice, the cultivation and mid-time storage in liquid nitrogen as well as the re-
cultivation.    
4.2 Selection of antibody fragments specific for murine 
mesangial cells (mMCs) 
Stability and consistence of antigen were absolutely essential for selecting highly 
specific antibody fragments. Although a culture of primary mesangial cells 
represents a maximum native and functionally expressing antigen provider, long-
term storage as well as stable and consistent fixation of the cells as antigen for 
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selection procedure was not guaranteed. Functional membrane fractions (3.1.6) of 
target cells were prepared and served as selection antigen during the whole 
Phage Display selection and screening process.  
4.2.1 Enrichment of antibody fragments from TL J 
Initially the Tomlinson library (TL) J was used for selection of mMC specific 
antibody fragments. It has a size of about 1.38 x 108 different single chain variable 
fragments and was side chain diversified by DVT diversification during 
establishment (2.3.5). Four consecutive selection rounds were performed, during 
which the antigen concentration was reduced from undiluted target antigen to one 
thousandth of the starting concentration. Additionally washing stringency was 
increased from round to round (Tab. 4.2). Both strategies were performed to 
enhance the specificity of selected binders. All phage preparations were 
performed using the M13KO7 helper phage. The determination of the phage input 
titre at the beginning of the phage selection rounds showed inconsistent results. 
Due to their enormous growth density it was not possible to determine the amount 
of helper-phage infected library colonies (cfu). The output titres of the single 
selections were determined as described before (3.3.3). Tab. 4.2 shows the 
selection strategy as well as the amount of applied (input titer) and obtained 
(output titer) numbers of scFv- phages per selection round. The enrichment factor 
of each round, normally calculated as the quotient of the output titer divided by the 
input titer, could not be determined.  
Tab. 4.2: Selection strategy Tomlinson Library J on murine mesangial cell membrane fractions   
Selection 
round 
Antigen 
concentration 
 Input titer Output titer Enrichment 
factor  
1st  Undiluted  not estimable Ø 7.6 * 1013 - 
2nd  Undiluted  not estimable Ø 1.34 * 1014 - 
3rd  1:100 (in PBS)  not estimable Ø 6.92 * 1010 - 
4th  1:1000 (in PBS)  not estimable Ø 7.0 * 104 - 
 
Enrichment of specific phage particles towards mMCs was determined by 
polyclonal phage ELISA analysis on  the selection antigen. Polyclonal binding 
analysis was performed with phages from the selection rounds 2 to 4, they were 
amplified and precipitated as described before. The antigen concentrations were 
appointed as done during the appropriate selection round, undiluted antigen was 
used in panning rounds 1 and 2, 1:100 and 1:1000 in rounds 3 and 4, respectively. 
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ScFv-phage particles were detected with anti-pVIII phage surface-protein 
antibody, labelled with HRP-labelled anti pVIII antibody. Positive binding on the 
antigen was classified as a 2.5 times higher signal value compared to the mean 
values of all negative controls. 
 
Fig. 4.3: Polyclonal phage ELISA after four rounds of selection on murine mesangial cell 
membrane fractions. The negative controls (NC) represent the average absorbance of all 
systemic controls, namely the empty plate, the omitted scFv- phages, the omitted 2nd 
antibody and the combination of both of them.   
Successful enrichment of mMC-specific phage particles was observed (Fig. 4.3). 
The binding activity of the scFv-phages from third selection round compared to the 
signal of the second round was significantly higher (p = 0,0037). The same was 
true for the compared signals of the 2nd and 4th rounds (p = 0.0014). An 
additional 4th round of selection on a further antigen dilution did not reveal an 
increase of the binding activity. All selected scFv-phages complied the guidelines 
defined for a positive binding to coated antigen, namely an at least 2.5 times 
higher absobance signal than the average absorbance of all systemic controls 
(see Fig. 4.3). A significant increase of the binding absorbance of Tomlinson 
Library J scFv-phages on murine mesangial cells during four selection rounds was 
observed.      
 
4.2.1.1 Screening for monoclonal, unique scFv-binders 
The polyclonal phage pool was detectably enriched for phages directed against 
mMCs. Next step was the identification of unique specific binders. The fourth 
round of the selected library was chosen for monoclonal analysis of mMC- binders.  
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All monoclonal screening ELISA experiments were performed using mMC 
membrane fractions at dilutions of 1:1000. Recombinant phages were detected 
with the anti-M13-HRP antibody at a dilution of 1:5000. Detection was visualized 
with ABTS substrate. Additionally to the systemic negative controls, a so called 
“plastic control” served as selection control during the monoclonal ELISA 
experiments. Thereby the binding of each selected, monoclonal phage was 
additionally analysed on non-coated wells to ensure positive signals were not the 
result of selecting scFv-phages against the plastic surface of the 96-well selection 
plates. Significant, positive binding signals were again defined at least as 2.5 times 
higher than the mean systemic or selection negative controls.  
 
Fig. 4.4: Phage ELISA (A) and corresponding colony PCR results (B) of single monoclonal phage 
preparations on membrane fractions of murine mesangial cells (dark grey). All phage 
preparations were additionally to the binding analysis on target antigen also tested on 
“plastic controls” (∆mMC). The negative control (NC) represented the average 
absorbance of the empty plate, the omitted scFv- phages, the omitted 2nd antibody and 
the combination of both of them.  
72 monoclonal colonies from the 4th selection round were analysed for their 
binding properties. In the beginning sixteen scFv- phages out of the tested ones 
showed positive binding towards murine mesangial cells (data not shown). After 
repetitive approval ELISA experiments only five of them could have been 
confirmed (Fig. 4.4 A). To ensure that the significant binding signals were no 
artefacts or due to non-artificial binding of empty or non-specific phages colony 
PCR of each monoclonal phage producing bacterial colony was performed to 
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check the potential positive binding phages for presence of de facto scFv-inserts 
(Fig. 4.4 B). 
The analysis of the five ELISA binder candidates with PCR insert control revealed 
that only four of the five recombinant phages, namely C2-, E4-, C9- and C12-
phage do carry a scFv- gene insert (Fig. 4.4 B, encircled in red). Compared to the 
average systemic negative controls (NC) all of them showed significant binding 
activity to murine mesangial cell membrane fractions. The corresponding p-values 
were as follows in the above given order: p = 0.0179, p = 0.0191, p < 0.0005 and 
p = 0.0183. The same was true for the control of unspecific binding towards plastic 
surfaces. The four selected scFv phage clones each showed an at least 2.5 times 
stronger binding signal on murine mMC membrane fractions compared to their 
corresponding signals measured on uncoated ELISA plates.       
4.2.1.2 Sequence determination and approval of unique phage binders 
After approval of positive binding and phage integrity their DNA sequence was 
analysed (MWG) to be checked for uniqueness. The nucleotide sequence of each 
binder was investigated according to edge-properties of the original sequence of 
the pIT2 library phagemid vector, the location of the lac-promotor, the ribosome 
binding site and the pelB leader.  
Additionally the location of the complementarity determining regions (CDRs), the 
glycine-serine linker region and the integrity of the ORF were aligned among all 
positive binding clones.     
 
Fig. 4.5: Amino acid-based sequence of the three unique scFv- clones specific for murine MC 
membrane fractions, selected from Tomlinson library J. Shown in detail are the 
complementarity determining regions (CDRs) as well as the glycin-serin linker. The 
determination of the CDRs was performed using the KABAT system for domain 
arrangement of immunoglobulins.   
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Within the sequences of the library`s antibody backbone the selected scFv-clones 
showed a unique consensus sequence. The uniqueness of each clone was figured 
out by the comparison of the different CDRs. Whereas the CDR1 of the heavy and 
light chain were consistent all over the single clones, there were clear sequence 
differences within the CDRs 2 and CDRs 3 of both, the heavy and the light chain. 
Despite repeated analysis amber stop codons were found in the CDR2 of each 
clone (marked in red circles and asterisk, respectively). The sequence analysis 
revealed three unique binders out of 72 tested phage clones, C2(scFv), C9(scFv) 
and E4(scFv) named according to their position on the screening plates. 
 
Fig. 4.6: Confirming monoclonal phage ELISA experiments of mMC specific scFv-phage binders. 
The candidates were named according to their position on the 96 well plates All three 
binders show significant binding to the target antigen compared to the systemic as well as 
experimental controls, with p- values of p < 0.004 for the corrected scFv-phages C2 and 
C9 and p < 0.011 for the E4 scFv-phage.  
The selected binders were classified according to their binding strength. Table 
below shows the different classes. 
Tab. 4.3: Classification of ELISA-tested scFv-binders 
Classification  ELISA binding signal  (compared to the average NC) 
Weak binder < 2.5- 5 times stronger 
Medial binder < 5- 7.5 times stronger 
Strong binder < 7.5-10 times stronger 
 
According to these classifications the phage- binders C2- and C9-, with a binding 
signal of 15 and 13 times stronger than the corresponding NCs, were rated as 
strong binders. The E4-phage binder, with a 6 times stronger binding signal was 
rated as medial binder. 
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4.2.1.3 Phage binding on intact cells 
Selection of single-chain binders on the basis of membrane fractions required 
validation of the binding ability on native antigens. Primary murine mesangial cells 
were cultured in-vitro under selective D-valine conditions at 37°C (5% CO2). 
   
Fig. 4.7: Whole cell ELISA with scFv-phages on primary murine mesangial cells. Significant 
positive binding signals for the three single-chain phages C2 (p < 0.0001), 
C9 (p < 0.0001) and E4 (p < 0.0001) were confirmed on whole target cell line. There was 
only a small, difference detectable between the binding signals on ethanol fixed cells 
compared to unfixed cells.   
Primary cells were ethanol fixed before starting ELISA procedure to improve cell 
adhesion and assay stability. A head to head comparison of fixed and unfixed 
target cells did not show significant differences in binding signal. All three selected 
scFv-phage clones showed significant, strong binding on primary target cells. 
4.2.1.4 Phage binding analysis on primary tissue 
Immunohistochemistry represented a possibility to rapidly check the selected 
Tomlinson single-chain phages for their binding characteristics against murine 
mesangial cells within the natural kidney tissues environment. Therefore the C2-, 
C9- and E4-binders were produced with M13∆pIII- hyper phage in large-scale and 
were used as primary detection antibodies on cryo-sections of healthy C57BL/6 
mouse kidneys. The scFv- phages were incubated on 4- 6 µm thick kidney slices 
over night at 4°C in a wet-chamber. Binding to the tissue was visualised with HRP 
labelled anti-M13 antibody (GE healthcare, Buckinghamshire, UK) and DAB as 
substrate for the enzymatic component of the secondary antibody. Counterstaining 
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of the tissue with methyl green was performed for having a better anatomic 
orientation within the tissue.  
 
Fig. 4.8: Immunohistochemistry binding analysis of LJ scFv-phages on 6 µm murine kidney tissues 
slices. Hyper-phage preparations of C2- (A), C9- (B) and E4-binders (C) were subjected 
to immunohistochemistry analysis. All three scFv-phages showed positive binding within 
the glomerular structures of the kidneys cortex (black arrows and black asterisk). 
Magnifications revealed positive binding of C2- (A) and C9-phages (B) within the 
cauliflower structure of the glomeruli, whereas the E4-binder revealed positive binding in 
the apical mesangial regions of the glomeruli.  
All three ELISA positive single-chain-phages confirmed positive binding on murine 
tissue sections, especially within the glomerular regions (Fig. 4.8). The staining 
pattern of the clones C2 and C9 was basically located in the central mesangial 
region of the cauliflower structure (green asterisk), whereas the E4-phage clone 
showed binding within the apical mesangial regions of the murine glomeruli (red 
asterisk).  
4.2.1.5 Cross reactivity on murine systemic organs 
Unwanted binding activity towards murine systemic organs was tested on systemic 
organs. This is of interest to evaluate potential bio-distribution pathways of the 
antibody fragments in-vivo. Therefore relevant mouse organs were prepared from 
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healthy C57BL/6 mice, embedded in Tissue-Tek® (Sakura Finetek Germany, 
Staufen) and cryopreserved at -80 °C. Slices of about 6 µm were cut out of the 
organs and used for immunohistochemistry analysis as described above. The 
main focus thereby was on systemic and immunological relevant organs like heart, 
liver, spleen and lung tissue sections.   
 
Fig. 4.9: Immunohistochemical staining of murine control cryo-tissue. Exemplary presentation of 
the C9-phage from Tomlinson Library J tested on the particular tissues. Additionally an 
ELISA- negative as well as the empty, non-scFv-bearing hyper-phage were analysed on 
the tissue sections. All tested phages showed unspecific, diffuse background staining 
patterns within the different organs.  
The analysis of cross reactivity towards organs like liver, heart, lung and spleen 
was carried out with hyper-phage preparations of the C2-, C9- and E4-single-
chains. In Fig. 4.9 the C9-clone was displayed, as an example, for the binding 
analysis. The C2-phage and E4-phage showed the same results (data not shown).  
ScFv-presenting phages, the clones selected against mMC membrane fractions as 
well as the ELISA negative D5(scFv)-phage (Fig. 4.4) showed results similar to the 
empty, non-scFv-presenting hyper M13KO7∆pIII hyper-phage used for the phage 
preparations. There was no specific binding detectable in none of the tested 
organs. Only undefined, diffuse background staining resulted from the binding 
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analysis of these phages on organs like heart (Fig. 4.9 B, J, N), spleen (Fig. 4.9 D, 
K, O) and liver (Fig. 4.9 F, L, P). Looking at the results on lung tissue sections it 
seemed as if there was specific binding of any type of bacteriophages (Fig. 4.9 G, 
H, M, Q, black asterisks), but this dark staining turned out to be unspecific 
boundary staining of the alveoli. Such type of false-positive staining often occurs 
due to unspecific depositions of binding molecules at regions topologically 
exposed within the tissue section. This was clearly the case for sections of lung 
tissue. Taken together the selected scFv-phages did not reveal undesired specific 
binding activity in critical organs.            
4.2.2 Enrichment of antibody fragments from Tomlinson Library I 
The diversification of the Tomlinson Library J seemed to be problematic in terms of 
revealing phage binders bearing amber stop-codons (see 4.2.1.2), because NNK 
diversification enables TAG as base-pare triplet within the CDRs. Therefore an 
additional Phage Display selection round on membrane fractions of murine 
mesangial cells was performed with the Tomlinson Library I. As already described 
in chapter 2.3.5 the Tomlinson Library I consists of 1.47 x 108 different scFv- 
genes and is diversified via DVT [87, 22] variation within the CDRs. The Tomlinson 
Library I was produced as described before with M13KO7 helper phage. The 
amount of applied and gained phages was investigated before and after each 
round of selection via indirect phage titration. Following a more stringent 
procedure  during this selection, one panning-round implied not only selection on 
target antigen but consisted of an upstreamed negative selection (depletion) of the 
phage library on irrelevant murine glomerular cell targets directly followed by a 
positive selection of the depleted library on murine mesangial target antigen. Cell 
membrane fractions of the negative as well as the positive targets were used as 
immobilised antigens on 96 well MaxiSorp® ELISA plates. 
Tab. 4.4: Selection strategy Tomlinson Library I on murine mesangial cell membrane fragments 
Selection 
round 
Antigen  
concentration 
Input titer Output titer Enrichment 
factor EF 
(Enrichment) 
1st  Undiluted neg. antigen Undiluted pos. antigen 
 Ø 5.81 x 1011 Ø 6.84 x 109 1.2 x 10-2 
2nd  Dil. neg. antigen (1:1000) Undiluted pos. antigen Ø 7.47 x 10
11 Ø 8.86 x 1012 
11.9 
(992 times) 
3rd  Dil. neg. antigen (1:1000) Dil. pos. antigen (1:1000) Ø 1.43 x 10
10 Ø 7.41 x 108 
5.2 x 10-2 
(0.004 times) 
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Concerning the washing stringency and the antigen concentrations some 
alterations were made, compared to the selection described before under 4.2.1. 
Here, the washing stringency was kept at a constant high level, in parallel the 
antigen concentrations were changed only minimal and were strongly diluted from 
an early time-point on. This selection strategy aimed to generate specific single-
chains with an enhanced, strong binding affinity against murine mesangial cells. 
The originated input and output titres were shown in Tab. 4.4 above.   
The enrichment factor (EF) as a measure for enrichment of antigen-specific 
phages during the selection was calculated by dividing the output titre by the input 
titre. The amount of enrichment of specific phages is defined as the enrichment 
factor of a selection round divided by the enrichment factor of the previous 
selection round. Both values are reference points for the success of a Phage 
Display selection. After the first and second round of selection, the amount of 
antigen-specific phages has increased by 900 times.  After the final, third round of 
exposition towards the antigen, only a minimal higher amount of positively binding 
phages was reached.   
Polyclonal phage ELISA experiments were used to emphasize the results gained 
from the phage titres. Membrane fractions of murine mesangial cells, diluted 
1: 1000 in PBS were used as coated ELISA antigen. Fig. 4.10 describes the 
absorbance results of all rounds of phage selection. 
 
Fig. 4.10: Polyclonal phage ELISA after three rounds of selecting the Tomlinson Library I on murine 
mesangial cell membrane fractions. The negative controls (NC) represent the average 
absorbance of all systemic controls, namely the empty plate, the omitted scFv- phages, 
the omitted 2nd antibody and the combination of both of them. Screening for monoclonal, 
unique scFv-binders from Tomlinson Library I  
A significant increase of positive binding towards the presented membrane 
fractions was determined, comparing round one and two (p = 0,0204) and round 
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two and three (p = 0,0046). Regarding the systemic controls, all phage binding 
signals were classified as positive due to their absorbance signal at least 2.5 times 
higher than the average systemic negative controls of the Tomlinson Library I. 
ScFv-phages showed significant binding towards membrane fractions of the target 
antigen of murine mesangial cell membrane fractions.  
4.2.2.1 Screening for monoclonal, unique scFv-binders 
ELISA experiments on selection antigen were used to screen the enriched phage 
pool for single monoclonal mMC- specific single-chain phages. According to the 
selection rounds performed with the TL I, the antigen used for monoclonal analysis 
was applied in a dilution of 1:1000. The antigen-bound bacteriophages were 
detected with the anti-M13 antibody and ABTS. Negative controls were defined as 
already described for the screening process of Tomlinson Library J (4.2.1.1). 
The analysis of 32 clones, picked after the third round of selection (negative + 
positive selection) revealed five putative antigen specific phage- antibodies. All of 
them displayed absorbance signals at least 2.5 times higher than the 
corresponding methodical and selection negative controls and therefore showed 
significant (p-values ranging between 0.0001 and 0.0029) binding towards 
membrane fractions of murine mesangial cells. Classified equivalent to table Tab. 
4.3 all selected LI scFv-phages show at least 17 times stronger binding signals 
than the corresponding negative controls and are therefore rated as strong 
binders. 
 
Fig. 4.11: Monoclonal phage ELISA of five mMC membrane fraction binding phages. All putative 
phage binders showed significant binding affinity towards the antigen compared to the 
systemic as well as to the selection control. The negative control (NC) was defined as the 
average absorbance of the empty plate, the omitted scFv- phages, the omitted 2nd 
antibody and the combination of both of them.  
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Fig. 4.12: Amino acid-based sequence of the single, unique B4(scFv)- phage specific for murine 
MC membrane fractions, selected from Tomlinson library I. Shown in detail are the 
complementarity determining regions (CDRs) as well as the glycin-serin linker which is 
necessary to arrange the variable domain of the heavy chain (VH) in an appropriate 
direction to the variable domain of the light chain (VL) and therefore building a good 
binding pocket.  
Sequence analysis of the five phage binders revealed a completely identical 
consensus sequence, meaning that the selected clones picked from the screening 
ELISA plate all are of the same library phagemid and represent one unique single-
chain binder. The severe selection strategy originated one single, unique scFv-
phage specific for mMC membrane fractions, further on named B4(scFv) 
according to it’ s location on the screening plate. 
4.3 Mutagenesis of mMC specific scFv-binders 
Expression of soluble single chain proteins derived from the phage particles 
should be carried out to get further insight into the binding characteristics of the 
selected antibody fragments. The sequence analysis of the three TL LJ binders 
C2(scFv), C9(scFv) and E4(scFv) showed amber stop codons within the CDR2 
regions (Fig. 4.5, encircled in red). Amber stop codons are characterized by the 
base triplet sequence TAG leading to chain termination during protein expression 
in non-supressor bacterial strains or eukaryotic expression systems. They are not 
recognized as stop signal by the Phage Display tool bacterial strain E.coli TG1, but 
are supressed and functionally translated as CAG (glutamine). Here, their 
incidences were due to the artificial NNK randomisation of the Tomlinson library J, 
described under 2.3.5. In order to produce intact, soluble single-chains these 
undesired TAG triplets were point mutated towards a CAG base triplet. 
Consequently soluble single-chain proteins would be produced with glutamine 
(CAG) as a replacement for the terminating TAG codon. Despite repeated 
sequence analysis of the B4(scFv) binder selected from the Tomlinson Library I 
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(DVT diversified) an extraordinary amber stop codon was found within the 
framework 3 (FW3) of the heavy chain. For reasons described above, the 
corresponding single-chain phagemid has also been reversed. All PCR driven 
exchanges of the undesired thymine (T) bases towards cystein (C) were carried 
out as described by site-directed mutagenesis (3.2.10).  Successful exchange of 
TAG to CAG triplets was verified by sequence analysis (data not shown). Three 
out of four phage binders were successfully mutated. The C2(scFv) sequence 
could not be adapted to produce soluble single-chain proteins and was therefore 
skipped for further usage.  
4.3.1 Binding analysis of mutated single-chain phagemids on 
selection antigen 
To analyse the back-mutated single-chains in terms of their antigen binding 
capacities, the sequence verified scFv phagemids were re-transformated into 
E.coli TG1 bacteria and the native, as well as the mutated, scFv- phages were 
produced/expressed in 96-well small-scale.  
 
Fig. 4.13: Monoclonal phage ELISA on mMC membrane fractions, comparison of native, selected 
scFv-binders (dark grey bars) and their site-directed mutated forms (black bars). 
Absorbance (after 30 minutes) of the light grey bars describes no unspecific binding of 
the mutated single chain phages on selection plates (“plastic control”). The D5 single-
chain represents a systemic negative control. This is a scFv presenting phage that did not 
show affinity to the selection antigen at any time. The negative control (NC) is the 
average absorbance of the empty plate, the omitted scFv- phages, the omitted 2nd 
antibody and the combination of both of them. 
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Comparative monoclonal phage ELISA on murine mesangial cell membrane 
fractions were used to identify the influence of the mutation to the binding affinity 
against the selection antigen.  
Fig. 4.13 demonstrates the behaviour of the scFv-phages C9(scFv) and B4(scFv) 
after the back-mutation of the amber stop-codons. A strong decrease in binding 
strength was seen from the ELISA experiments. Both clones showed a reduced 
absorbance signal of about 35 % off compared to its native signal (black bars 
compared to dark grey bars). Nevertheless the crucial binding signal of at least 2.5 
times higher than the average negative controls (dashed line in Fig. 4.13) still was 
reached in both cases, clearly declaring them as strong binders towards mMCs. 
The specific antigen binding was significant with p-values for the C9(m) of p = 
0.0057 (vs. plastic control) and p = 0.001 (vs. averaged negative controls). 
Corresponding values for the B4(m)-phage were p < 0.0001 and p < 0.0001. 
Contrary to these results, the point-mutated E4 single-chain shows a clearly 
increased binding strength to murine mesangial cell membrane fractions. Here the 
site- directed mutation lead to more than 9 times higher binding signal than the 
corresponding negative controls. The binding characteristics towards mMC 
membrane fractions compared to plastic control and all other averaged negative 
controls were significant with p-values of p = 0.0057 and p = 0.001 respectively.  
4.4 Construction of scFv-Fc fusion proteins 
The Phage Display selections revealed three potential binders for mMC specific 
cell detection, which will be used as minibodies in a mouse model similar to the 
anti-thy 1.1 model described before. Therefore each of the selected, rectified 
single-chain Fv genes was equipped with a complement activating feature, namely 
an Fc-part. The murine IgG2a Fc-part, provided by Invivogen (San Diego, CA, 
USA), consisting of the CH2- and CH3-region is described to strongly induce 
antibody and complement derived immune reactions [58]. As an additional feature, 
the pFUSE-mIgG2aFc2 plasmid, which was used as vector for the Fc-part, also 
includes the corresponding hinge-region, located upstream of the CH2-CH3 
domain. This hinge region enables agglomeration of two scFv-Fc moieties to an 
antibody like structure by covalent binding via disulphide bridges.  
Despite all efforts performed in-house, the manual cloning of these chimeric scFv-
Fc constructs was not successful (data not shown), hence the C9(scFv)-, 
E4(scFv)- and B4(scFv)- mIgG2a-Fc genes needed to be artificially synthesized. 
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This was performed by GeneArt AG (Regensburg) and followed by sub-cloning 
into the eukaryotic expression vector system pMS-SNAP (see A.8.3).  
4.5 Expression of soluble scFv-Fc fusion proteins  
After the artificial fusion of confirmed single-chain-genes to the murine Fc-part 
IgG2a, the production of soluble phage-particle-free antibody-fragments was 
performed in eukaryotic systems.  Therefore the scFv-mIGg2a-Fc genes were 
introduced into the pMS-SNAP expression vector (described under A.8.3) and 
transfected into HEK293T cells as expression system. Zeocin as additive of the 
culture medium was used to promote the growth of recombinant plasmid bearing 
cells. The success of transfection was verified by means of co-expression of 
enhanced green fluorescence protein (GFP).          
 
 
Fig. 4.14: A) Design of the eukaryotic pMS expression cassette. The single-chain-Fc gene was 
expressed under the control of the pCMV promoter combined with recombinant SNAP-, 
6x His- and myc tag for detection and purification. The proteins were secreted into the 
eukaryotic cell culture supernatant via the Igĸ-leader. In case of successful transfection 
with pMS-scFv-Fc plasmids, a linked internal ribosomal entry site (IRES) led to co-
expression of eGFP. B) Single-chain-Fc transfected HEK293T cells after four weeks of 
cultivation under selective Zeocin® pressure.          
The EGFP reporter gene as part of the pMS vector allowed direct control of the 
recombinant antibody-fragment protein expression (see Fig. 4.14). After a time 
A 
B 
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period of about 1 week under selective conditions the amount of non-transfected 
HEK293T cells was dramatically reduced due to the lack of Zeocin resistance 
gene in the naïve genome of the cells. About 70% of the cells died within the first 
48 hours (data not shown). The Sh ble gene product in pMS transfected cells 
prevented the Zeocin antibiotic to bind and cleave the HEK293T DNA and 
therefore enabled the recovery of cell amount within the culture. The transiently 
transfected cells were cultivated to collect the cell culture supernatant for further 
expression controls and processing. After removal from cultured cells, the scFv-Fc 
containing supernatants were cleared from cell debris by centrifugation and were 
stored at 4°C. For long term storage the eukaryotic cells were detached from the 
culture flasks by Accutase treatment (described under 3.1.3), collected in culture 
medium with a final concentration of 20% DMSO and were deep frozen at -196°C 
(liquid nitrogen).   
4.5.1 Analysis of eukaryotic scFv-Fc protein expression 
In consequence of visual transfection control, the expression of single-chain-Fc 
proteins was checked in SDS-PAGE and immunoblot (see under 3.4.2) analysis. 
To discriminate whether not only the transfection of the scFv-Fc plasmids, but also  
the expression of these recombinant proteins was successful, the collected 
supernatants were separated according to their size and electrophoretic mobility, 
respectively, and were finally blotted onto nitrocellulose membranes as already 
described under 3.4.1.  
The detection of recombinant single-chain-Fc proteins in the cell culture 
supernatant visualised with coomassie stain (Fig. 4.15, A) allowed no declaration 
of expression control due to strong overlaying signals of side proteins like albumin 
from FCS in the cell culture medium. Nevertheless, recombinant scFv-Fc proteins 
(green boxes) were clearly detectable in subsequent Western Blot analysis 
performed with α-His antibody (Fig. 4.15, B) or other antibodies, each specific for 
one of the recombinant tags (data not shown for α-snap and α-myc antibody). 
Immunobands at an expected height of about 75 kDa showed successful 
expression of the proteins of interest by HEK293T cells.  
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Fig. 4.15: Eucaryotic cell culture supernatants analysed on SDS-PAGE and immunoblot 
A Coomassie stained supernatants showed large amounts of unspecific HEK293T cell 
proteins and FCS included albumin at a height of about 60 kDa. B Corresponding 
immunoblot; recombinant single-chain-Fc proteins with a size of about 75 kDa (green 
boxes) were detected with α-His antibody. C9-Fc and B4-Fc antibody fragments showed 
nearly no degradation or unspecific purified protein bands, whereas the E4-Fc clone 
always showed degradation bands at the heights of 50 and 25 kDa. The negative control 
protein Ki4-snap was detected at the expected height of 50 kDa (black asterisk).          
For all scFv-Fc related experiments an unspecific, single-chain protein from our 
group was included as negative control. The Ki4- scFv is as well expressed based 
on the pMS-SNAP vector system as described for the scFv-Fc fusion proteins in 
this work. It did not show any binding affinity towards murine kidney tissues or 
kidney cells.  
4.5.2 Purification of single-chain Fc fusion proteins 
To avoid potential side effects of unspecific medium proteins during binding 
analysis antibody-fragments had to be purified. The cell culture supernatant was 
processed as described above (under 4.5) and was used to purify recombinant 
proteins using the IMAC batch technique (3.4.3.1). Stepwise elution (5 steps, each 
with 250 mM imidazole) of the Histidine residues from the metal ions (data not 
shown) as well as one-step elution (Fig. 4.16) with elution buffer containing 250 
mM imidazole revealed good purification results of scFv-Fc proteins.  
* *
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Fig. 4.16: Elution fractions after Talon™ IMAC batch purification of scFv-Fc proteins analysed on 
SDS-PAGE and immunoblot A Coomassie stained, eluted C9-, E4- and B4-Fc proteins 
were nearly free of unwanted protein residues from the expression. B Corresponding 
immunoblot; purified single-chain-Fc proteins with a size of about 75 kDa (green boxes) 
were detected with α-snap antibody. Again small amounts of degradation or unspecific 
purified protein band at the heights of 50 and 25 kDa were detected. The negative control 
protein Ki4-snap was detected at the expected height of 50 kDa (black asterisks).  
After purification with Talon™ resins the isolated scFv-Fc proteins could have 
been visualised within the elution fractions in the coomassie staining (Fig. 4.16, A) 
as well as by immunoblotting with α-snap-tag antibody (Fig. 4.16, B). 
Densitometric determination of protein concentrations with the “AIDA Image Data 
Analyzer” Software and BSA standards as reference (data not shown) revealed 
mean scFv-Fc concentrations about 100 µg/ml. The scFv-protein purity after IMAC 
was estimated around 50-80%.      
4.6 Co-localisation study on murine kidney tissues 
Beside intra- and extraglomerular mesangial cells the renal corpuscle mainly 
consists of two different cell types: podocytes and endothelial cells (see 2.1.2). 
After the isolated binding analysis of the soluble candidate binders C9-Fc, E4-Fc 
and B4-Fc on primary murine kidney tissues (data not shown) histological co-
localisation studies should confirm the specificity of the single clones. Different 
antibodies were used to discriminate and identify cells closely located to the 
mesangial cells. Mesangial cell-specific single-chain fusion proteins and the non-
mesangial antibodies were used in parallel in fluorescence histological analysis on 
cryo- tissue of healthy C57BL/6 mouse kidneys. Therefore 4 µm thick kidney slices 
* *
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were incubated with the corresponding scFv-Fc cell culture supernatants of 
transfected HEK293T cells as already described (3.4.5.2). In parallel each tissue 
section was incubated with antibodies specific for podocytes or endothelial 
glomerular cells.  Again, the negative control cell culture supernatant of Ki4-SNAP 
was used to exclude unspecific non-scFv related binding signals in the kidney 
tissue.  
4.6.1 Podocyte specific co-staining with α-nephrin 
Podocytes are located on top of the basal membrane and the glomerular 
capillaries and hence cover the complete mesangial structure (see Fig. 2.2). To 
exclude binding affinity of the scFv-Fc clones towards podocytes, co-localisation 
was analysed with an antibody against nephrin, an accounted podocyte 
marker (see 3.4.5.2).  
The scFv-Fc proteins could have either been detected via their Fc-part, the HIS-
tag or the SNAP-tag and the corresponding green fluorescent (Alexa Fluor 488) 
secondary antibodies (see Tab. 7.8) The co-staining of podocytes was detected 
with anti-nephrin antibody and red fluorescent AlexaFluor-546 (AF546) or Cy-3 
coupled secondary antibody (Tab. 7.8). Successfully investigated antibody 
combinations for podocyte co-localisation analysis are shown in the table below, 
further detailed information are described under A.7111.  
Tab. 4.5: Antibody combinations for co-localisation analysis of podocyte and scFv-Fc proteins  
Detection 
setting 
Cell type 1st antibody  2nd antibody  3rd antibody  
α-HIS  murine 
mesangial cells 
scFv-Fc protein 
 
mouse, anti-penta 
HIS AF 488 
(Qiagen, Hilden) 
- 
α-Fc murine 
mesangial cells 
scFv-Fc protein 
 
goat, anti-mouse Fc-
part 
(Sigma Aldrich, St. 
Louis, USA) 
anti-goat-AF 488 
(Invitrogen, 
Darmstadt) 
α-SNAP murine 
mesangial cells 
scFv-Fc protein 
 
rabbit, anti-SNAP 
(Genescript, 
Piscataway, USA) 
anti-rabbit-AF488 
(Molecular Probes, 
Eugene, USA) 
α-
podocyte 
podocyte 
detection 
Pab anti-nephrin  
(GP-N2) 
(Progen, 
Heidelberg) 
anti-GP-Alexa546 
(Invitrogen, 
Darmstadt) 
- 
 
Separate analysis of each tissue slice at the corresponding wavelengths of the 
fluorescent antibodies was performed and pictures were merged with Axiovision 
software.  
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Fig. 4.17: Immunofluorescence co-localisation analysis of C9-Fc culture supernatant from 
HEK293T cells on C57BL/6 murine kidney cryo-sections. The mMC-specific binding of 
scFv-clone is, as a representative, displayed with anti-SNAP tag antibody and the AF488 
conjugated secondary antibody (Tab. 4.5). The localisation of podocytes is shown with 
the Pab anti-nephrin antibody and its corresponding AF546-coupled 2nd antibody (Tab. 
4.5). Exemplary specific mesangial cell binding of the C9-Fc clone is marked with white 
arrows, podocytes are marked with red arrows. 
The classification of the staining was carried out according to its pattern: separate 
green and red colours represent separate scFv-Fc and nephrin staining, 
respectively. Orange colour indicated co-localisation of the detected proteins. In 
case of the C9-Fc/podocyte double-stained tissue sections clear binding affinity of 
the α-nephrin antibody towards podocytes could be evaluated in separate red 
staining (see Fig. 4.17, α-nephrin). The same held true for the distinct green 
staining pattern within the mesangial region of the glomerular structure. An overlap 
of the α-podocyte with the detection regions of the mMC-specific C9-Fc protein 
could not be detected.  
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Fig. 4.18: Immunofluorescence co-location analysis of E4-Fc culture supernatant from HEK293T 
cells on murine kidney cryo-sections. The mMC-specific binding of scFv-clone is, as 
shown for the C9-Fc clone, displayed with anti-SNAP tag antibody and an AF488 
conjugated secondary antibody. The localisation of podocytes is shown with the Pab anti-
nephrin antibody and its corresponding AF546-coupled 2nd antibody. Exemplary specific 
mesangial cell binding of the E4-Fc clone is marked with white arrows, podocytes are 
marked with red arrows. 
The E4-Fc fusion protein was used in the described set-up (see Tab. 4.5). Kidney 
sections of 4 µm from healthy C57BL/6 mice were incubated with the E4 clone ON 
at 4°C. They were proceeded to be co-stained with the α-podocyte specific 
antibody and the corresponding secondary antibodies. The micrographs of the 
tissue sections showed separate green and red staining of the targeted cell types. 
As well as seen for the C9-Fc clone, there were some, here about 40%, co-
localizations of the regions to be stained, mainly within the centre of the glomerular 
structure.   
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Fig. 4.19: Immunofluorescence co-location analysis of B4-Fc culture supernatant from HEK293T 
cells on murine kidney cryo-sections. The mMC-specific binding of scFv-clone is shown 
with anti-SNAP tag antibody and an AF488 conjugated secondary antibody. The 
localisation of podocytes is shown with the Pab anti-nephrin antibody and its 
corresponding AF546-coupled antibody. The specific binding of scFv-clone was detected 
with AF488-coupled antibodies, the co-staining of podocytes with AF546-coupled 
antibodies. Exemplary specific mesangial cell binding of the B4-Fc clone is marked with 
white arrows, podocytes are marked with red arrows.  
In cases of the B4-Fc clone, there was a distinct, separate staining pattern 
detectable on all co-stained kidney sections. Podocytes and mesangial cells dod 
not show regions of overlap. Investigated in all B4-Fc staining experiments was 
the fact that this clone does not exclusively stain classic mesangial cells, but also 
binds distinctively the glomerular side of the Bowmann`s capsule.  
The glomerular cryo-sections described here were all investigate with the α-SNAP 
antibody as detection vehicle for the scFv-Fc fusion proteins. They serve as 
representatives for all other established fluorescent co-staining approaches (see 
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Tab. 4.5). ScFv-Fc and detection was equally successful with the α-HIS and α-Fc 
specific staining approach.  
4.6.2 Endothelial specific co-staining with α-CD31 
Endothelial cells, lying in between the mesangial cells and the basal membrane 
also represented a putative target for cross-reactivity of selected scFv-Fc antibody 
fragments. Therefore analysis of undesired false-positive signals was also 
performed by co-staining of cryo-sections of primary C57BL/6 murine kidney 
tissues with scFv-binders and the endothelial marker CD31. This surface protein, 
also known as PECAM-1 was targeted by incubation with red fluorescence 
labelled (AF546) α-CD31 antibody.  Staining procedure for the detection of murine 
mesangial cells was adopted as described before (see 4.6.1).  
Tab. 4.6: Antibody combinations for co-localisation analysis of podocyte and scFv-Fc proteins  
Detection 
setting 
Cell type 1st antibody  2nd antibody  3rd antibody  
α-HIS  murine 
mesangial cells 
scFv-Fc protein 
 
mouse, anti-penta 
HIS AF 488 
(Qiagen, Hilden) 
- 
α-Fc murine 
mesangial cells 
scFv-Fc protein 
 
goat, anti-mouse Fc-
part 
(Sigma Aldrich, St. 
Louis, USA) 
anti-goat-AF 488 
(Invitrogen, 
Darmstadt) 
α-SNAP murine 
mesangial cells 
scFv-Fc protein 
 
rabbit, anti-SNAP 
(Genescript, 
Piscataway, USA) 
anti-rabbit-AF488 
(Molecular Probes, 
Eugene, USA) 
α-CD31 detection of 
murine 
endothelial cells 
rat, α-mPECAM-1 
(Invitrogen, 
Darmstadt) 
goat, anti-rat-AF546 
(Molecular Probes, 
Eugene, USA) 
- 
  
Tab. 4.6  summarizes successfully performed antibody combinations used for all 
endothelial co-localisation studies. The scFv-Fc detection via the proteins HIS tag 
was as well investigated as the detection via the Fc-part and the SNAP-tag. None 
of the different anti-scFv-Fc antibodies showed practical advantages compared to 
the other ones. Pictures shown were depicted randomly. For reasons of overview 
and clarity the following antibody stainings are used as representatives.  
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Fig. 4.20: Binding analysis of C9-Fc culture supernatant from HEK293T cells (AF488) on murine 
kidney cryo-sections, co-stained with α-CD31 antibody (AF546). The specific binding of 
scFv-clones was detected here with α-HIS antibodies and their corresponding AF488-
coupled antibodies, the co-staining of endothelial cells was performed with AF546-
coupled antibodies. Exemplary, specific mesangial cell binding of the C9-Fc clone is 
marked with white arrows, endothelium is marked with red arrows.  
As already described for the studies of mMCs and podocytes, the endothelial co-
localization investigations were as well performed on 4 µm kidney sections of 
healthy C57BL/6 mice. Overnight incubation with the scFv-Fc fusions was 
performed followed by endothelial α-PECAM detection on top. The C9(scFv)-Fc 
picture illustrates the C9-clone-specific, cauliflower-like binding pattern. Merged 
with the α-CD31 picture, only very few regions of overlap were detectable. The C9-
Fc fusion protein shows a predominantly single staining on mesangial cells no 
specificity for endothelial regions.  
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Fig. 4.21: Binding analysis of E4-Fc culture supernatant from HEK293T cells (AF488) on murine 
kidney cryo-sections, co-stained with α-CD31 antibody (AF546). The specific binding of 
scFv-clones was detected here with α-HIS antibodies and their corresponding AF488-
coupled antibodies,, the co-staining of the endothelial regions within the glomerulus was 
performed with AF546-coupled antibodies. Exemplary, specific mesangial cell binding of 
the E4-Fc clone is marked with white arrows, endothelium is marked with red arrows. 
The same held true for the E4-Fc fusion protein. As already investigated, this 
scFv-clone shows an overall glomerular mMC staining profile including hilus and 
complete glomerular centre regions in the same extent (see Fig. 4.21). Co-staining 
with epithelial cells was not detectable.  
As described under 4.6.1, the B4-Fc clone shows a very special staining profile. 
Besides the very clear and distinct binding within the intraglomerular, mesangial 
regions, the localization at the Bowmann`s capsule was confirmed for any 
performed staining study. Besides that, co-localisation with endothelial cells were 
clearly not the case.  
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Fig. 4.22: Binding analysis of B4-Fc culture supernatant from HEK293T cells (AF488) on murine 
kidney cryo-sections, co-stained with α-CD31 antibody (AF546). The specific binding of 
scFv-clones was detected here with α-HIS antibodies and their corresponding AF488-
coupled antibodies,, co-stained endothelial cells with AF546-coupled antibodies. 
Exemplary, specific mesangial cell binding of the B4-Fc clone is marked with white 
arrows, endothelial regions are marked with red arrows. 
As already performed in previous analysis, the Ki4-SNAP single-chain protein was 
used as systemic control to exclude unspecific binding signals of applied scFv 
proteins.  No binding of this control protein could have been shown (data not 
shown) in any of the kidney slices used. Concerning the selected and so far 
confirmed single-chain-Fc fusion proteins C9, E4 and B4, positive binding towards 
murine mesangial cells was shown, but no co-localisation with endothelial cells 
was detectable. All three binders showed their own appropriate binding pattern, as 
seen during the whole immunohistological analysis processes. 
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4.6.3 Immunofluorescence binding analysis with purified 
scFv-Fc 
In comparison to pure proteins, eukaryotic cell culture expression supernatants 
contain additives like FCS and antibiotics as well as contaminations and waste 
originating from lapsing cells. Both could lead to interactions during the 
immunofluorescence staining and could, despite all performed controls, show false 
positive results. The binding analysis of selected scFv-Fc proteins on primary 
murine kidneys therefore included application of purified proteins on corresponding 
tissue sections. ScFv-Fc proteins were purified via NiNTA- or Talon® IMAC and 
dissolved in PBS as described under 3.4.3.    
 
 
Fig. 4.23: Detection of murine mesangial tissue on kidney cryo-sections with purified C9- and E4-
Fc proteins, respectively. Here, as representative, staining via the protein’s HIS-tag is 
shown. Corresponding secondary antibodies (AF488, green) as well as the co-staining 
with endothelial cell specific antibodies (AF546 detection, red) are described in Tab. 4.6. 
As shown before, mesangial cell binding is represented in green, endothelial cells are 
marked in red, co-localisation is represented as orange staining. 
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As shown above, the scFv-proteins were detected via the Fc-part, the HIS-tag or 
the SNAP-tag and the corresponding green fluorescent (Alexa Fluor 488) 
secondary antibodies (see 4.6.1). In parallel again co-staining against podocytes 
and endothelial cells (Alexa Fluor 546, see 4.6) was performed to classify the 
binding specificity of C9-Fc, E4-Fc and B4-Fc proteins against murine mesangial 
cells. 
The mMC specific binding patterns of the unpurified scFv-Fc proteins (4.6.1 and 
4.6.2) on murine kidney slices could have been confirmed by using the purified 
fusion proteins. 
 
 
Fig. 4.24: Detection of murine mesangial tissue on kidney cryo-sections with purified B4-Fc clone 
and control protein Ki4-SNAP, respectively. Here, as representative, staining via the 
protein’s HIS-tag is shown. Corresponding secondary antibodies (AF488, green) as well 
as the co-staining with endothelial cell specific antibodies (AF546 detection, red) are 
described in Tab. 4.6. As shown before, mesangial cell binding is represented in green, 
endothelial cells are marked in red, co-localisation is represented as orange staining. 
There was no specific binding detectable for control protein Ki4-SNAP (negative control).  
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The described immunohistological stainings shown above under 4.6.1 and 4.6.2 
serve as representatives for all investigated staining protocols established within 
this work. Tab. 4.7 summarizes all entrenched antibody combinations to 
distinguish between scFv-Fc fusion proteins and adjacent podocytes and 
endothelial cells, respectively.   
Tab. 4.7: Overview about successfully established scFv-Fc staining protocols 
C
o-
st
ai
ni
ng
 
scFv detection 
Cell culture 
supernatant α-HIS-tag α-Fc part α-SNAP-tag 
α-podcyte  
α-CD31  
Purified 
scFv-Fc α-HIS-tag α-Fc part α-SNAP-tag 
α-podcyte  
α-CD31  
 
4.7 In-vivo capability analysis of scFv-Fc fusion 
proteins  
The genetic fusion of murine mesangial cell specific single-chains to murine 
immune compatible IgG2aFc parts revealed the possibility to analyse their in-vivo 
binding and their capability in terms of inflammatory disease induction in mice 
similar to the anti-thy-1 nephritis in rats (described under 2.2.1).  
Eucaryotic HEK293T cells were transfected with the pMS-scFv-Fc-SNAP-tag 
vector (see A.8.3), including one of the corresponding DNAs for C9(scFv)-Fc, 
E4(scFv)-Fc and B4(scFv)-Fc. The proteins were expressed under selective 
pressure and cell-culture supernatants were collected as described before under 
4.5. To enhance throughput and finally quantitative protein amount, the protein 
supernatants were purified via their HIS-tag by fast liquid protein chromatography 
(FPLC) using a NiNTA-based 5 mL column instead of batch purification like before 
(see 3.4.3.1). Imidazole eluted scFv-Fc protein fractions were collected and used 
for further size exclusion via HPLC to ensure maximum protein purity. After 
analysis of the integrity of purified proteins on SDS-PAGE and Western-Blot 
analysis sterile filtration steps were performed to minimize potential contaminant 
side effects within the animal experiments.    
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Twelve male C57BL/6 mice, 8 weeks of age and about the same weight, were 
separated into 4 groups with three animals per group. Each group represented 
one in-vitro characterized mMC specific single-chain-Fc binder. Administration of 
50 µg purified and sterile filtered protein per animal via the tail vein was performed. 
The amount of administered protein was chosen according to the established anti-
Thy 1.1 rat model (see 2.2.1 and [6]) in which disease induction is performed with 
2 mg/kg administered antibody. All scFv-Fc samples were dissolved in 200 µl 
phosphate buffered saline. The control group was injected with 200 µl sterile PBS.  
  
Tab. 4.8: Applied scFv-Fc clones and their corresponding concentrations 
 Volume 
[µl] 
Total protein injected 
[µg/animal] 
Concentration 
[mg/kg/body weight] 
C9-Fc 200 50 2 
E4-Fc 200 50 2 
B4-Fc 200 50 2 
PBS 200 - - 
 
The progress of the experiment was monitored daily by eye, parameters like body 
weight of the animals and behaviour were recorded at the beginning of the 
experiment at day 0, at day 3 and finally at day 7. Urine and blood samples were 
collected 24 h before sacrifice to document urine and serum parameter as well as 
to calculate the glomerular filtration rate (GFR). The experimental setup was 
graphically summed up in Fig 4.25.  
 
–––––
 
 
Fig 4.25: Experimental design of in-vivo application of scFv-Fc in mice. Male C57BL/6 were 
injected with 50 µg target protein at day 0, were monitored daily according to their 
behaviour and on day 0, 3 and 7 according to their weight.    
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4.7.1 Weight and physical condition 
In the course of the in-vivo experiment the vitality as well as the weight of all 
animals was continuously controlled. Changes should give an early hint on 
intended disease development as a consequence of anti-mMC scFv-Fc 
administration. In terms of animal welfare, negative developments like excessive 
weight loss, poor agility and decreased feeding habits should as well serve as 
experimental endpoints. 
No unexpected behaviour or weight development was recognized. With a starting 
weight of about 25 g/mouse in all experimental groups the animals developed 
properly within the course of one week of the experiment. Visible body conditions 
like groomed coat did not deduce any kind of worsening health status.  
4.7.2 Physiological read out  
Analysis of renal functionality was performed by determination of pivotal clinical 
read out matrices. Accumulation of metabolic break down products in urine and 
plasma were investigated as marker for renal injury.  
4.7.2.1 Serum parameter 
At day 7, the scheduled end of the experiment, blood samples were taken via 
heart puncture of the mice. Clinical blood parameters were investigated in the in-
house clinical chemistry department. The focus of interest was thereby on 
creatinine and urea as central indicator for renal function. Urea and creatinine 
levels of all scFv-Fc groups were detected via established colorimetric detection 
techniques. Assessment of the values investigated from the scFv-Fc fusion protein 
groups was performed by comparison to the concentrations of the PBS control 
group (see Fig. 4.26 below).  
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Fig. 4.26: Investigation of clinical serum parameter in C57BL/6 mice. Blood samples were taken 
seven days after administration of scFv-Fc fusion proteins. Creatinine (A), urea (B) and 
alanine transaminase ALT (C) concentrations were investigated. Depicted are the mean 
values of each experimental group. Standard deviation is shown as error bars.   
The PBS treated sham group showed haematological creatinine values around 
0.27 mg/dL plasma. These values were slightly below standard reference values 
for mice [36] ranging between 0.5 and 1.1 mg/dL and might be founded in mice 
strain variations. Creatinine values for all analysed scFv-antibody groups ranged 
around 0.25 mg/dL for the B4-clone and in average around 0.30 mg/dL and 0.31 
mg/dL for the E4- and the C9-clone, respectively. 
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The urea concentrations within the PBS group determined in plasma were about 
70 mg/dL and as well differed from standard values published [36] with 12 to 
31 mg/dL, but still served as experimental reference value. Urea levels 
investigated from plasma of the scFv-Fc administered groups did not show 
significant differences compared to untreated sham group. With averaged urea 
values of 85.3 mg/dL (C9 fusion protein), 72.7 mg/dL (E4 fusion protein) and 
80.7 mg/dL (B4 fusion protein), there was neither a significant difference between 
the single experimental groups nor a difference for one of the groups compared to 
the sham group.  
Plasma levels of alanine transaminase (ALT), or former called glutamic-pyruvic 
transaminase (GPT), were taken at the end of the experimental period as indicator 
for liver toxic effects of the administered single-chain antibodies. The PBS sham 
group with GPT levels of 44 U/L fitted to published reference values [36] of 28-87 
U/L. For the C9-Fc as well as the E4-treated group 80 U/L and 38 U/L in average 
were investigated and therefore did not show significance compared to PBS 
group. The B4-Fc treated experimental group revealed slightly high GPT plasma 
level of 158 U/L in average, which was at least not significantly different to sham 
group. 
4.7.2.2 Urine parameter 
At day six of the in-vivo mouse experiment animals were separated and moved 
into single metabolic cages. Urine was collected over 18 hours before the 
experiment was finalized by animal sacrifice at day seven. Analysis of the urine 
parameter was as well as described for blood parameter determined at the in-
house clinical chemistry department. Again creatinine and urea, augmented by 
total protein amount excreted via urin, served as main read outs for renal 
functionality (see Fig. 4.27 below). 
The PBS or sham group as reference showed creatinine concentrations of 
19 mg/dL in average. The administration of the E4- and B4-Fc scFv-antibodies did 
not lead to measurable changes in creatinine excretion, the concentration ranged 
at 19.4 and 19.3 mg/dL, respectively. Urine creatinine concentration in the group 
exposed to C9-Fc clone was detected with slightly, but not significantly decreased 
values of 14.7 mg/dL in average.  
The same was visible for urea concentrations determined in urine. Compared to 
the PBS group with averaged values of 3489 mg/dL, the E4- and B4-Fc fusion 
proteins did not lead to different amounts. They showed 3176.6 and 3142.3 mg/dL 
in average.  
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Fig. 4.27: Investigation of clinical urine parameter in C57BL/6 mice. Animals were housed in 
metabolic cages for 18 hours from day six after administration of scFv-Fc fusion proteins 
on. Creatinine (A) and urea (B) concentrations were investigated. Total amount of protein 
(C) was determined and correlated with creatinine concentrations as proteinuria read out. 
Depicted are the mean values of each experimental scFv-antibody group. Standard 
deviations are shown as error bars. 
Again the C9-Fc fusion protein showed decreased amounts of urea in urine of 
about 2383.2 mg/dL. Significance was not given for none of the applied scFv-
antibodies.  
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The determination of the total amount of excreted protein in the urine revealed 
huge variations, especially in the sham group, in consequence directly influencing 
the correlation of the protein/creatinine ratio. The PBS group ranged between 5 
and 64 mg/dL leading to an average concentration of 26 mg/dL as reference. 
Administration of C9-Fc and E4-Fc clones revealed amounts of total protein 
excretion of 27.7 and 29 mg/dL, respectively. B4-Fc administration showed higher, 
but not significant amounts of 34.3 mg/dL within 18 hours. As a consequence the 
total protein/creatinine ratios could be determined with 1.6 for the sham group and 
2.0, 1.1 and 1.8 for the C9-, E4- and B4-Fc groups, respectively. None of the 
fusion protein administered groups showed significant differences to the PBS 
administered control group. 
Tab. 4.9: Summary table of in-vivo effect study with mMC-specific scFv-Fc fusion proteins 
 C9-Fc E4-Fc B4-Fc PBS control literature healthy mice 
Amount protein 
administered  2 mg/kg 2 mg/kg 2 mg/kg 
corresponding 
volume  
Serum (mean arithmetic values) 
Creatinine  
[mg/dL] 0.31 0.30 0.25 0.27 0.5-1.1 
Urea  
[mg/dL] 85.3 72.7 80.7 70 12-31 
GPT/ALT  
[U/L] 80 38 158 44 28-87 
Urine (mean arithmetic values) 
Creatinine  
[mg/dL] 14.7 19.4 19.3 19 n. a. 
Urea  
[mg/dL] 2383.2 3176.6 3142.3 3489 n. a. 
tot. protein  
[mg/dL] 27.7 29 34.3 26* (5-64) n. a. 
protein/crea ratio 2.0 1.1 1.8 1.6 n. a. 
IHC findings - + - - n. a. 
 
 
4.7.3 Immunohistochemical analysis of murine kidneys after 
injection of mMC specific scFc-Fc 
The first visualization of potential morphological changes within the murine 
mesangium or the kidney in total was performed via PAS reaction. Periodic acid-
Schiff (PAS) reaction was used to detect glycogens, glycoproteins and -lipids, 
which were represented within collagen and connective tissues, in the glycocalyx 
of cell walls and in the basal membrane. The reaction leaded to a magenta 
coloured staining of the abovementioned structures, whereas nuclei and 
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cytoplasm were coloured blue and light pink, respectively. Paraffin embedded 
kidney sections of 1 µm thickness were used for the PAS reaction.     
 
Fig. 4.28: PAS staining of 1 µm murine kidney sections. Nucleic regions were stained blue, 
whereas glycoproteins, -lipids and glycogen as representatives for connective tissues and 
cell walls were stained in magenta colour.  
The overall investigation of the PAS staining after administration of scFv-Fc 
proteins to C57BL/6 mice showed only little amount of significant pathological, 
histological findings. Compared to the PBS control group C9- and B4-Fc binders 
revealed similar, unsuspicious results. Only the in-vivo administration of E4-Fc 
fusion protein led to increased amount of extracellular matrix, collagen and cell 
nuclei within the glomerular structure. Resulting swelling of the glomeruli could be 
clearly detected in tissue sections from the E4-Fc administered animals.  
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 Discussion 5
Phage Display as a molecular affinity selection method for highly specific target 
detection was used since nearly three decades. During the last ten years its 
impact in the fields of immunology and drug discovery, especially in antibody-
generation has become even stronger. The selection of antibody fragments, so 
called single-chain variable fragments (scFv) from vast gene libraries against 
certain antigens using Phage Display technology is as well subject of this thesis. 
Recombinant bacteriophages are used as carriers capable of displaying foreign 
antibody fragments at their surface [137]. In addition they have incorporated the 
corresponding nucleotide sequence of the presented proteins within their phage 
shell [116, 138], making them a perfect vehicle for a process called clonal 
selection [1]. At any stage of the technique’s progress, the genetic information 
(genotype) of the displayed protein or peptide is physically linked to its encoded 
product (phenotype). Depending on the choice of a certain Phage Display library 
system, as well as the decision towards an antigen, antibodies against nearly any 
kind of target can be generated applying this technique. Within this thesis the 
Tomlinson libraries I and J were used to generate scFv-Fc minibodies specific for 
murine mesangial cells (mMC).  
The major difficulty of this thesis consisted of screening for antibody fragments 
specific for a primary cell type with undefined antigen composition. Phage Display 
screening on living cells and primary cell compartments is not a worldwide 
standard method and several reputable groups [103, 85, 74] tried to establish 
appropriate library screening and selection protocols for such approaches with 
only limited success [34, 46, 95]. The particular antigen and selection choices 
taken to pioneer and address these questions within this thesis will be described in 
the following section.  
5.1 The selection strategy as crucial step 
The affinity selection during Phage Display involves library exposure to the target 
to allow antigen-specific binding of phage particles, recovery of the antigen bound 
phages and subsequent infection of suitable bacteria for backup and 
reamplification of the selected gene library. Various factors can influence the 
quality of a Phage Display selection. The exposure of the phage particles to the 
target antigen and the encounter and interaction of the two binding partners are of 
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major interest throughout the biopanning. Thereby the success of the selection 
process is mainly driven by the accessibility of the chosen antigen [137, 47].  
 
 
 
Fig. 5.1: Possible Phage Display selection strategies. In general affinity selection can be performed 
in-vitro, ex-vivo or in-vivo on targets of interest. The strategy used during this thesis is 
marked in grey and is further described in detail within the text 
As shown in Fig. 5.1 different strategies can be pursued. Besides in-vivo [100, 
129] and ex-vivo [80] selection of antibody libraries, which both often are error-
prone and neither feasible nor promising, especially in-vitro Phage Display is used 
for antibody generation. It is less time consuming and takes less effort in respect 
of animal experiments. The decision tree taken towards a suitable selection 
antigen in this thesis is described in detail in Fig. 5.1 and coloured in grey.  
 
5.1.1 The antigen  
Using in-vitro Phage Display, up to now, the choice of selection target widely relied 
on recombinant or purified antigens (Fig. 5.1), which enables a stable and easy 
selection on well-characterized targets [8, 93, 73]. However, for cell bound 
receptors or other unknown cell surface molecules, conformation-stable isolation 
of the antigen is difficult or even not possible. This has also been the case for the 
generation of antibodies specific for murine mesangial cells (mMC) during this 
thesis. A promising strategy to go for successful enrichment of binders against 
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unknown and undefined targets came to be the use of viable target cells of 
interest. This enables a selection of antibody fragments directed against surface 
molecules available in their maximum native and biologically active form [62, 126, 
135]. Only very few investigations were reported, that succeeded in selecting 
antibody fragments from Phage Display libraries by screening on native, living 
target cells or their derivatives [33, 74]. Our group at the Helmholtz Institute 
Aachen around Prof. Dr. Dr. Stefan Barth has pioneered this field [104, 127, 126]. 
Ideally the targeted cell type is well characterised and standardised by certain 
biological cell databases like ATCC and is accessible at any time [40, 54, 114]. 
Since there is no mMC- cell line available, primary murine mesangial cells were 
chosen to serve as antigen for affinity selection in our case. However, eucaryotic 
cells strongly change and differentiate during in-vitro cultivation and thereby lose 
parts of their native expression phenotype over time [38, 50, 55, 110, 123, 139]. 
Additionally the physical conditions during the Phage Display selection process 
can release intracellular components serving as undesirable potential antigens 
[104, 127]. To minimize these problems, a special type of selection antigen was 
chosen here: membrane fractions of murine mesangial cells were used during the 
screening process. While separating the target antigen from any kind of 
contamination by surplus cell material a maximum native antigen constitution is 
kept. As described (see 4.1), primary mMCs were isolated from healthy C57BL/6 
mice. They were cultivated for a period of about 6-10 weeks under selective 
pressure with D-Valin containing medium [48] until a pure, fibroblast free, primary 
mMC culture was reached. Changes in surface molecule expression were 
minimized during the cultivation process by keeping the primary, pure cells culture 
not for more than 8 passaging steps (data not shown) before preparing membrane 
fractions. After this cell isolation process, membrane fractions were produced via 
ultrasound and ultracentrifugation as described (4.1.1). This production process 
was already proven to favour the so called “right-side-out” orientation of the 
membrane fractions [127]. Therefore they combine a maximum native cell surface 
composition (like viable cells have) with the advantage of storage- and usage-
stability. The mMC membrane fractions represent a reproducible, reliable and 
nearly native antigen.  
5.1.2 The selection process 
The choice of membrane fractions as stable antigen has been retained for all 
selections performed during this work. Still, the use of impure target antigens like 
cells or cell membrane fractions is difficult because of limited amounts of antigen 
available, compared to purified targets. The enrichment of phage antibodies 
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against potentially underrepresented antigens can be strongly influenced by 
washing and panning variations. This thesis pursued two different approaches.  
In principal the affinity selection can either be performed on antigens solubilised in 
carrier liquids, like for example on cells [135] or on paramagnetic liposoms [84] or 
immobilised on solid structures like microtiter plates or on tissue sections [127, 
131, 39]. For reasons of practicability all Phage Display selections performed 
during this thesis were carried out on microtiter plates.   
5.1.2.1 Selecting scFv-phages from the Tomlinson Library J 
At first, the Tomlinson Library J was screened aiming for single-chain binders 
against mMCs. The major interest was to primarily generate positive binders with a 
broad variety of specificity towards the mMCs. Selection concepts have been 
described in literature that force the outcome of binders with at least medial 
binding activity and high specificity, driven by increasing the antigen’s accessibility 
by stepwise dilution during the selection procedure [53]. Combined with an 
increasing washing stringency and extended washing periods from step to step 
[137, 138] our selection was pushed towards binders with increased affinity. The 
panning procedure of the TL J revealed three unique binders selectively binding to 
mMC membrane fractions membrane fractions in ELISA experiments, which 
verifies the concept described above.   
Binding specificity tested on membrane fractions was confirmed by the analysis on 
primary cultured murine mesangial cells (see 4.2.1.3). A classification according to 
criteria described under 4.2.1.3. declares three strong scFv-phage binders from 
the Tomlinson library J which are highly selective against mMCs. 
Tab. 5.1: Classification of scFv-phages from Tomlinson library J and I 
Classification ELISA binding signal (compared to the average NC) scFv-phage library 
Weak binder < 2.5- 5 times stronger - - 
Medial binder < 5- 7.5 times stronger - - 
Strong binder < 7.5-10 times stronger 
C2 (scFv) 
C9 (scFv)  
E4 (scFv) 
B4 (scFv)  
J 
J 
J 
I 
 
A primary investigation of the binding capabilities on scFv-phage level gave a hint 
on specificity of the selected binders within their natural tissue environment. 
Binding investigation on cryo sections of mouse kidneys (see Fig. 4.8) clearly 
underlines, what was already assumed: each of the scFv-phages is able to bind 
the mesangial supportive tissue region within the glomerular structure of the 
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kidney sections. Since we already showed that the C2 (scFv)-, C9 (scFv)- and the 
E4 (scFv)-clone are unique binders concerning their amino acid sequence (see 
Fig. 4.5) it is not surprising, that each of the phage binders shows its own staining 
pattern. The C2 (scFv)- and C9 (scFv)- phages show selectivity for mesangial 
regions spread all over the cauliflower, glomerular structure, whereas the E4 
(scFv)-phage seems to have strong affinity to mesangial regions located at the 
apical region of the glomerulus. Further investigations on the regions of binding 
will be discussed later on. So far the scFv-phage selectivity for murine mesangial 
regions and cells could have been proven in three different experimental setups.  
5.1.2.2 Selection of the Tomlinson Library I 
The affinity selection of the Tomlinson Library I was performed under more 
complex and stricter conditions: continuously low antigen concentrations together 
with permanently intense washing procedures were applied to this library 
screening. An upstream depletion step on membrane fractions of negative target 
cell was performed before each positive selection step on the target antigen. That 
finally ended up with a low amount of different mMC-positive phage particles 
showing very high binding affinities towards the antigen. In contrast to the library J 
approach only one unique scFv-phage binder was selected during the screening 
procedure of the library I. The DNA sequence of the B4 (scFv)-clone prevailed 
during the panning rounds on murine MC membrane fractions (see 4.2.2.1). The 
B4 (scFv)-phage is classified as strong binder (see Tab. 5.1) based on results of 
repeated ELISA experiments.  
The choice of a certain selection procedure for a certain library during this thesis 
was independent of the available library characteristics but was chosen at random.  
The successful selection and multiple proof of four different scFv-phages 
selectively binding towards murine MCs justifies the selection strategies performed 
with the Tomlinson libraries I and J. 
5.2 The scFv-gene libraries 
The Phage Display selections in this work were performed with the Tomlinson 
Libraries I and J. These scFv-libraries are both naïve, human gene libraries 
encoded on a phagemid vector. Provided in E. coli TG1F+ bacteria, each of the 
two libraries encodes for more than one billion different single-chain (scFv) 
antibodies [45]. The structure for all of these scFv genes is defined by the linkage 
of the variable regions of a heavy and a light antibody gene fused via a synthetic 
multiple glycine-serine-linker- the (Gly4Ser)3 linker [52]. The antigen binding scFv-
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antibody domains are genetically linked to the gene of the M13 bacteriophages 
minor surface coat protein pIII. Expression of the scFv-libraries by infection of the 
host bacteria cells with helperphages leads to incorporation and presentation of 
the scFv-pIII proteins on the shell of new bacteriophages. 
The diversity of phage display libraries mainly depends on two different facts. On 
the one hand the transformation efficiency of foreign phagemid vectors into host 
bacteria cells is limiting for the library size. In the case of the Tomlinson library I 
(size: 1.47 x 108) and library J (size: 1.37 x 108), an averaged physical bacterial 
transformation efficiency of 107 to 1010 [17] is not critical. On the other hand it is 
described in literature, that the amount and affinity of antibodies selected against a 
special antigen directly depends on the library size and diversity [111]. Naïve 
libraries already show advantages versus immunized, preselected libraries [26, 
53]. Additionally artificial diversification within the side chains of the 
complementarity determining regions (CDRs) enhances the library diversity.  
Tab. 5.2: Amino acid residues artificially diversified in Tomlinson libraries  
 diversified amino acide resiudues 
VH H50, H52, H52a, H53, H55, H56, H58, H95, H96, H97, H98 
VL L50, L53, L91, L92, L93, L94 and L96 
 
In the present case of the Tomlinson Libraries I + J, diversification was performed 
mainly on 18 amino acid residues which are described to be highly diverse within 
the primary human antibody repertoire and are key players within antigen binding 
process. 
5.3 Mutagenesis of amber stop codons 
As described under 4.2.1.2, all selected clones from the Tomlinson Library J 
showed undesired TAG amber stop codons within the nucleotide sequence of the 
variable gene regions. To understand the occurrence of these types of problematic 
triplets one needs to take a closer look to the generation of the Tomlinson 
Libraries. In both libraries the single human framework V3-23/DP-47 and JH4b 
(encoding for VH: 1-3) and O12/O2/DPK9/Jκ1 (encoding for Vκ:2-1-1) represent 
the antibody fragment backbone.  
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Fig. 5.2: Genetic design of the naїve Tomlinson Libraries I + J. Both Libraries are based on the 
human frameworks encoding for VH:1-3 and encoding for Vκ:2-1-1 and therefore share 
the identical constant regions. However, the complement determining regions (CDRs), 
responsible for the diversity of the libraries are randomized at 18 side chain residues: 
H50, H52, H52a, H53, H55, H56, H58, H95, H96, H97, H98 in the heavy chains and L50, 
L53, L91, L92, L93, L94 and L96 in the light chains.   
Randomization of the variable regions (CDR) of gene libraries is used to enhance 
the variability and library size or to specify the affinity of potential binders towards 
their antigen [21]. In the case of the Tomlinson Library J NNK diversification is 
used as already described (see 2.3.5). This principle naturally leads to the TAG 
nucleotide triplet with a statistical probability of about 3 % (1 out of 32 possible 
triplets). However, the iterative affinity selection of the Tomlinson library J 
performed in this work created 100 % mMC specific binder candidates that show 
amber stop codons in their CDR 2 regions (see 4.2.1.2). As already seen phage 
[32] candidates with amber stop codons [78] seem to have an enormous selection 
advantage during the panning procedure, leading to an enrichment of such scFv-
binders. This phenomenon has already been described by other groups working 
with the Tomlinson libraries I and J with incidences ranging from 10 [78, 97] -100% 
[32, 140] “amber-positive” binders during selections. Reason for that over-
excessive representation of these stop codon bearing clones is the usage of 
bacterial “suppressor” strains during phage display selection [66, 109]. During the 
Phage Display selection process these clones are amplified instead of being 
eliminated due to their ability of incorporating a CAG instead of TAG base triplet, 
which consequently leads to the translation into the functional amino acid 
glutamine (see 4.3) [78, 97] Though allowing the production of scFv-presenting 
bacteriophages in suppressor bacteria, amber stop codons do prevent the full 
expression of phage-particle-free, soluble antibody fragments in non-suppressor 
strains or in eukaryotic cell lines [92, 30], consequently leading to translational 
abort directly downstream of the amber stop codon. If this increased presence of 
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amber stop codons has already been fixed within the original Tomlinson libraries 
or if it is a consequence of repeated panning rounds is not investigated during this 
thesis.  
For the Tomlinson library I such TAG base triplets cannot develop naturally due to 
the DVT diversification strategy and thus were not found within the CDRs of any of 
the selected mMC binding scFv-phages. Nevertheless the B4-scFv binder, 
originating from the Library I, showed an unexpected amber stop codon, though 
not within the randomized, variable regions but within the framework 3 of the 
heavy chain gene. This was not yet reported in literature and can only be 
explained by an exceptional point mutation during the selection process.  
To avoid fragmentary single-chain expression, site directed mutagenesis was 
performed [78, 109] for all J- and I-selected scFv-phage binders (results shown in 
subchapter 4.3). The PCR driven exchange of randomly produced TAG base 
triplets towards CAG results in glutamine integration instead of translational stop 
and therefore leads to fully expressed soluble single-chains (see chapter 4.3 and 
4.6). This method mimics the suppressive effect of phage production during affinity 
selection.  
The two selection strategies described under 5.1.2 followed by the mutagenesis of 
extraordinary, unwanted amber stop codons within the CDR sequence of the scFv 
clones finally resulted in three antigen binding scFv-antibodies. Two of them are 
selected from the Tomlinson library J, the C9 (scFv) and E4 (scFv). The DNA 
sequence of the C2 (scFv) binder could not be mutated towards exchange of the 
TAG amber stop codon. Another antigen binding B4 (scFv) antibody fragment 
raises from the library I. The site directed mutations in the gene of every clone 
preserve binding to the murine mesangial cells in ELISA experiments- on 
membrane fractions (Fig. 4.13) as well as on primary cultured cells.  
Tab. 5.3: Overview of binding charactersistcs of scFv-phages selected from Tomlinson libraries   
 specific binging on 
mMC MF primary mMCs mesangium/ 
cryo tissue 
cross reactive/ 
cryo tissue 
C9 (scFv)--phage + + + - 
E4 (scFv)--phage + + + - 
B4 (scFv)--phage + + + - 
 
The following sections will discuss the modification, functionalization and 
application of these three mMC specific single-chain binders.  
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5.4 Generation of mMC specific scFv-Fc fusion proteins 
Three single-chain binders detecting mMCs originate from the selection of the 
Tomlinson library I and J on membrane fractions. Their target detection domain 
expressed as pIII-fusion proteins and presented on bacteriophages could have 
been proven on membrane fractions, vital primary cells and as well on kidney 
tissue sections as shown above (Tab. 5.3). Since there were no hints on cross 
reactivity on other murine systemic organs after mutagenesis (data shown under 
4.2.1.5) functionalization of the single chain variable fragments was initiated. The 
aim of this study was to generate chimeric, antibody-like fusion proteins which are 
able to on the one hand selectively bind to murine mesangial cells and on the 
other hand have the potential to induce an immune modulated disease 
comparable to the anti-thy 1 nephritis [6, 69]  
For the latter topic, the trigger of the immunoreaction at the site of binding (the 
murine mesangium) an implementation of a fragment, crystallisable (Fc) -portion is 
essentially required. Basically the genetic linkage of a single chain variable 
fragment (scFv) to such a Fc-part mimics the structure of a natural antibody by 
bringing together an antigen binding portion with an immune modulating Fc-part.  
The Fc-domain in general consists of two constant regions of the heavy 
immunoglobulin chains (the CH2 and CH3 domains) and a so called hinge region 
which serves as a flexible spacer. The hinge additionally enables two scFv-Fc 
fusion proteins to accumulate via disulfid bonds and to build functional antibody 
like dimers with a size of about 120 kDa [129] (see Fig. 5.3).  
 
Fig. 5.3: Schematic representation of a full length antibody compared to a scFv-Fc fusion. In both 
cases the hinge region leads to accumulation of two Fab- or scFv-Fc domains via disulfid 
bonds. Source:[129]  
The effector function of the Fc-part mainly includes two mechanisms: 
 the recruitment of effector cells via binding to the FcγR on immune effector 
cells like macrophages or natural killer (NK) cells followed by cell lysis or 
phagocytosis of the targed cell [130] 
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 the killing of the cells by setting off the complement cascade at the targeted 
cell surface [83, 65, 86] 
Depending on the subtype of Fc-domain, the two mechanisms are represented at 
differential intensities, which are described [58] to increase in the following order: 
    IgG4 < IgG2 < IgG1 ≤ IgG3.     
A decision towards an Fc part as effector domain for a special kind of application 
is mainly driven by the effector function to be addressed. For the purpose of this 
thesis the Fc part was chosen to preferably induce, as described for the OX-7 
antibody, complement driven immune reactions in mice. Based on it` s reviewed 
characteristics of very strong ADCC and CDC effector activities [58], the murine 
IgG2a-Fc part was chosen as fusion partner for the selected scFv-domains in this 
thesis. 
Due to technical difficulties the scFv-Fc gene fusions were carried out at a CRO 
and were afterward processed in-house into the eukaryotic pMS-SNAP expression 
vector (see 0).  
5.5 Expression of the selected and functionalized scFv-
Fc antibodies 
Within this work, scFv antibodies against primary murine mesangial cells were 
selected from two naïve phage libraries, the Tomlinson library I and J. After the 
successful binding characterisation of the phage-presented single-chain proteins, 
the generation of chimeric scFv-Fc proteins was carried out to further use the 
fusion proteins in animal experiments. First, however, the selectivity and binding 
characteristics of the chimera needed to be figured out. Therefore the scFv-
mIgG2a-Fc genes were introduced into the bi-cistronic pMS-SNAP vector, 
generated and established in our group by Michael Stöcker [118, 117].  The 
plasmids were transiently transfected into HEK293T cells and expressed under 
antibiotic selective pressure with Zeocin®. An eGFP gene introduced into the 
expression vector system via an IRES site was used as read out parameter for 
successful scFv-Fc expression. In case of translation initiation both proteins are 
expressed and secreted into the supernatant of the eukaryotic cell culture. 
Successful expression was evaluated via green fluorescence of the eGFP protein 
by using a fluorescence microscope (Fig. 4.14 B).  
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Since the scFv-Fc proteins were used for in-vitro binding analysis as well as for in-
vivo animal experiments, different purification procedures were investigated and 
will be briefly described as follows: 
1. For quick binding analysis of the scFv-Fc proteins cell culture supernatant 
was directly used in ELISA experiments on mMC membrane fractions, vital 
mesangial cells and on cryo tissue sections of murine kidneys.  
2. As precaution, in-vitro binding analysis described above was as well 
performed with batch-purified protein. Thereby IMAC purification was 
performed via the HIS- and SNAP-tag, respectively.  
3. For the animal experiment scFv-proteins were purified from eukaryotic cell 
culture supernatant with NiNTA and their HIS-tag, respectively. A 
subsequent size exclusion chromatography (SEC) and a sterile filtration 
step were carried out to minimize side effects after protein administration to 
mice. 
Independent of the degree of purity, the expressed scFv-Fc were shown to be 
functional in all investigated assays. Comparing the results of the in-vitro analysis 
generated with unpurified cell culture supernatants containing scFv-Fc proteins 
and the batch-purified proteins, the unpurified supernatant seems to show better 
signals in all assays. This can be explained with the composition of the cell culture 
medium. High protein concentrations and addition of glycerol or sucrose have 
been previously reported to stabilize protein solutions for example during freezing 
and thawing procedures. Limited amounts of unspecific, unspecified proteins like 
BSA in the FCS seem to have the same stabilizing effect towards the storage of 
expressed fusion proteins [115]. In case of low protein amounts stored in e.g. 
Eppendorf tubes, a high amount of protein of interest might be loss due to 
interaction with and low level binding of the protein and the container material.  
Higher concentrations with BSA as carrier protein prevent protein loss on artificial 
surfaces.  
Within this thesis the specific detection of the scFv-Fc chimeric proteins carried out 
in in-vitro assays was either performed via antibodies directed against the Fc-part 
or antibodies directed against the HIS- and SNAP tag, respectively. Since each of 
the detection domains was represented once per chimeric protein portion no 
differences in signal strength could have been detected.  For reasons of clarity 
only representative data were shown.  
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5.6 Characterisation of generated chimeric scFv-Fc 
proteins in terms of target binding and cross-
reactivity on cryo sections of murine kidneys 
To answer the questions about the specificity of the generated scFv-Fc fusion 
proteins towards the target cells, the mMCs, binding analysis was investigated in 
direct tissue environment as already described for the scFv-phages. Again cryo 
sections of murine tissues were used for binding analysis. Here the soluble scFv-
Fc antibodies were incubated overnight on the tissue sections as primary antibody. 
In parallel co-stainings were performed with commercial antibodies highly specific 
for cells in direct proximity to the mesangial cells. For better visualization 
fluorescence detection of the scFv-Fc fusion proteins was performed in green, 
whereas the counter staining antibodies were detected with red fluorescent 
secondary antibodies. As described by Kriz et al. [70, 61, 71] endothelial cells and 
podocytes are, besides mesangial cells the major cell types represented within the 
glomeruli (also shown in Fig. 2.2).  
Since the cell specific targets of the generated scFv-Fc chimera are not known the 
co-staining approach with commercial antibodies against defined targets is 
performed as a substractive method:  
1. no co-localisation but separate staining of the green (anti-mMC) and the red 
(anti-podocyte and anti-endothelial cells, respectively) antibody patterns is 
interpreted as highly specific binding of the single-chain-Fc fusion proteins 
towards murine Mesangial Cells, whereas  
2. overlay of stainings resulting in orange or yellow colour is interpreted as co-
localisation of the antibodies and therefore positive binding towards both 
cell types.  
3. A control staining specific for murine Mesangial Cells is not possible due to 
the lack of any mMC specific antibody.  
First of all, comparing the staining patterns of the soluble C9- and E4-Fc proteins 
with the corresponding scFv-phage ones described before (see 4.2.1.4), the 
specificity of the scFv-domains can be confirmed. The C9- and the E4- scFv 
clearly bind within the mesangial supportive tissue regions in the centre of the 
glomerular structure. That holds true for the B4-Fc protein, whereas an additional 
selective binding region of this clone seems to be situated along the Bowman`s 
capsule.   
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Concerning the podocyte specific staining shown under 4.6.1, the C9-Fc chimera 
shows a mainly separate staining pattern within the mesangial regions. More than 
90% of the C9-Fc green fluorescence signal is detected solely. Nearly no orange 
spots can be recognised within the stained kidney sections, underlining the 
specificity towards mesangial cells.  
The E4-Fc clone in contrast shows a proportion of nearly 50% overlaying staining 
pattern, appearing in orange regions, especially at the bottom of the Bowman`s 
capsule. The co-localisation does not directly imply the same target, namely 
nephrin, for the commercial antibody and the E4-Fc clone. It rather looks like the 
specific target for the E4-Fc clone is not only represented on mMCs but as well on 
podocytes.  
Only the B4-Fc clone revealed a 100 % clear and separate staining pattern. The 
B4-Fc clone does not bind to any kind of podocyte structures visualised by anti- 
nephrin antibody. The staining for this chimera is basically located in the centre of 
the mesangial supportive region, but as well shows a distinct staining along the 
Bowman`s capsule. Further investigations in the direction of co-staining with 
parietal cells are ongoing [3].   
Investigation of co-localisation of endothelial and mesangial antibody binding (see 
chapter 4.6.2) did not show merged co-localisation of any of the generated scFv-
Fc proteins and the commercial anti-PECAM 1 antibody, highly specific for 
endothelial cells. In cases of the C9-, E4- and B4-Fc fusion proteins the green 
fluorescence signal was clearly separated from any kind of red anti-PECAM 
staining. 
To summarize the binding analysis: all of the three mesangial cell targeting scFv-
Fc fusion proteins generated within this work show unique and distinct positive 
staining patterns within the mesangial regions of murine kidney sections. Staining 
studies with proximately located glomerular cell type specific antibodies show no 
overlapping stainings. Only for the E4-Fc fusion protein a slight hint on non-
specificity can be assumed due to a partial co-localisation with podocyte cell 
staining.  
Nevertheless one can clearly postulate that we were able to successfully select 
murine mesangial cell specific single-chain antibodies by screening the human, 
naïve Tomlinson libraries I and J. 
5 Discussion 99 
5.7 Approval of functionalization of the generated scFv-
Fc chimera  
One of the major aims of this work was to generate the so far first mMC specific 
antibodies for highly specific detection of this cell type.  The urgent need for such 
an antibody is absolute clear: the usage for tissue staining and cell type 
recognition of murine mesangial cells in in-vitro analysis of various kidney 
diseases is obvious. But even more, the functional use as an external trigger for 
the induction of a mesangioproliferative disease model comparable to the thy-1 
nephritis in rats (described under 2.2.1) is of great interest for the academic 
research community.  
To figure out the capability of such disease induction the single scFv-Fc fusion 
proteins were intravenously administered to healthy C57BL/6 mice. Comparable to 
the anti-thy-1 nephritis model where 2 mg/kg of the OX-7 rat MC specific antibody 
are injected for disease induction, here 50 µg (corresponding to 2 mg/kg) of each 
scFv-Fc protein were applied to the mice. The experimental time course of seven 
days was arranged as described before for the rat model. Investigations of urine 
and blood read-out for renal core parameter were performed at the end of the 
experiment, at day seven. Immunohistological analysis of the kidney tissues in 
terms of mesangial hyper-proliferations, vascular damage or accumulation of 
extracellular matrix were, as well, carried out at the final end point of the 
experiments.  
Creatinine and urea, as central indicators for renal diseases, are expected to 
increase in urine as consequence of renal breakdown. The same holds true for the 
amount of total protein excreted in the urine. For none of the scFv-Fc groups a 
significant difference compared to the PBS sham group can be detected in terms 
of any of the investigated urine parameter. Additionally it is not possible to identify 
one of the single antibodies to show a consistent tendency towards influence on 
the readout parameter. Neither for the urine creatinine, nor for the urine urea 
concentration or the amount of total excreted protein. 
The corresponding observation concerning the read-out parameter in the blood 
samples taken at the end of the in-vivo experiment is equally conclusive. A 
significant differentiation of the scFv-Fc administered animal groups compared to 
the sham group was not possible, neither for the urea nor for the creatinine 
concentrations. Only the GPT/ALT concentration, as an indicator for liver injury, 
showed an increase in blood concentration in the B4-Fc group. Even though not 
5  100 
significant, this increase of the alanine transaminase (ALT) concentration is 
mentionable.   
Based on the physiological read-outs of this animal experiment, we are not able to 
postulate the induction of renal injury so far. One reason could be the wrong time 
point for the determination of the systemic parameters. Increased metabolism of 
mice compared to rats can lead to early recovery from an antibody-induced renal 
injury and therefore pretend normal urine and blood profiles. In such a case of 
weak or recovered renal damage, the histological investigation of the kidneys by 
PAS staining serves as an explicit pre-indicator: uninjured tissue can be 
distinguished from already recovered ones due to the lack of scarred areas within 
the glomerulus. If induction of a mesangioproliferative disease with one of our 
scFv-Fc fusion proteins was successful, enlarged, highly cell proliferated glomeruli 
with accumulation of extracellular matrix and agglutination of the capillary 
structures can act as read out observations.  Compared to the PBS group (shown 
in Fig. 4.28) only small tendencies towards structural changes can be seen in the 
scFv-Fc groups. Concerning the C9-Fc administered animals, the supposed 
agglutination of glomerular tissue can be explained with normal technical 
variations in the generation of 1 µm thin tissue sections. The B4-Fc administered 
group shows none of the mentioned changes concerning cell proliferation or 
accumulation of extracellular matrix. Only the E4-Fc injected animal group 
revealed glomerular changes comparable to the ones expected in 
mesangioproliferative kidney disease models like the rat anti-thy 1 GN.  For this 
group we can show single glomeruli with enlarged areas, hyperproliferated 
mesangial regions and accumulation and agglutination of extracellular matrix 
within the cauliflower like glomeruli. Nevertheless these findings were only present 
in a small portion of about 20-30 % of all investigated tissue sections and group 
members.  
Taken together the physiological and histological observations investigated during 
present in-vivo study we were not able to reflect a disease model for a 
mesangioproliferative disease following the anti-thy 1 nephritis in rats. One 
explanation for that may be the robustness of the mouse strain towards renal 
injury which has already been described by other groups [16, 19, 49, 61, 76]. 
Therefore a change in the strain for example to BALB/c could result in enhanced 
sensitivity for induction of renal disease.  
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 Summary 6
One of the most prevalent and widespread diseases in western countries still is 
chronic renal failure. The reasons for that are manifold: besides genetically fixed 
renal issues, renal failure often is a concomitant disease induced as a 
consequence of severe intoxications, diabetes or rheumatoide diseases. Due to 
these complex correlations, therapeutic approaches are often difficult and more of 
a palliative than a curative character, only to mention immune suppression, organ 
transplantations or dialysis. Especially in mesangioproliferative diseases like the 
IgA Nephropathy a basic mechanistic understanding is of absolutely urgent need, 
due to very limited access to suitable animal models.  
Within this work an innovative, unique Phage Display selection procedure was 
established, from which antibody fragments highly specific for murine mesangial 
cells were generated and characterized. This cell type represents a key player in 
mesangioproliferative glomerulonephritis. The C9-(scFv), E4-(scFv) and B4-(scFv) 
antibody fragments were each fused to a murine IgG2a-Fc portion, leading to an 
antibody-like chimera protein. Their binding characteristics towards the target cells 
in different matrices were investigated. The analysis performed during this thesis 
aimed to show mMC specificity on the basis of a substractive approach. Cross-
reactivity investigations on healthy competitor tissues like lung, heart, spleen and 
liver were performed followed by substractive co-localization studies with cell types 
closely related to the mesangial cells. It was clearly shown that all of the generated 
scFv-binders are highly specific for mesangial regions and do not bind on other 
tissues or cell types neighboured in the glomerulus. Nevertheless, the target 
antigens of the three selected mMC binders were not yet identified. Such 
investigations are of urgent need to promote therapeutic approaches. Regarding 
this, mass spectrometry analysis of cross-linked and immunoprecipitated scFv-Fc 
binders on the target cells is a promising step. So far we were not able to establish 
such experiments within our group, but this is still of major interest and appropriate 
steps are initiated.  
A highly specific recognition of murine mesangial cells within their natural tissue 
environment was proven for each of the three scFv-Fc fusion proteins. The 
utilization of these exclusive and newly murine MC specific, antibody-like fusion 
proteins is a reasonable path forward in diagnostic and descriptive approaches of 
murine kidney disease models. Fused to the Fc-portion the highly specific mMC 
binders should be used as an external trigger for the initiation of a new murine 
animal model for mesangioproliferative glomerulonephritis (GN). Following the 
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disease progress and transformation of the anti-thy 1 nephritis in rats, the idea 
was to induce mesangial cell lysis, hyper-proliferation of residual cells within the 
glomerular structure as well as accumulation and agglutination of extracellular 
matrix within the mesangium by injection of a single portion of scFv-Fc fusion 
protein. Within the present work we did not succeed to establish such a murine 
animal model, but prepared the ground for further investigations into this direction. 
Especially the functionalization of the scFv-Fc proteins via their included 
recombinant SNAP-tag anchor allows a huge variety of further disease induction 
approaches. It allows the usage of the generated scFv-Fc fusions as highly cell 
specific delivery vehicles for different effector moieties. Direct labelling of our 
proteins with specific cytotoxic agents like Pseudomonas exotoxin A (ETA) [9, 88, 
136] or immune stimulating agents like growth factors via the SNAP-tag have the 
potential to induce site directed cell lysis and macrophage recruitment within the 
glomerular tuft and therefore mimic the complement derived inflammatory 
response described for the anti-Thy 1.1 nephritis. 
Further engineering of our scFv-Fc fusion proteins via the SNAP-tag combined 
with alterations and modifications in the experimental in-vivo set-up can help to 
open the wide field of genetically manipulated mouse models and utilize them to 
gain better understanding of the mechanisms involved in mesangioproliferative 
glomerulonephritis.  
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 Zusammenfassung 7
Chronische Niereninsuffizient zählt nach wie vor zu den vorherrschenden und am 
meist verbreitetsten Erkrankungen in den westlichen Ländern. Ihre Ursachen sind 
vielfältig: neben genetisch fixierten Nierendefekten ist ein Nierenversagen häufig 
auch eine Begleiterkrankung, welche durch schwere Vergiftungen, Diabetes oder 
rheumatoide Erkrankungen ausgelöst werden kann. Durch die Komplexität dieser 
Zusammenhänge sind therapeutische Ansätze oft schwierig und eher von 
palliativem, als von kurativem Charakter und beinhalten Immunsuppression der 
Patienten, Organtransplantationen und Dialyse, um nur die wichtigsten zu nennen. 
Gerade im Fall von mesangioproliferativen Erkrankungen wie der IgA 
Nephropathie ist jedoch ein mechanistisches Verständnis absolut dringlich von 
Nöten. Noch immer fehlt es an ausreichenden, passenden Tiermodellen.   
In Rahmen dieser Arbeit wurde eine innovative, einzigartige Phage Display 
Selektionsmethode etabliert, die es uns ermöglichte höchst spezifische 
Antikörperfragmente gegen murine Mesangialzellen zu generieren und diese zu 
charakterisieren. Dieser spezielle Zelltyp spielt eine Schlüsselrolle in 
mesangioproliferativen Glomerulonephritiden. Die selektierten C9-(scFv), E4-
(scFv) und B4 (scFv) Antikörperfragmente wurden mithilfe eines murinen IgG2a 
Fc-Teils zu antikörperähnlichen Chimeren fusioniert deren Bindeeigenschaften auf 
den Zielzellen in verschiedenen Matrizes untersucht wurden. Der in dieser Arbeit 
zur Spezifitätsanalyse verfolgte Ansatz war von subtraktivem Charakter. Neben 
der Bindeanalyse auf gesunden systemischen Organen wie  Lunge, Herz, Milz 
oder Leber wurden die Antikörperchimeren zusätzlich in Co-Lokalisationsstudien 
gegen einzelne Zelltypen eingesetzt. Es konnte eindeutig gezeigt werden, dass 
die scFv-Binder hochspezifisch für murine, mesangiale Regionen sind und weder 
in anderen Geweben noch an Zelltypen binden die zu den Mesangialzellen im 
Glomerulus benachbart liegen. Nichts desto trotz wurde das Zielantigen der drei 
selektierten mMC Binder noch nicht identifiziert. Untersuchungen hierzu sind 
jedoch von großer Wichtigkeit um therapeutische Ansätze glomerulärer 
Nephritiden voran zu treiben. Eine massenspektrometrische Analyse von 
quervernetzen und nachfolgend immunpräzipitierten scFv-Fc Bindern und deren 
Zielzellen ist hier ein vielversprechender Weg. Bisher waren wir in unsere 
Arbeitsgruppe nicht in der Lage solche Experimente erfolgreich zu etablieren, 
allerdings ist dies nach wie vor von hohem Interesse und entsprechende Schritte 
werden verfolgt.  
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Wir konnten für jedes einzelne scFv-Fc Protein eine hoch spezifische Erkennung 
und Detektion muriner Mesangialzellen in deren natürlicher Gewebsumgebung 
zeigen. Die Nutzbarmachung dieser exklusiven und neuen mMC spezifischen, 
antikörperähnlichen Fusionsproteine stellt einen guten Startpunkt für 
diagnostische und deskriptive Ansätze muriner Nierenkrankheitsmodelle dar. 
Durch die Fusion an eine Fc-Domäne sollten die Antikörperchimere als externer 
Trigger für die Krankheitsinduzierung eines neuen murinen Tiermodels der 
mesangioproliferativen Glomerulonephritis eingesetzt werden. Entsprechend der 
Progression und Transformation der anti-Thy1.1 Rattennephritis sollte die 
einmalige Applikation unsere mMC spezifischen Antikörper zu einer mesangialen 
Zelllyse, einer Hyperproliferation verbleibender Mesangialzellen, sowie eine 
Akkumulation und Agglutination extrazellulärer Matrix im Mesangium auslösen. 
Innerhalb dieser Arbeit ist es uns nicht gelungen ein solches Tiermodell in der 
Maus zu etablieren. Mit der Generierung der scFv-Fc Fusionen wurde jedoch der 
Grundstein für weitere Untersuchungen in diese Richtung gelegt. Speziell die 
Funktionalisierung der Fusionsproteine über ihren recombinanten SNAP-Tag-
Anker ermöglicht eine Vielzahl unterschiedlicher Wege eine mesangioproliferative 
Entzündung zu induzieren. Der rekombinante Tag macht die generierten scFv-Fc 
Proteine zu einer hochspezifischen Trägersubstanz verschiedener 
Effektordomänen. Gerade das direkte Markieren unserer Proteine mit 
spezifischen, toxischen Agentien wie dem Pseudomonas Exotoxin ETA oder 
immunsystemstimulierender Substanzen wie Wachstumsfaktoren haben hier 
großes Potential. Sie könnten dadurch eine direkte Zelllyse, sowie das Rekrutieren 
von Makrophagen in den glomerulären Knoten initiieren und dadurch eine 
komplementvermittelte, entzündliche Antwort ähnlich der des anti-thy-1 Modells 
hervorrufen.  
Weitere Verbesserungen und Optimierungen unserer scFv-Fc Fusionsproteine, 
zusammen mit Veränderungen und Anpassungen des experimentellen in-vivo 
Ansatzes können den Zugang zu einem großen Gebiet genetisch manipulierter 
Mausmodelle eröffnen. Sie können diese Modelle nutzbar machen um ein 
besseres Verständnis für die Mechanismen mesangioproliferativer 
Glomerulonephritiden und möglicher Therapieansätze zu erhalten. 
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A Material  
A.1 Devices 
Tab. 7.1: Devices  
Application Equipment 
Autoclaves Varioklav (Thermo Scientific, Karlsruhe), 
Zentracert Typ 5169 (Lautenschläger, Köln)  
Balances LA310S analytic balance, CP6201-OCE (Sartorius, Göttingen) 
Centrifuges Multifuge 4KR, Biofuge Haemo (Heraeus Instruments & Co. KG, 
Hanau) 
Galaxy MiniStar (VWR International GmbH, Darmstadt) 
Eppendorf centrifuge 5804K (Eppendorf AG, Hamburg) 
Corresponding rotors #3325B (Heraeus), # A-4-44 and A-2-DWP (Eppendorf) 
Magnetic bead separator Dynal MPC™ -S (Dynal, Oslo, Norway) 
Electrophoresis Mini-PROTEAN®Tetra Cell,  
Mini Trans-Blot® Electrophoretic Transfer Cell,  
Sub- Cell GT Cell (BioRad Laboratories Inc., Hercules, USA) 
Electroporation Gene Pulser Xcell™ Electroporation System with Gene Pulser 
cuvettes (BioRad Laboratories Inc., Hercules, USA) 
ELISA plate reader Infinite M200, Sunrise (Tecan Group Ltd., Crailsheim) 
UV- transluminators Bio Imager DH-30132 (Biostep, Jahnsdorf) 
LAS-3000 doc.-system (Fujifilm, Tokio, Japan) 
Incubators HeraCell 150 (Thermo Scientific, Karlsruhe),  
Memmert Incubator Memmert GmbH + Co. KG, Schwabach),  
GFL- 3031 (Hilab, GFL - Gesellschaft für Labortechnik mbH, 
Burgwedel) 
Laminar flow HeraSafe HS18 (Heraeus Instruments & Co. KG, Hanau) 
PCR thermocycler GeneAmp PCR system 9700 (Applied Biosystems),  
Eppendorf Mastercycler® PCR cycler (Eppendorf, Hamburg) 
PCR bench Hepa/UV sterilizing PCR working station (UVP),  
Labcaire PCR 6 Workstation (Labcaire, Hertfordshire, UK) 
pH meter Five Easy™ pH meter (Mettler-Toledo GmbH, Giessen) 
Photometer Biophotometer Plus (Eppendorf, Hamburg) 
Sonificator Digital Sonifier (Branson Ultraschall, Dietzenbach) 
Sonoplus HD 2070, Tip: UW 2070, KE76 (Bandelin electronic 
GmbH & Co. KG, Berlin) 
Ultracentrifugation Optima L-80-XP (Beckman Coulter GmbH, Krefeld) with Ti70.1 
rotor 
Water distillation System Milli Q Synthesis with Quantum ® Ex Ultra pure cartridge filter  
(Millipore) 
Microscopes (fluorescence) Axio Observer.Z1 (Carl Zeiss GmbH, Jena) 
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A.2 Software 
 Vector NTI® Software (Invitrogen Life Technologies, Darmstadt) 
 Geneious 5 (Biomatters Ltd., Auckland, New Zealand),  
 Chromas Lite 2.01  
 Aida Advanced Image Data Analyzer 4.27.039 (Raytest 
Isotopenmessgeräte GmbH, Straubenhardt),  
 Axiovision 4.7.1 (Carl Zeiss GmbH, Jena) 
 Argus X1 (biostep GmbH, Jahnsdorf),  
 i-control for Tecan Readers (Tecan Group Ltd., Männedorf, Schweiz) 
 GraphPad Prism 5.01 (GraphPad Software, Inc., La Jolla, CA, USA) 
A.3 Consumables and Chemicals 
If not noted otherwise, all consumables and chemicals were purchased from 
following manufacturers (in alphabetical order):  
Becton Dickinson Bioscience (Franklin Lakes, USA), BioChrom (Berlin), BioRad 
(München), Biozym (Hessisch Oldendorf), Clontech (Mountain View, USA), 
Corning Inc. (Corning, USA), Eppendorf (Hamburg), Fermentas (St. Leon-Rot), 
Greiner (Solingen), Invitrogen (Darmstadt), Millipore (Schwalbach/Ts.), MWG-
Biotech (Ebersberg), New England Biolabs (NEB, Ipswich, USA), Nunc 
(Langenselbold), Novagen (Madison, USA), Pall Filtron (Port Washington, USA), 
Perkin-Elmer (Applied Biosystems, Waltham, USA), Pierce (Rockford, USA), 
Promega (Mannheim), Qiagen (Hilden), Roche Molecular Biochemicals 
(Mannheim), Roth (Karlsruhe), Sarstedt (Nümbrecht), Schott-Glaswerke GmbH 
(Mainz), Serva (Heidelberg), Sigma-Aldrich (München), Starlab (Ahrensburg), TPP 
(Trasadingen, Switzerland),  Whatman (Maidstone, England) or VWR (Darmstadt). 
A.4 Buffer and solutions 
All buffers and solutions were produced according to established protocols [107] 
with de-ionized water. If possible, solutions were sterilized by autoclaving (121°C, 
21min, 2 bar) or, in case of heat-sensitive components, by filtration through a 
0.22 µm pore filter. pH-values have been calibrated with 5 M NaOH and 5 M HCl, 
respectively. 
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Tab. 7.2: Media Compositions and standard buffers 
No Buffer Composition final concentration 
1 M9 minimal salt stock: NaCl 0.25 % (w/v) 
 (5x)(pH 7.4) NH4Cl 0.5 % (w/v) 
  Na2HPO4 3.39 % (w/v) 
  KH2PO4 1.5 % (w/v) 
2 M9 minimal agar plates: Agar-Agar 1.5 % (w/v) 
  H2O 78 % (v/v) 
  5x M9 salt stock 20 % (v/v) 
  MgSO4 2 mM 
  CaCl2 0.1 mM 
  H2O 1 % (v/v) 
  glucose   0.4 % (w/v) 
  thiamine hydrochloride  
(100 µg / ml H2O) 
0.04 % (v/v) 
3 TYE agar plates: Bacto-Agar 1.5 % (w/v) 
  tryptone 1.0 % (w/v) 
  yeast extract 0.5 % (w/v) 
  NaCl 0.8 % (w/v) 
4 LB agar plates: Bacto-Agar 1.5 % (w/v) 
  tryptone 1 % (w/v) 
  yeast extract 0.5 % (w/v) 
  NaCl 1 % (w/v) 
5 2x TY Medium: tryptone 1.6 % (w/v) 
  yeast extract 1 % (w/v) 
  NaCl 0.5 % (w/v) 
6 LB medium: tryptone 1 % (w/v) 
  yeast extract 0.5 % (w/v) 
  NaCl 1 % (w/v) 
7 SOC medium: tryptone 2 % (w/v) 
  yeast extract 0.5 % (w/v) 
  NaCl 10.3 mM 
  KCl 2.7 mM 
  MgCl2 10.5 mM 
  MgSO4 10 mM 
  glucose 20 mM 
8 Homogenisation sucrose 320 mM 
 buffer Tris-HCl (pH 7.4) 25 mM 
  complete inhibitor tablet 1 tabl./50 ml  
10 PEG /NaCl (pH 2.2) PEG 6000 20 % (w/v) 
  NaCl 2.5 M 
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11 Glycerol glycerol 60 % (v/v) 
12 PBS NaCl 1.4 M 
 (10x stock solution) KCl 26.8 mM 
  Na2HPO4 101 mM 
  KH2PO4 17.6 mM 
13 PBST 
(in 1x PBS) 
Tween20 0,05 % (v/v) 
14 MPBS 
(in 1x PBS) 
milk powder 2- 5 % (w/v) 
15 MPBST 
(in 1x PBST) 
milk powder 2- 5 % (w/v) 
16 BSA 
(in 1x PBS) 
bovine serum albumine 1 % (w/v) 
17 ELISA coating buffer Na2CO3 50 mM 
 (pH 9.6) NaHCO3 50 mM 
18 ABTS ABTS buffer (Roche, Penzberg) 0.835 g  
  ABTS tablette 1 tabl./50 ml  
19 Elution Buffer glycine 200 mM 
 (phage selection, pH 2.2) NaCl 0.5 M 
20 Neutralization Buffer: 
(phage selection, pH 9.1) 
Tris 1 M 
21 50x TAE Tris 2 M 
 (electrophorese buffer, acetic acid 5.7 % (v/v) 
 pH 8.0) EDTA (pH 8.0) 50 mM 
22 OrangeG loading buffer OrangeG 0.01 % (w/v) 
 (in 1x TAE buffer) Glycerol 30 % (v/v) 
23 Agarose gel 
(in 1x TAE buffer) 
agarose 1 % (w/v) 
24 SDS PAGE gel 
(1x stacking gel, denaturating) 
Acrylamide/Bisacrylamide 
(30 %, w/v; 1 %, w/v) 
0.38 ml 
  Tris (pH 6.8) (1.0 M) 0.38 ml 
  SDS (10%, w/v) 0.05 ml 
  APS (10 %, w/v) 0.05 ml 
  TEMED 0.002 ml 
  H2O 0.86 ml 
25 SDS PAGE gel 
(1x resolving gel, denaturating)
Acrylamide/Bisacrylamide 
(30 %, w/v; 1 %, w/v) 
1.65 ml 
  Tris- HCl (pH 8.8) (1.5 M) 1.25 ml 
  SDS (10%, w/v) 0.015 ml 
  APS (10 %, w/v) 0.015 ml 
  TEMED 0.015 ml 
  H2O 2 ml 
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26 Lämmli buffer (10x) Tris 0.25 M 
  SDS 1 % (w/v) 
  Glycine 1.92 M 
27 Protein sample buffer Tris- HCl (pH 6.8) 62.5 mM 
 (5x, reducing) SDS 4 % (w/v) 
  ß-mercapto-ethanol 10 % (v/v) 
  Glycerol 30 % (v/v) 
  Bromphenol-blue 0.05 % (w/v) 
28 Coomassie stain MeOH 45 % (v/v) 
  Glacial acetic acid 10 % (v/v) 
  SERVA blue R 0.1 % (w/v) 
29 Coomassie destain MeOH 20 % (v/v) 
  Glacial acetic acid 10 % (v/v) 
 
Tab. 7.3: Buffers for protein work  
No. Buffer Composition final concentration 
1 Protein purification NaH2PO4 (pH7.5) 200 mM 
 equilibration/wash buffer 
(4x) 
NaCl 1.2 M 
2 Protein purification NaH2PO4 (pH7.5) 50 mM 
 elution buffer NaCl 300  mM 
 (1x) Imidazole 250 mM 
 
Tab. 7.4: Extraordinary media compositions for eucaryotic cell culture 
No Medium Composition final concentration 
1 RPMI 1640 D-Valin (FZ1295) D-Valin 90 mg/l 
 (murine mesangial cell  Phenol red 5 mg/l 
 selection medium) NaHCO3 2 g/l 
 Tissue digestion medium  RPMI 1640 D-Valin (FZ1295)   
  Collagenase Type I 1 mg/ml 
2 GM- VSMC   
(C-22062) 
(Vascular Smooth Muscle Cell 
growth medium ) 
Supplement Mix (C-39267)   
3 DM- VSMC GM- VSMC   
 (digestion medium) Elastase 10 µl/ml 
  Collagenase  2 mg/ml 
  Amphotericin B 10 µl/ml 
  Gentamycin 1 µl/ml 
  DNAse 50 µg/ml 
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Tab. 7.5: Extraordinary material for isolation of primary Mesangial cells and in-vivo experiments 
No Chemicals Diluents  final concentration 
1 Isoflurane - -  
2 Avertin®   
(2,2,2 Tribromoethanol) 
H2O 15  µg/ml 
3 Ketamine/Xylazine  30  µl/10 g bw 
 Ketamine (10%)  0.2 ml 
 Xylazine (2%)  0.25  ml 
 NaCl (0.9%)  0.25 ml  
4 Dynabeads450  Tris buffer (200 mM) 4x 108 /ml 
A.5 Enzymes and reaction kits 
Restriction enzymes, as well as enzymes for dephosphorilation and ligation of 
DNA together with all corresponding buffers were, if not mentioned otherwise, 
supplied by NEB (Ipswich, USA), Invitrogen (Darmstadt) and Fermentas (St. Leon-
Rot). DNA polymerase for standard PCR reactions was obtained from Promega 
(Madison, USA), proof-reading polymerase for special DNA-mutagenesis reactions 
was supplied by Fermentas (St. Leon-Rot, Germany). All enzymes were applied 
following the manufacturer’s instructions. The following kits were used: 
Tab. 7.6: Enzyme and reaction kits 
Purpose Kit Company 
Plasmid DNA isolation (small scale) NucleoSpin® Plasmid Macherey & Nagel 
Plasmid DNA isolation (middle scale) NucleoBond® PC100 Macherey & Nagel  
DNA extraction (from agarose gel) QIAquick® Gel Extraction 
Kit 
Qiagen 
DNA transfection FuGENE HD Transfection 
Reagent 
Roche 
Quantification of protein concentration BC Assay Protein 
Quantifikation Kit 
Uptima 
Detection of mycoplasma contamination 
in eukaryotic cell culture 
MycoAlert® Mycoplasma 
Detection Kit 
Lonza  
A.6 Molecular weight standard 
Tab. 7.7: Molecular weight standards  
Standard Company 
MassRuler DNA Ladder Mix Fermentas (St. Leon-Roth) 
Spectra Multicolor Broad Range Protein Ladder  Fermentas (St. Leon-Roth) 
Prestained Protein Ladder, Broad Range (10-230 kDa) NEB (Ipswich, USA) 
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A.7 Primary and secondary antibodies 
The following antibodies were used throughout this work. The appropriate 
applications for the antibodies are mentioned within the table below. 
Tab. 7.8: Antibodies 
Antibody (supplier) Antigen/specificity Properties Application 
Antibodies for phage detection: 
HRP/Anti-M13 
(GE healthcare, 
Buckinghamshire, UK) 
bacteriophage M13  
(mcp pVIII) 
(source: mouse) 
monoclonal, 
HRP conjugated 
ELISA, IHC 
anti-M13 g8p-FITC 
(Acris Antibodies GmbH, 
Hiddenhausen) 
bacteriophage M13  
(mcp pVIII) 
(source: mouse) 
monoclonal, 
FITC conjugated 
ELISA 
Primary antibodies: 
Pab anti-nephrin  
(GP-N2) 
(Progen, Heidelberg) 
Nephrin on podocytes 
(human + mouse) 
(source: guinea pig) 
polyclonal, 
unconjugated 
 
ELISA, IHC 
α-mPECAM-1 
(Invitrogen, Darmstadt) 
CD 31  
(source: rat) 
monoclonal, 
unconjugated 
IHC 
anti-poly HIS 
(Sigma Aldrich, St. Louis, 
USA) 
poly Histidine  
(-tagged proteins) 
(source: goat) 
monoclonal, 
HRP conjugated 
ELISA, 
Western Blot, 
IHC 
anti-mouse IgG (H+L) 
HRP 
(Vector, Burlingame, 
USA) 
mouse IgG (H+L) 
(source: goat) 
polyclonal, 
HRP conjugated 
ELISA, 
Western Blot, 
IHC 
anti-mouse Fc-part 
(Sigma Aldrich, St. Louis, 
USA) 
mouse IgG Fc-part 
(source: goat) 
polyclonal ELISA, 
Western Blot, 
IHC 
anti-SNAP 
(Genescript, Piscataway, 
USA) 
recombinant SNAP-tag 
(source: rabbit) 
polyclonal ELISA, 
Western Blot, 
IHC 
Secondary antibodies: 
anti-goat-AF 488 
(Invitrogen, Darmstadt) 
goat IgG (H+L) 
(source: donkey) 
polyclonal, 
AF488 conjugated 
ELISA, IHC 
anti-goat-Cy2 
(Abcam, Cambridge, UK) 
goat IgG (H+L) 
(source: donkey) 
polyclonal, 
Cy2 conjugated 
IHC 
anti-rabbit-AF488 
(Molecular Probes, 
Eugene, USA) 
rabbit IgG (H+L) 
(source: goat) 
polyclonal, 
AF488 conjugated 
IHC 
anti-rabbit-AF546 
(Molecular Probes, 
Eugene, USA) 
rabbit IgG (H+L) 
(source: goat) 
polyclonal 
AF546 conjugated 
IHC 
anti-GP-Alexa546 
(Invitrogen, Darmstadt) 
guinea pig IgG (H+L) 
(source: goat) 
polyclonal 
AF546 conjugated 
IHC 
anti-rat-AF546 
(Molecular Probes, 
Eugene, USA) 
rat IgG 
(source: goat) 
polyclonal 
AF546 conjugated 
IHC 
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anti-mouse Cy3 mouse  polyclonal 
Cy3 conjugated 
IHC 
anti-penta HIS AF 488 
(Qiagen, Hilden) 
poly Histidine  
(-tagged proteins) 
(source: mouse) 
monoclonal 
AF488 conjugated 
IHC 
A.8 Vector systems 
A.8.1 Phagemid vector- pIT2 
As described (see 2.3.5), the pIT2 vector served as a clonal selection vector 
during phage display procedure. It was used to produce single-chain fragments 
fused to the pIII surface proteins of M13 bacteriophages to be presented by 
recombinant phages. The pIT2 vector is a derivative of the pHEN1 vector [51]. The 
orientation of the single-chain gene inserts is described in Fig. 7.1 below, N-
terminal SfiI and a C-terminal NotI restriction site were used as cloning sites for 
the single-chain antibody fragment.  
 
 
 
Fig. 7.1: Schematic illustration of the pIT2 vector used in Tomlinson Libraries I + J. As a derivative 
of the pHEN1 vector, the pIT2 includes an ampicillin resistance gene (AmpR), M13 origin 
of replication (M13 ori) and colE1 origin of replication (colE1 ori) to be translated in M13 
phages and E.coli bacteria, respectively. ScFv-genes can be introduced as SfiI-NotI or 
NcoI-NotI fragments. 
The scFv-fragments are expressed under the control of the lacZ promoter and are 
secreted into the periplasmic space of E.coli TG1 bacteria via the N-terminal pelB 
leader.  Additionally, the phagemid enables the detection of the scFv-proteins via 
two C-terminal tags- a myc tag and a 6x His tag.  
A Material 113 
A.8.2 Cloning vector for scFv-Fc proteins 
After successful selection of murine mesangial cell specific antibody-fragments, 
the corresponding scFv-genes were used for the synthetic generation of scFv-Fc 
fusion proteins, by fusing them to a murine IgG2a-Fc part. The gene synthesis was 
processed by GeneArt AG (Regensburg).  
 
Fig. 7.2: Schematic illustration of the scFv-Fc-pMA plasmid provided by GeneArt. After 
transformation into E.coli XL-1 blue supercompetent cells and ON growth of the bacterial 
culture, the ampicillin resistance gene (AmpR) was used as selective antibiotic. The scFv-
Fc gene was extracted from the plasmid using SfiI/NotI digestion, followed by ligation into 
appropriate, prepared expression vectors.  
The provided plasmid was exclusively used as cloning vector to extract the 
synthetic scFv-Fc genes of interest by digestion of the scFv-Fc (pMA) plasmid with 
SfiI and NotI.  
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A.8.3 Eucaryotic expression vector- pMS 
The pMS-scFv-Fc-SNAP vector as a derivative of the pSecTag2 vector 
(Invitrogen, Carlsbad, USA) and the pIRES-eGFP vector (Clontech, Mountain 
View, USA) was used for the expression of soluble single-chain-Fc fragments in 
eukaryotic HEK293T cells. The protein expression is controlled by the pCMV 
promotor and the soluble proteins are secreted into the cell culture supernatant via 
an N-terminal Ig-κ leader sequence. Purification of the soluble proteins can be 
performed via the C-terminal 6x His-tag. An additional internal ribosomal binding 
site (IRES) regulates the co-translation of an enhanced green fluorescent reporter 
protein (eGFP) that serves as optical control mechanism of successful vector 
transfection and protein expression.   
 
 
Fig. 7.3: Schematic illustration of the eukaryotic expression vector pMS-scFv-Fc. The ampicillin 
resistance gene (AmpR), in combination with the colE1 origin of replication is used for the 
plasmid propagation in E.coli bacteria, whereas the Zeocin® resistance gene (ZeoR) 
enables the selection of positively transfected HEK293T expression cells in Zeocin® 
containing growth medium.    
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A.9 Bacterial strains 
Tab. 7.9: Bacterial strains 
Bacterial strain Genotype 
XL1-blue MR: ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 
relA1 lac (Agilent Technologies, Waldbronn)  
TG1  
(Tomlinson 
Library): 
K12 ∆(lac-proAB) thi/F’ traD36 proA+B laclq lacZ∆M15  
(MRC, Cambridge, UK)  
A.10 Eucaryotic cells 
The following cell lines and primary cells were used for expression and for 
functional verification of recombinant proteins and phages, respectively: 
 
Tab. 7.10: Eucaryotic cells 
Cell lines  Source  Growth Function 
HEK 293T  
(ATCC-Nr.: CRL-11268) human embryonal kidney cells 
adherent expression of 
recombinant proteins 
NiH/3T3  
(ATCC-Nr.: CRL-1658) murine fibroblasts 
adherent control cell line 
L540cy  
(DSMZ-Nr.: ACC 72) human hodgkin lymphoma cells 
suspension control cell line 
Primary cells  Source  Growth Function 
mMC murine mesangial cells adherent antigen cell line 
MCT murine tubular cells adherent control cell line 
Podocytes  
(“Mundel cells”)  murine podocytes  
adherent control cell line 
VSMC murine vascular smooth muscle cells 
adherent control cell line 
A.11 Helperphages 
Tab. 7.11: Phages 
Phage Company  
M13KO7 New England Biolabs, Frankfurt 
Hyperphage 
(M13KO7∆pIII) 
Progen Biotechnik GmbH, Heidelberg 
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A.12 Oligonucleotides 
Tab. 7.12: Oligonucleotides 
Oligonucleotides for analysis of pIT2-scFv 
LMB3 cag gaa aca gct atg ac 
fdseq1 gaa ttt tct gta tga gg 
Oligonucleotides for mutagenesis of exceptional amber stop codons within pIT2-scFv 
MutQC-C2forw. gtc tca gct att cag cct tct ggt gct acg aca c 
MutQC-C2forw. gtg tcg tag cac cag aag gct gaa tag ctg aga c 
MutQC-C9forw. gtc tca aat att cag cct ctt ggt atg gct aca ctt tac gc 
MutQC-C9backw. gcg taa agt gta gcc ata cca aga ggc tga ata ttt gag ac 
MutQC-E4forw. ggt cag agg aca cag tac gca gac tcc gtg aag gg 
MutQC-E4backw. ccc ttc acg gag tct gcg tac tgt gtc ctc tga cc 
MutQC-B4forw. cca gag aca att ccc aga aca cgc tgt atc tgc 
MutQC-B4backw. gca gat aca gcg tgt tct ggg aat tgt ctc tgg 
Oligonucleotides for construction and analysis of pMS-scFv-Fcm 
mSNAP forward cga ctc act ata ggg aga ccc aag c 
mSNAP reverse I (after NotI) cct ttg ccc agc agc ttg atc tcg 
delSTOP_Fc-Teil_SNAP forw. ccc ggt ctc tgg gta aag cgg ccg ca 
delSTOP_Fc-Teil_SNAP rev. tgc ggc cgc ttt acc cag aga ccg gg 
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B Abbreviations 
ABTS 2,2'-azino-bis(3-ethylbenzothiazoline)-6-sulphonic acid 
ADCC antibody-dependent cell-mediated cytotoxicity 
AF AlexaFluor, fluorescent dye 
AGT O6-alkylguanine DNA alkyltransferase 
ALT alanine transaminase 
Amp ampicillin  
AmpR ampicillin resistance gene 
ATCC American Type Culture Collection 
b base  
BG benzylguanine 
BSA bovine serum albumin 
CD cluster of differentiation 
CDC complement-dependent cytolysis 
CDR complementarity determining region 
cfu colony forming unit 
CH constant region of the heavy antibody chain 
CL constant region of the light antibody chain 
CMV Cytomegalovirus 
CRO contract research organization 
Da dalton 
DAB 3,3'-Diaminobenzidine 
df dilution factor 
DMSO dimethyl sulfoxide  
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide 
ds double stranded 
ECM extracellular matrix 
E.coli Escherichia Coli 
EDTA ethylenediaminetetraacetic acid 
EF enrichment factor 
eGFP enhanced green fluorescent protein 
ELISA enzyme-linked immunosorbent assay  
eMC extraglomerular mesangial cell 
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ESRD end-stage renal disease  
ETA exotoxin A 
Fab fragment antigen binding 
Fc fragment crystallizable 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FP fluorescent protein 
F-pilus fertilization pilus  
FPLC fast protein liquid chromatography 
FW framework 
g gram 
gIII gene for the phage coat protein pIII 
GFP green fluorescent protein 
GFR glomerular filtration rate  
GN glomerulonephritis 
GPT glutamate pyruvate transaminase 
h hour 
HPLC high-performance liquid chromatography  
HRP horseradish peroxidase  
IgA immunoglobulin A 
IgG immunoglobulin G 
IHC immunohisochemistry 
ILAS Institute for Laboratory Animal Science 
IMAC immobilized metal ion affinity chromatography 
iMC intraglomerular mesangial cell 
IPTG isopropyl β-D-1-thiogalactopyranoside 
IRES internal ribosome entry site 
IUPAC International Union of Pure and Applied Chemistry 
kb kilobase 
L/l litre  
LB lysogeny broth or Luria-Bertani  
LI Tomlinson library I 
LJ Tomlinson library J 
m metre 
M molarity in mol/L 
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mAB monoclonal antibody 
MesPGN mesangioproliferative glomerulonephritis 
MF membrane fraction 
min minute(s) 
mMC murine mesangial cell 
MOI multiplicity of infection 
MRC Medical Research Council 
myc myelocytomatosis oncogene 
NC negativ control 
Ni-NTA nickel-nitrilotriacetic acid  
NKC natural killer cells 
NTP nucleoside triphosphate 
OD optical density 
ON overnight 
ORF open reading frame 
pIII phage coat protein pIII 
pVI phage coat protein pVI 
pVII phage coat protein pVII 
pVIII phage coat protein pVIII 
pIX phage coat protein pIX 
PAS periodic acid–Schiff  
PBS phosphate buffered saline 
PBST phosphate buffered saline with 0.05% (v/v) Tween20 
PCR polymerase chain reaction 
PDGF platelet-derived growth factor 
PEG polyethylene glycol 
pelB pectate lyase B 
PFA paraformaldehyde 
pfu phage forming unit 
ph phage 
P/S combination of penicillin and streptomycin antibiotics  
RBS ribosome binding site 
RNA ribonucleic acid 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute  
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RT room temperature  
s second(s) 
ss single stranded 
scFv single-chain fragment variable 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEC size exclusion chromatography 
taq Thermus aquaticus bacterium  
TEMED tetramethylethylenediamine 
TL Tomlinson Library 
Tris tris(hydroxymethyl)aminomethane 
U unit(s) 
V Volt 
VH variable region of the heavy antibody chain 
VL variable region of the light antibody chain 
v/v volume per volume 
w/v weight per volume 
 
B.1 Greek letters  
α alpha 
β beta  
γ gamma 
  
B.2 Quantities & Units  
°C degree Celsius 
% percent 
< smaller/less than 
> greater/more than 
*g times gravity 
* significant (p-value ≤ 0.05)  
** highly significant (p-value ≤ 0.01)  
*** highly significant (p-value ≤ 0.001)  
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B.3 Prefixes  
k kilo (103) 
d dezi (10-1) 
c zenti (10-2) 
m milli (10-3) 
µ mikro (10-6) 
n nano (10-9) 
p piko (10-12) 
B.4 Nucleotides 
A Adenine 
C Cytosine 
G Guanine 
T Thymine  
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B.5 Amino acid nomenclature according to IUPAC 
Amino acid  1-letter code  3-letter code 
Alanine A Ala 
Arginine R Arg 
Asparagine N Asn 
Aspartic acid  D Asp 
Cysteine C Cys 
Glutamine Q Gln 
Glutamic acid E Glu 
Glycine  G Gly 
Histidine  H His 
Isoleucine I Ile 
Leucine L Leu 
Lysine  K Lys 
Methionine M Met 
Phenylalanine F Phe 
Proline P Pro 
Serine  S Ser 
Threonine T Thr 
Tryptophan W Trp 
Tyrosine  Y Tyr 
Valine V Valine 
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